Saatja:
[email protected] <
[email protected]>
Teema: WHO: C.L.41.2019 (recommended INN list 81)
Dear Member States of the World Health Organization,
Please find attached, in the six official languages, C.L.41.2019 regarding the list of recommended international nonproprietary names for pharmaceutical substances which has been published by the World Health Organization in WHO Drug Information, Vol. 33, N°1, 2019.
The annex is the same in all languages and is attached to the English version.
Best regards,
Department of Governing Bodies
World Health Organization
Saatja: <
[email protected]>
Saadetud: 23.09.2019 17:12
Teema: WHO: C.L.42.2019 (proposed INN list 121)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L.42.2019 regarding the list of proposed
international nonproprietary names for pharmaceutical substances which
has been published by the World Health Organization in WHO Drug
Information, vol. 33, n°2, 2019.The list is similar in the six languages
and is attached to the English version.Best regards,Department of
Governing BodiesWorld Health Organization
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.42.2019
The World Health Organization presents its compliments and has the honour to transmit, in
accordance with Article 3 of the “Procedure for the Selection of Recommended International
Nonproprietary Names for Pharmaceutical Substances”, 1 a list of proposed international
nonproprietary names (prop. INN) which has been published by the World Health Organization
in WHO Drug Information, Vol. 33, No. 2, 2019.
It would be appreciated if this communication could be forwarded to the appropriate
patent and trade-mark office and to any other organization dealing with the introduction of
nonproprietary names for pharmaceutical substances. Any comments that may be made, or
notifications of a conflict between proposed names and existing proprietary rights, should be
addressed to the INN Programme, World Health Organization, 1211 Geneva 27, within four
months following the publication of the above-mentioned journal, i.e. no later than
21 December 2019.
The selection of international nonproprietary names by the World Health Organization for
use in all Member States presents many difficulties. It would therefore be appreciated if this
were borne in mind when it is contemplated to exercise the right to raise objections.
Furthermore, the World Health Organization would be grateful if, in the interest of public
health and pursuant to the procedure referred to in the first paragraph of this communication, the
... enclosed list of names* could be granted protection in Member States during the period they are
under consideration by the World Health Organization as international nonproprietary names.
GENEVA, 19 September 2019
1
Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended
by resolution EB43.R9, Off. Rec.Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board,
115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2.
... ENCL.: (1) * Prop. INN: List 121 published in WHO Drug Information, Vol. 33, No. 2, 2019.
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
International Nonproprietary Names
for Pharmaceutical Substances (INN)
Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of
Recommended International Nonproprietary Names for Pharmaceutical Substances, the
names given in the list on the following pages are under consideration by the World Health
Organization as Proposed International Nonproprietary Names. The inclusion of a name in the
lists of Proposed International Nonproprietary Names does not imply any recommendation of
the use of the substance in medicine or pharmacy.
Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can
be found in Cumulative List No. 17, 2017 (available in CD-ROM only). The statements
indicating action and use are based largely on information supplied by the manufacturer. This
information is merely meant to provide an indication of the potential use of new
substances at the time they are accorded Proposed International Nonproprietary Names.
WHO is not in a position either to uphold these statements or to comment on the efficacy of
the action claimed. Because of their provisional nature, these descriptors will neither be
revised nor included in the Cumulative Lists of INNs.
Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue
du choix de Dénominations communes internationales recommandées pour les Substances
pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation
mondiale de la Santé en tant que dénominations communes internationales proposées.
L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune
recommandation en vue de l'utilisation de la substance correspondante en médecine ou en
pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–117)
et recommandées (1–78) dans la Liste récapitulative No. 17, 2017 (disponible sur CD-ROM
seulement). Les mentions indiquant les propriétés et les indications des substances sont
fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner
une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont
l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni
de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur
caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de
DCI.
Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de
Denominaciones Comunes Internacionales Recomendadas para las Sustancias
Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en
las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud
233
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
como Denominaciones Comunes Internacionales Propuestas. La inclusión de una
denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor
del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas
(1–78) se encuentran reunidas en Cumulative List No. 17, 2017 (disponible sólo en CD-ROM).
Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información
facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente
de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI
Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular
comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter
provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.
Proposed International Nonproprietary Names: List 121
Comments on, or formal objections to, the proposed names may be forwarded by any person
to the INN Programme of the World Health Organization within four months of the date of
their publication in WHO Drug Information, i.e., for List 121 Proposed INN not later than 21
December 2019.
Publication date: 21/08/2019
Dénominations communes internationales proposées: Liste 121
Des observations ou des objections formelles à l'égard des dénominations proposées
peuvent être adressées par toute personne au Programme des Dénominations communes
internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à
compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste
121 de DCI Proposées le 21 décembre 2019 au plus tard.
Date de publication : 21/08/2019
Denominaciones Comunes Internacionales Propuestas: Lista 121
Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones
propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización
Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación
en WHO Drug Information, es decir, para la Lista 121 de DCI Propuestas el 21 diciembre de
2019 a más tardar.
Fecha de publicación: 21/08/2019
234
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
Proposed INN Chemical name or description: Action and use: Molecular formula
(Latin, English, French, Chemical Abstracts Service (CAS) registry number: Graphic
Spanish) formula
DCI Proposée Nom chimique ou description: Propriétés et indications: Formule
brute : Numéro dans le registre du CAS: Formule développée
DCI Propuesta Nombre químico o descripción: Acción y uso: Fórmula molecular
Número de registro del CAS: Fórmula desarrollada
DFLGXPDUOLSRLFXP
DUOLSRLFDFLG > R GLWKLRODQ\O@SHQWDQRLFDFLG
antioxidant
DFLGHDUOLSRwTXH DFLGH> R GLWKLRODQ\O@SHQWDQRwTXH
antioxydant
iFLGRDUOLSyLFR iFLGR> R GLWLRODQLO@SHQWDQRLFR
antioxidante
&+26
DFWLQLXP $F OLQWX]XPDEXPVDWHWUD[HWDQXP
DFWLQLXP $F OLQWX]XPDEVDWHWUD[HWDQ
LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &'
VLDOLFDFLGELQGLQJ,JOLNHOHFWLQ6,*/(&
6,*/(&JSS @KXPDQL]HGPRQRFORQDO
DQWLERG\FRQMXJDWHGWRVDWHWUD[HWDQ '27$
GHULYDWLYH DQGUDGLRODEHOOHGZLWKDFWLQLXP
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+. KLQJH
&+ &+' /
&+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens ,*.& .P$ 9
@GLPHU
ELVGLVXOILGHSURGXFHGLQ63$JPXULQH
P\HORPDFHOOOLQHJO\FRIRUPDOIDDFWLQLXP $F
UDGLRODEHOOHGVDWHWUD[HWDQ '27$GHULYDWLYH
FRQMXJDWHRQDQDYHUDJHRIRUO\V\O
)RUWKHsatetraxetanSDUWSOHDVHUHIHUWRWKHGRFXPHQWINN
for pharmaceutical substances: Names for radicals, groups &
others
antineoplastic
235
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
DFWLQLXP $F OLQWX]XPDEVDWpWUD[pWDQ
LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &'
OHFWLQHGHW\SH,JOLNHOLDQWO DFLGHVLDOLTXH6,*/(&
6,*/(&JSS @DQWLFRUSVPRQRFORQDO
KXPDQLVpFRQMXJXpDXVDWpWUD[pWDQ GpULYp'27$ HW
UDGLRPDUTXpjO DFWLQLXP $F
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+.
FKDUQLqUH &+ &+'
/ &+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens ,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWHGDQVODOLJQpHFHOOXODLUHGH
P\pORPHPXULQ63$JJO\FRIRUPHDOIDFRQMXJXp
DXVDWpWUD[pWDQ GpULYp'27$ VXUjO\V\OHQ
PR\HQQHHWUDGLRPDUTXpjO DFWLQLXP $F
3RXUODSDUWLHsatétraxétanYHXLOOH]YRXVUpIpUHUDXGRFXPHQW
INN for pharmaceutical substances: Names for radicals,
groups & others
antinéoplasique
DFWLQLR $F OLQWX]XPDEVDWHWUD[HWiQ
LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &'
OHFWLQDGHWLSR,JOLNHTXHVHXQHDOiFLGRVLiOLFR
6,*/(&6,*/(&JSS @DQWLFXHUSR
PRQRFORQDOKXPDQL]DGRFRQMXJDGRFRQVDWHWUD[HWiQ
GHULYDGR'27$ \UDGLRPDUFDGRFRQDFWLQLR $F
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens ,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
ELVDJUD &+ &+'
/ &+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
KXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens ,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODOtQHDFHOXODUGHPLHORPDPXULQR63$J
JOLFRIRUPDDOIDFRQMXJDGRFRQVDWHWUD[HWiQ GHULYDGR
'27$ HQRUHVWRVOLVLOSRUWpUPLQRPHGLR\
UDGLRPDUFDGRFRQDFWLQLR $F
3DUDODIUDFFLyQsatetraxetánVHSXHGHUHIHULUDOGRFXPHQWR
INN for pharmaceutical substances: Names for radicals,
groups & others
antineoplásico
236
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYNMHWVRQA PGQGLEWIGY 50
IYPYNGGTGY NQKFKSKATI TADESTNTAY MELSSLRSED TAVYYCARGR 100
PAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPSS LSASVGDRVT ITCRASESVD NYGISFMNWF QQKPGKAPKL 50
LIYAASNQGS GVPSRFSGSG SGTDFTLTIS SLQPDDFATY YCQQSKEVPW 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ 63$JW\SH JO\FDQV JO\FDQHV GH W\SH 63$J
ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR 63$J ELDQWHQDULRV FRPSOHMRV
IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
0RGLILHG UHVLGXHV 5pVLGXV PRGLILpV 5HVWRV PRGLILFDGRV
rac 2&
5
.
$Q DYHUDJH RI WR DUH NVXEVWLWXWHG E\ 5 2&
(QYLURQ j VRQW NVXEVWLWXpV SDU 5 1 1
8QD PHGLGD GH D HVWiQ NVXVWLWXLGRV SRU 5 + 6
$F +
&
1
1 1 +
2& &2
DPLYDQWDPDEXP
DPLYDQWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens(*)5 HSLGHUPDOJURZWK
IDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%(5%%+(5
+(5(5%% @DQGDQWL>Homo sapiens0(7 PHWSURWRRQFRJHQH
KHSDWRF\WHJURZWKIDFWRU +*) UHFHSWRU+*)5VFDWWHUIDFWRU 6)
UHFHSWRU+*)6)UHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHFPHWSDSLOODU\
UHQDOFHOOFDUFLQRPD5&&3 @Homo sapiensPRQRFORQDODQWLERG\
ELVSHFLILF
JDPPDKHDY\FKDLQHomo sapiensDQWL(*)5 >9+ Homo sapiens
,*+9 ,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5 KLQJH
&+ &+( 0 )!/
&+6 @ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
Homo sapiensDQWL(*)5 >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @
JDPPDKHDY\FKDLQHomo sapiensDQWL0(7 >9+ Homo sapiens
,*+9 ,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5 KLQJH
&+ &+( 0 .!5
&+6 @ GLVXOILGHZLWKNDSSDOLJKW
FKDLQHomo sapiensDQWL0(7 >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @
237
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
DPLYDQWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(*)5 UpFHSWHXU
GXIDFWHXUGHFURLVVDQFHpSLGHUPLTXHUpFHSWHXUW\URVLQHSURWpLQH
NLQDVHHUE(5%%+(5+(5(5%% @HWDQWL>Homo sapiens
0(7 SURWRRQFRJqQHPHWUpFHSWHXUGXIDFWHXUGHFURLVVDQFH
KpSDWRF\WDLUH+*)5UpFHSWHXUGXIDFWHXUGHGLVSHUVLRQUpFHSWHXU
GHO +*)6)UpFHSWHXUSURWpLQHW\URVLQHNLQDVHF0HWFDUFLQRPH
SDSLOODLUHjFHOOXOHVUpQDOHV5&&3 @DQWLFRUSVPRQRFORQDOHomo
sapiensELVSpFLILTXH
FKDvQHORXUGHJDPPDHomo sapiensDQWL(*)5 >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 FKDUQLqUH &+
&+( 0 )!/ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
Homo sapiensDQWL(*)5 >9.$33$ Homo sapiens
,*.9 ,*.- >@ Homo
sapiens,*.& .P$ 9 @
FKDvQHORXUGHJDPPDHomo sapiensDQWL0(7 >9+
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 FKDUQLqUH &+
&+( 0 .!5 &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
Homo sapiensDQWL0(7 >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
DPLYDQWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(*)5 UHFHSWRUGHO
IDFWRUGHFUHFLPLHQWRHSLGpUPLFRUHFHSWRUWLURVLQDSURWHtQDNLQDVD
HUE(5%%+(5+(5(5%% @\DQWL>Homo sapiens 0(7
SURWRRQFRJpQPHWUHFHSWRUGHOIDFWRUGHFUHFLPLHQWRKHSDWRFLWDULR
+*)5UHFHSWRUGHOIDFWRUGHGLVSHUVLyQUHFHSWRUGHO +*)6)
UHFHSWRUSURWHtQDWLURVLQDNLQDVDF0HWFDUFLQRPDSDSLODUGHFpOXODV
UHQDOHV5&&3 @DQWLFXHUSRPRQRFORQDOHomo sapiens
ELHVSHFtILFR
FDGHQDSHVDGDJDPPDHomo sapiensDQWL(*)5 >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 ELVDJUD &+ &+
( 0 )!/ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo
sapiensDQWL(*)5 >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @
FDGHQDSHVDGDJDPPDHomo sapiensDQWL0(7 >9+
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 ELVDJUD &+ &+
( 0 .!5 &+6
@ GLVXOIXURFRQOD
238
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FDGHQDOLJHUDNDSSDHomo sapiensDQWL0(7 >9
.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL(*)5
QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV 50
IWDDGSYKYY GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG 100
ITMVRGVMKD YFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL 250
FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR 300
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFLLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450
LSPGK 455
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD DQWL(*)5
AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD 50
ASSLESGVPS RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL0(7
QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW 50
ISAYNGYTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL 100
RGTNYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD DQWL0(7
DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA 50
ASSLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
/RZ IXFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IDLEOHPHQW IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV EDMRV IXFRVLODGRV
DQHWXPDEXPFRUL[HWDQXP
DQHWXPDEFRUL[HWDQ LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens 06/1
PHVRWKHOLQSUHSURPHJDNDU\RF\WHSRWHQWLDWLQJIDFWRU
PHJDNDU\RF\WHSRWHQWLDWLQJIDFWRU03)&$. @Homo sapiens
PRQRFORQDODQWLERG\FRQMXJDWHGWRFKHODWRUFRUL[HWDQ
JDPPDKHDY\FKDLQ Homo sapiens >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.
KLQJH &+ &+'
/ &+6 @
GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo sapiens >9
/$0%'$ Homo sapiens,*/9 ,*.-
>@ Homo sapiens ,*/&
$!* @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 6FHOO
OLQHJO\FRIRUPDOIDFRQMXJDWHGWRFKHODWRUFRUL[HWDQZLWKDQ
DYHUDJHRIFKHODWRUSHUDQWLERG\
antineoplastic
239
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
DQpWXPDEFRUL[pWDQ FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.
FKDUQLqUH &+ &+' /
&+6 @ GLVXOIXUHDYHFOD
FKDvQHOpJqUHODPEGDHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*.- >@
Homo sapiens ,*/& $!* @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPHDOID
FRQMXJXpDXFKpODWHXUFRUL[pWDQDYHFXQHPR\HQQHGHFKpODWHXU
SDUDQWLFRUSV
antinéoplasique
DQHWXPDEFRUL[HWiQ LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens 06/1 PHVRWHOLQD
IDFWRUSRWHQFLDGRUGHSUHSURPHJDFDULRFLWRIDFWRUSRWHQFLDGRUGHORV
PHJDFDULRFLWRV03)&$. @DQWLFXHUSRPRQRFORQDOHomo sapiens
FRQMXJDGRFRQHOTXHODQWHFRUL[HWiQ
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.
ELVDJUD &+ &+' /
&+6 @ GLVXOIXURFRQODFDGHQD
OLJHUDODPEGDHomo sapiens >9/$0%'$ Homo sapiens
,*/9 ,*.- >@ Homo
sapiens ,*/& $!* @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 OtQHDFHOXODU&+26JOLFRIRUPDDOIDFRQMXJDGR
FRQHOTXHODQWHFRUL[HWiQFRQXPDPHGLDGHTXHODQWHVSRU
DQWLFXHUSR
antineoplásico
240
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
DUSUD]LTXDQWHOXP
DUSUD]LTXDQWHO ER F\FORKH[DQHFDUERQ\O E
KH[DK\GURHS\UD]LQR>a@LVRTXLQROLQRQH
anthelmintic
DUSUD]LTXDQWHO ER F\FORKH[DQHFDUERQ\O b
KH[DK\GURHS\UD]LQR>a@LVRTXLQROpLQRQH
antihelmintique
DUSUD]LFXDQWHO ER FLFORKH[DQRFDUERQLO E
KH[DKLGURHSLUD]LQR>a@LVRTXLQROHLQRQD
antihelmíntico
&+12
2
1
1
+
2
DVWHJROLPDEXP
DVWHJROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens ,/5/
LQWHUOHXNLQUHFHSWRUOLNH'(5),7JURZWK
VWLPXODWLRQH[SUHVVHGJHQH67,/5 @Homo
sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH
&+ &+ &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
Homo sapiens >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GLPHU
WHWUDNLVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator
DVWpJROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
,/5/ UpFHSWHXUOLNHGHO LQWHUOHXNLQH'(5),7
JqQHH[SULPpORUVGHODVWLPXODWLRQGHOD
FURLVVDQFH67,/5 @DQWLFRUSVPRQRFORQDOHomo
sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH
&+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQH
241
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
OpJqUHNDSSDHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @
GLPqUH
WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur
DVWHJROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
,/5/ UHFHSWRUOLNHGHODLQWHUOHXNLQD'(5
),7JHQH[SUHVDGRHQODHVWLPXODFLyQGHO
FUHFLPLHQWR67,/5 @DQWLFXHUSRPRQRFORQDO
Homo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD
&+ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @GtPHUR
WHWUDNLVGLVXOIXUR
SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV
&+2 JOLFRIRUPDDOID
inmunomodulador
242
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
DWOHUDGVWURFHOXP
DWOHUDGVWURFHO KXPDQFXOWXUHH[SDQGHGDXWRORJRXVDGLSRVHVWURPDO
SURJHQLWRUFHOOV $6& IRUFHOOEDVHGWKHUDS\7KHFHOOV
H[SUHVV&'DQG&'FHOOVXUIDFHPDUNHUVDQGDUH
QHJDWLYHIRU&'&'DQG&'PDUNHUV
cell therapy (neurology)
DWOpUDGVWURFHO FHOOXOHVSURJpQLWULFHVVWURPDOHVLVVXHVGXWLVVX
DGLSHX[ $6& KXPDLQHVDXWRORJXHVHQFXOWXUH
G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV
H[SULPHQWOHVPDUTXHXUVGHVXUIDFH&'HW&'HW
VRQWQpJDWLYHVSRXUOHVPDUTXHXUVGHVXUIDFH&'
&'DQG&'
thérapie cellulaire (neurologie)
DWOHUDGVWURFHO FpOXODVSURJHQLWRUDVHVWURPDOHVGHWHMLGRDGLSRVR
DXWyORJDVKXPDQDVH[SDQGLGDVHQFXOWLYRSDUD
WHUDSLDFHOXODU/DVFpOXODVH[SUHVDQORVPDUFDGRUHV
GHVXSHUILFLH&'\&'\VRQQHJDWLYDVSDUDORV
PDUFDGRUHV&'&'\&'
terapia celular (neurología)
DYDORWFDJHQXPRQWDSDUYRYHFXP
DYDORWFDJHQHRQWDSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV
W\SH U$$95HS&DS YHFWRUHQFRGLQJFRGRQ
RSWLPL]HGZLOGW\SHKXPDQRUQLWKLQH
WUDQVFDUEDP\ODVH 27& XQGHUWKHFRQWURORIDK\EULG
KXPDQWK\UR[LQHELQGLQJJOREXOLQ 7%* KXPDQDOSKD
PLFURJOREXOLQELNXQLQSUHFXUVRU $0%3
SURPRWHUHQKDQFHU7KHYHFWRUJHQRPHLVDKHDGWR
KHDGGLPHUZLWKWKHYHFWRUJHQRPHFDVVHWWHORFDWHG
RIWKHPXWDWHGLQWHUQDOLQYHUWHGWHUPLQDOUHSHDW ,75
LQDUHYHUVHRULHQWDWLRQDQGWKHYHFWRUJHQRPH
FDVVHWWHORFDWHG RIWKHPXWDWHGLQWHUQDO,75LQD
IRUZDUGRULHQWDWLRQ
gene therapy (ornithine transcarbamylase (OTC)
deficiency)
DYDORWFDJqQHRQWDSDUYRYHF YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW
QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXU
O RUQLWKLQHWUDQVFDUEDP\ODVHKXPDLQHVDXYDJH 27&
DYHFGHVFRGRQVRSWLPLVpVVRXVOHFRQWU{OHGH
O DFWLYDWHXUSURPRWHXUK\EULGHGHODJOREXOLQHOLDQWOD
WK\UR[LQH 7%3 KXPDLQHSUpFXUVHXUGH
PLFURJOREXOLQHDOSKDELNXQLQH $0%3 /HJpQRPH
GXYHFWHXUHVWXQGLPqUHHQWrWHjWrWHDYHFOD
FDVVHWWHFRQWHQDQWOHJpQRPHGXYHFWHXUHQSRVLWLRQ
GHODVpTXHQFHLQYHUVHWHUPLQDOHUpSpWpH ,75
LQWHUQHHWPXWpHGRQWO RULHQWDWLRQHVWLQYHUVHHWOD
FDVVHWWHFRQWHQDQWOHYHFWHXUGXJpQRPHHQSRVLWLRQ
GHO ,75LQWHUQHHWPXWpHGRQWO RULHQWDWLRQHVWYHUV
O DYDQW
thérapie génique (déficit en ornithine transcarbamylase
(OTC))
DYDORWFDJpQRQWDSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR
UHSOLFDWLYRGHOVHURWLSR U$$95HS&DS TXH
FRGLILFDSDUDODRUQLWLQDWUDQVFDUEDPLODVDVLOYHVWUH
243
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
KXPDQD 27& FRQFRGRQHVRSWLPL]DGRVEDMRHO
FRQWUROGHXQSURPRWRUSRWHQFLDGRUKtEULGRGHOD
JOREXOLQDILMDGRUDGHWLUR[LQDKXPDQD 7%*
SUHFXUVRUGHPLFURJOREXOLQDDOIDKXPDQDELFXQLQD
$0%3 (OJHQRPDGHOYHFWRUHVXQGtPHURGH
FDEH]DFRQFDEH]DFRQHOFDVHWHGHOJHQRPDGHO
YHFWRUHQSRVLFLyQ DODUHSHWLFLyQWHUPLQDOLQYHUWLGD
,75 LQWHUQD\PXWDGDORFDOL]DGRHQRULHQWDFLyQ
LQYHUVD\HOFDVHWHGHOJHQRPDGHOYHFWRUHQSRVLFLyQ
DOD,75ORFDOL]DGRHQRULHQWDFLyQKDFLDDGHODQWH
terapia génica (deficiencia en ornitina
transcarbamilasa (OTC))
DYGRUDOLPDEXP
DYGRUDOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&$5
FRPSOHPHQW&DUHFHSWRUFRPSOHPHQW&
DQDSK\ODWR[LQ &D&3U UHFHSWRU
&' @Homo sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P!*PQ*P &+.
KLQJH &+/!$
/!( *!$ $!6 3!6
&+( 0
&+6 @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 .69FHOOOLQH
JO\FRIRUPDOID
immunomodulator, antineoplastic
DYGRUDOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&$5 UpFHSWHXUGXFRPSOpPHQW&DUpFHSWHXU
GHO DQDSK\ODWR[LQHGXFRPSOpPHQW& &D&
3U &' @DQWLFRUSVPRQRFORQDOHomo
sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P!*PQ*P &+.
FKDUQLqUH &+/!$
/!( *!$ $!6
3!6 &+( 0
&+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH.69
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
244
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
DYGRUDOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&$5 UHFHSWRUGHO
FRPSOHPHQWR&DUHFHSWRUGHODDQDILODWR[LQDGHOFRPSOHPHQWR&
&D&3U &' @DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P!*PQ*P &+.
ELVDJUD &+/!$ /!( *!$
$!6 3!6 &+( 0
&+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDHomo sapiens >9.$33$ Homo sapiens
,*.9 ,*.- >@ Homo
sapiens,*.& .P$ 9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYVMHWVRQA TGKGLEWVSA 50
IDTGGGTYYA DSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARDYY 100
YYASGSYYKA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE AEGAPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPSSIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK 454
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SRYLAWYQQK PGQAPRLLIY 50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
DYL]DNLPDEXP
DYL]DNLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens,/ LQWHUOHXNLQ @
KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5 KLQJH
&+0!< 6!7 7!(
,*+*Y &+( 0 &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.91/ ,*.-
>@ Homo sapiens,*.& .P$
9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU
2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator
245
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
DYL]DNLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens,/
LQWHUOHXNLQH @DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPD >9+ Homo sapiens
,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
Q*P &+5 FKDUQLqUH
&+0!< 6!7 7!(
,*+*Y &+( 0
&+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH
>9.$33$ Homo sapiens,*.91/
,*.- >@ Homo
sapiens,*.& .P$ 9
@
GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOID
immunomodulateur
DYL]DNLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens,/
LQWHUOHXNLQD @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPD >9+ Homo sapiens
,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
Q*P &+5 ELVDJUD
&+0!< 6!7 7!(
,*+*Y &+( 0
&+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD
>9.$33$ Homo sapiens,*.91/
,*.- >@ Homo
sapiens,*.& .P$ 9
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador
246
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
D[DWLOLPDEXP
D[DWLOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
&6)5 FRORQ\VWLPXODWLQJIDFWRUUHFHSWRU&6)5
&6)5PDFURSKDJHFRORQ\VWLPXODWLQJIDFWRU
UHFHSWRUFIPV)06&' @KXPDQL]HG
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ KLQJH6!3 &+
&+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens ,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 '*FHOOOLQH
JO\FRIRUPDOID
immunomodulator, antineoplastic
D[DWLOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&6)5 UpFHSWHXUGXIDFWHXUVWLPXODQWGHFRORQLHV
&6)5&6)5UpFHSWHXUGXIDFWHXUVWLPXODQW
GHVFRORQLHVGHPDFURSKDJHVFIPV)06&' @
DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ +RPR
VDSLHQV,*+9 ,*+' ,*+-
>@ Homo sapiens ,*+*
&+ FKDUQLqUH6!3
&+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens ,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH'*
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
D[DWLOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
&6)5 UHFHSWRUGHOIDFWRUHVWLPXODQWHGHFRORQLDV
&6)5&6)5UHFHSWRUGHOIDFWRUHVWLPXODQWHGH
ODVFRORQLDVGHPDFUyIDJRVFIPV)06&' @
DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
+RPRVDSLHQV,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3
&+ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDKXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD
FHOXODU'*JOLFRIRUPDDOID
inmunomodulador, antineoplásico
247
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVTLKESGPA LVKPTQTLTL TCTFSGFSLT TYGMGVGWIR QPPGKALEWL 50
ANIWWDDDKY YNPSLKNRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
GPIKYPTAPY RYFDFWGQGT MVTVSSASTK GPSVFPLAPC SRSTSESTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTKTYTCN VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300
QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350
EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450
LGK 453
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPSS LSASVGDRVT ITCLASEDIY DNLAWYQQKP GKAPKLLIYY 50
ASSLQDGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCLQ DSEYPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
EDPRFDIWRUXP
EDPRFDIWRU S N EHQ]HQHVXOIRQ\O WULPHWK\O
WULIOXRURPHWK\O R[D S\ULGLQD S\UD]ROD
S\UUROLGLQD F\FORSURSDQDKHSWDSKDQH
FDUER[DPLGH
cystic fibrosis transmembrane regulator (CFTR) protein
modulator
EDPRFDIWRU S N EHQ]qQHVXOIRQ\O WULPpWK\O
WULIOXRURPpWK\O R[D S\ULGLQD S\UD]ROD
S\UUROLGLQD F\FORSURSDQDKHSWDSKDQH
FDUER[DPLGH
modulateur de la protéine régulatrice de la perméabilité
transmembranaire impliquée dans la mucoviscidose
(CFTR)
EDPRFDIWRU S N EHQFHQRVXOIRQLO WULPHWLO
WULIOXRURPHWLO R[D SLULGLQD SLUD]ROD
SLUUROLGLQD FLFORSURSDQDKHSWDIDQRFDUER[DPLGD
modulador de la proteína reguladora de la conductancia
transmembrana de la fibrosis quística (CFTR)
&+)126
+
&+
+&
+& 1 2 2 2
6
1 1
+
)& 1
1
2
248
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
EDWRFOLPDEXP
EDWRFOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens)&*57
)FIUDJPHQWRI,J*UHFHSWRUDQGWUDQVSRUWHUQHRQDWDO)F
UHFHSWRU)F5QWUDQVPHPEUDQHDOSKDFKDLQRIWKH
QHRQDWDOUHFHSWRU @Homo sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 KLQJH
&+/!$ /!$
&+( 0 &+6.!GHO
@ GLVXOILGHZLWKODPEGDOLJKWFKDLQ
Homo sapiens >9/$0%'$ Homo sapiens
,*/9 ,*/- >@
Homo sapiens,*/& @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU
2YDU\ &+2 6FHOOOLQHJO\FRIRUPDOID
immunomodulator
EDWRFOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens)&*57
WUDQVSRUWHXUHWUpFHSWHXUGXIUDJPHQW)FGHV,J*
UpFHSWHXU)FQpRQDWDO)F5QFKDvQHDOSKD
WUDQVPHPEUDQDLUHGXUpFHSWHXUQpRQDWDO @DQWLFRUSV
PRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 FKDUQLqUH
&+/!$ /!$
&+( 0 &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
ODPEGDHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*/- >@
Homo sapiens,*/& @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH
FHOOXODLUH&+26JO\FRIRUPHDOID
immunomodulateur
EDWRFOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens)&*57
WUDQVSRUWDGRU\UHFHSWRUGHOIUDJPHQWR)FGHODV,J*
UHFHSWRU)FQHRQDWDO)F5QFDGHQDDOID
WUDQVPHPEUDQDULDGHOUHFHSWRUQHRQDWDO @DQWLFXHUSR
PRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 ELVDJUD
&+/!$ /!$
&+( 0 &+6.!GHO
@ GLVXOIXURFRQODFDGHQDOLJHUD
ODPEGDHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*/- >@
Homo sapiens,*/& @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU
&+26JOLFRIRUPDDOID
inmunomodulador
249
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
EHIRYDFLPDEXP
EHIRYDFLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens 7)3,
WLVVXHIDFWRUSDWKZD\LQKLELWRUOLSRSURWHLQDVVRFLDWHG
FRDJXODWLRQLQKLELWRU @PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH &+
&+ &+6.!GHO
@ GLVXOILGHZLWKODPEGDOLJKWFKDLQ
KXPDQL]HG >9/$0%'$ Homo sapiens
,*/9 ,*.- >@
Homo sapiens,*/& @
GLPHU
WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 .69FHOOOLQHJO\FRIRUPDOID
hemostatic
EpIRYDFLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens
7)3, LQKLELWHXUGHODYRLHGXIDFWHXUWLVVXODLUH
LQKLELWHXUGHODFRDJXODWLRQDVVRFLpHDX[
OLSRSURWpLQHV @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH
&+ &+ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
ODPEGDKXPDQLVpH >9/$0%'$ Homo
sapiens,*/9 ,*.-
>@ Homo sapiens,*/&
@GLPqUH
WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH
FHOOXODLUH.69JO\FRIRUPHDOID
hémostatique
250
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
EHIRYDFLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens7)3,
LQKLELGRUGHODYtDGHOIDFWRUWLVXODULQKLELGRUGHOD
FRDJXODFLyQDVRFLDGDFRQODVOLSRSURWHtQDV @
DQWLFXHUSRKXPDQL]DGR
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD
&+ &+ &+6.!GHO
@ GLVXOIXURFRQODFDGHQDOLJHUD
ODPEGDKXPDQL]DGD >9/$0%'$ Homo
sapiens,*/9 ,*.-
>@ Homo sapiens,*/&
@GtPHUR
WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU
.69JOLFRIRUPDDOID
hemostático
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMDWVRQA PGKGLEWVSS 50
IRGSRGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLY 100
RYWFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300
VLTVVHQDWL NGKEYKCKVS NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPMLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PG 442
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
SYELTQPPSV SVSPGQTARI TCSGDNLPKY YAHWYQQKPG QAPVVVIFYD 50
VNRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYYCQAW WSSTPVFGGG 100
TKLTVLGQPK AAPSVTLFPP SSEELQANKA TLVCLISDFY PGAVTVAWKA 150
DSSPVKAGVE TTTPSKQSNN KYAASSYLSL TPEQWKSHRS YSCQVTHEGS 200
TVEKTVAPTE CS 212
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K K K
,Q DGGLWLRQ WR WKH LVRIRUP $ LVRIRUP $% FKDUDFWHUL]HG E\ DQ LQWHU++ K &+
DQG DQ LQWHU+/ K &/ LQVWHDG RI WKH LQWHU++ K K
DQG RI RQH RI WKH WZR LQWHU+/ &+ &/
(Q SOXV GH O LVRIRUPH $ LVRIRUPH $% FDUDFWpULVpH SDU XQ LQWHU++ K &+
HW XQ LQWHU+/ K &/ DX OLHX GH O LQWHU++ K K
HW GH O XQ GHV GHX[ LQWHU+/ &+ &/
$GHPiV GH OD LVRIRUPD $ LVRIRUPD $% FDUDFWHUL]DGR SRU XQ LQWHU++ K &+
\ XQ LQWHU+/ K &/ HQ OXJDU GHO LQWHU++ K K
\ XQR GH ORV GRV LQWHU+/ &+ &/
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
EHQXIXWDPDEXP
EHQXIXWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
71)56)% WXPRUQHFURVLVIDFWRUUHFHSWRU
VXSHUIDPLO\PHPEHU%GHDWKUHFHSWRU'571)
UHODWHGDSRSWRVLVLQGXFLQJOLJDQGUHFHSWRU75$,/
575&' @PRQRFORQDODQWLERG\
251
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JDPPDKHDY\FKDLQFKLPHULF >9+ Mus
musculus ,*+9 *!7 ,*+'
,*+- Homo sapiens,*+9 *!7
,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+
5 KLQJH &+
&+( 0 (!*
&+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG >9
.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 '*FHOO
OLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
EpQXIXWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
71)56)% PHPEUH%GHODVXSHUIDPLOOHGHV
UpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOHUpFHSWHXU
GHPRUW'5UpFHSWHXUGH75$,/75$,/575
&' @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDFKLPpULTXH >9+ Mus
musculus ,*+9 *!7 ,*+'
,*+- Homo sapiens,*+9 *!7
,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+
5 FKDUQLqUH &+
&+( 0 (!*
&+6.!GHO @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPqUH ELVGLVXOIXUH
SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 OLJQpHFHOOXODLUH'*JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
EHQXIXWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
71)56)% PLHPEUR%GHODVXSHUIDPLOLDGHORV
UHFHSWRUHVGHOIDFWRUGHQHFURVLVWXPRUDOUHFHSWRUGH
PXHUWH'5UHFHSWRUGH75$,/75$,/575
&' @DQWLFXHUSRPRQRFORQDO
FDGHQDSHVDGDJDPPDTXLPpULFD >9+ Mus
musculus ,*+9 *!7 ,*+'
,*+- Homo sapiens ,*+9 *!7
,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+
5 ELVDJUD &+
&+( 0 (!*
&+6.!GHO @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GtPHUR ELVGLVXOIXUR
SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV
&+2 OtQHDFHOXODU'*JOLFRIRUPDDOID
inmunomodulador, antineoplásico
252
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
EHWLEHJORJHQXPDXWRWHPFHOXP
EHWLEHJORJHQHDXWRWHPFHO DXWRORJRXV&'KHPDWRSRLHWLFVWHPFHOOV
WUDQVGXFHGex vivoZLWKbetibeglogene darolentivec
(116)(78)DVHOILQDFWLYDWLQJKXPDQLPPXQRGHILFLHQF\
YLUXV +,9 GHULYHGOHQWLYLUDOYHFWRUHQFRGLQJD
74PXWDWHGIRUPRIWKHKXPDQKHPRJORELQVXEXQLW
EHWD +%%EHWDJORELQ JHQHXQGHUWKHFRQWURORID
KXPDQȕJORELQSURPRWHUDQGD ȕJORELQHQKDQFHU
cell therapy (beta-thalassemia and sickle cell disease)
EpWLEpJORJqQHDXWRWHPFHO FHOOXOHVVRXFKHVKpPDWRSRwpWLTXHV&'DXWRORJXHV
WUDQVGXLWHVex vivoDYHFOHbétibéglogène darolentivec
(116)(78)YHFWHXUOHQWLYLUDODXWRLQDFWLYDQWGpULYpGX
YLUXVGHO LPPXQRGpILFLHQFHKXPDLQH +,9 FRGDQW
SRXUXQHIRUPHPXWpH 74 GXJqQHGHODVRXV
XQLWpErWDGHO KpPRJORELQHKXPDLQH +%%ErWD
JORELQH VRXVOHFRQWU{OHG XQSURPRWHXUGHODȕ
JORELQHKXPDLQHHWXQDFWLYDWHXUGHODȕJORELQHHQ
SRVLWLRQ
thérapie cellulaire (bêta-thalassémie et anémie
falciforme)
EHWLEHJORJpQDXWRWHPFHO FpOXODVPDGUHKHPDWRSR\pWLFDV&'DXWyORJDV
WUDQVGXFLGDVex vivoFRQbetibeglogeéne darolentivec
(116)(78)XQYHFWRUOHQWLYLUDODXWRLQDFWLYDQWH
GHULYDGRGHOYLUXVGHODLQPXQRGHILFLHQFLDKXPDQD
9,+ TXHFRGLILFDSDUDXQDIRUPDPXWDGD74GHO
JHQGHODVXEXQLGDGEHWDGHODKHPRJORELQDKXPDQD
+%%EHWDJORELQD EDMRHOFRQWUROGHOSURPRWRUGHOD
EJORELQDKXPDQD\XQSRWHQFLDGRUGHODEJORELQD
ORFDOL]DGRHQSRVLFLyQ
terapia celular (beta-talasemia y anemia falciforme)
253
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
EUDQHEUXWLQLEXP
EUDQHEUXWLQLE > S EXW\QDPLGR SLSHULGLQ\O@IOXRUR
GLPHWK\OHLQGROHFDUER[DPLGH
Bruton's tyrosine kinase inhibitor
EUDQpEUXWLQLE > S EXW\QDPLGR SLSpULGLQ\O@IOXRUR
GLPpWK\OHLQGROHFDUER[DPLGH
inhibiteur de la tyrosine kinase de Bruton
EUDQHEUXWLQLE > S EXWLQDPLGR SLSHULGLQLO@IOXRUR
GLPHWLOHLQGROFDUER[DPLGD
inhibidor de la tirosina quinasa de Bruton
&+)12
EUHQVRFDWLEXP
EUHQVRFDWLE S N^ S F\DQR> PHWK\OR[R
GLK\GUREHQ]R[D]RO\O SKHQ\O@HWK\O`
R[D]HSDQHFDUER[DPLGH
cathepsin C inhibitor
EUHQVRFDWLE S N^ S F\DQR> PpWK\OR[R
GLK\GUREHQ]R[D]RO\O SKpQ\O@pWK\O`
R[D]pSDQHFDUER[DPLGH
inhibiteur de la cathepsine C
EUHQVRFDWLE S N^ S FLDQR> PHWLOR[RGLKLGUR
EHQ]R[D]ROLO IHQLO@HWLO`R[D]HSDQR
FDUER[DPLGD
inhibidor de la catepsina C
&+12
EUHSRFLWLQLEXP
EUHSRFLWLQLE > S GLIOXRURF\FORSURS\O@ ^> PHWK\OH
S\UD]RO\O DPLQR@S\ULPLGLQ\O`
GLD]DELF\FOR>@RFWDQ\O PHWKDQRQH
Janus kinase inhibitor
254
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
EUpSRFLWLQLE > S GLIOXRURF\FORSURS\O@ ^> PpWK\OH
S\UD]RO\O DPLQR@S\ULPLGLQ\O`
GLD]DELF\FOR>@RFWDQ\O PpWKDQRQH
inhibiteur de la kinase de Janus
EUHSRFLWLQLE > S GLIOXRURFLFORSURSLO@ ^> PHWLOHSLUD]RO
LO DPLQR@SLULPLGLQLO`GLD]DELFLFOR>@RFWDQ
LO PHWDQRQD
inhibidor de la quinasa de Janus
&+)12
FDWHTXHQWLQLEXP
FDWHTXHQWLQLE > ^> IOXRURPHWK\OHLQGRO\O R[\@
PHWKR[\TXLQROLQ\O`R[\ PHWK\O@F\FORSURSDQDPLQH
tyrosine kinase inhibitor, antineoplastic
FDWpTXHQWLQLE > ^> IOXRURPpWK\OHLQGRO\O R[\@
PpWKR[\TXLQROpLQ\O`R[\ PpWK\O@F\FORSURSDQ
DPLQH
inhibiteur de la tyrosine kinase, antinéoplasique
FDWHTXHQWLQLE > ^> IOXRURPHWLOHLQGROLO R[R@
PHWR[LTXLQROHLQLO`R[L PHWLO@FLFORSURSDQDPLQD
inhibidor de la tirosina quinasa, antineoplásico
&+)12
FHQWKDTXLQXP
FHQWKDTXLQH ^> PHWK\OSKHQ\O SLSHUD]LQ\O@HWK\O@TXLQROLQH
Į2-adrenoreceptor agonist
FHQWKDTXLQH ^> PpWK\OSKpQ\O SLSpUD]LQ\O@pWK\O@TXLQROpLQH
agoniste des récepteurs Į2-adrénergiques
FHQWKDTXLQD ^> PHWLOIHQLO SLSHUD]LQLO@HWLO@TXLQROHLQD
agonista de los receptores Į2-adrenérgicos
255
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
&+1
&+
1
1 1
FLQUHEDIXVSXPDOID
FLQUHEDIXVSDOID >6!3)!$/!$@LPPXQRJOREXOLQ*NDSSD FKLPHULFKXPDQMus
musculusDQWL UHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%(5%%+(5
IXVHGRQERWKKHDY\FKDLQV YLDD *6 OLQNHU
WRD&' WXPRUQHFURVLVIDFWRUUHFHSWRUVXSHUIDPLO\
PHPEHU71)56)%% WDUJHWLQJPXWDQW H[FKDQJHGUHVLGXHV
RIKXPDQOLSRFDOLQ QHXWURSKLOJHODWLQDVHDVVRFLDWHGOLSRFDOLQ1*$/
RQFRJHQHSVLGHURFDOLQ
JDPPDKHDY\FKDLQIXVHGWROLSRFDOLQPXWHLQ >Homo sapiens
9+&+&+&+ Homo sapiens,*+9 ,*+' ,*+-
>&'5.DEDW+'7<,+ &'5.DEDW+5,<371*<75<$'69.*
&'5.DEDW+:**'*)<$0'< @ Homo
sapiens,*+* &+ KLQJH 6!3 &+
)!$/!$ &+ &+6
*6 OLQNHU KXPDQOLSRFDOLQ>PXWDQW4!+/!4$!,
,!54!,<!01!'6!0/!.5!'.!''!0:!'
5!:&!61!.<!)/!+<!6.!)6!)<!(
.!< @ @ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
>Homo sapiens9/&/ Homo sapiens,*.9 ,*.-
>&'5.DEDW/5$64'917$9$ &'5.DEDW/6$6)/<6
&'5.DEDW/44+<77337 @ Homo sapiens
,*.& @GLPHU ELVGLVXOILGHSURGXFHG
LQ&KLQHVHKDPVWHURYDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
FLQUpEDIXVSDOID >6!3)!$/!$@LPPXQRJOREXOLQH*NDSSD FKLPpULTXHKXPDLQH
Mus musculusDQWL UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE%(5%%
+(5 IXVLRQQpHVXUOHVGHX[FKDvQHVORXUGHV YLDXQ
OLQNHU *6 jXQPXWDQWGHODOLSRFDOLQH
KXPDLQH OLSRFDOLQHDVVRFLpHjODJpODWLQDVHQHXWURSKLOH1*$/
RQFRJqQHSVLGpURFDOLQH FLEODQWOH&' PHPEUHGHOD
VXSHUIDPLOOHGHVUpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOH71)56)
%% UpVLGXVpFKDQJpV
FKDvQHORXUGHJDPPDIXVLRQQpHjXQHPXWpLQHGHODOLSRFDOLQH
>Homo sapiens9+&+&+&+ Homo sapiens,*+9
,*+' ,*+- >&'5.DEDW+'7<,+ &'5.DEDW+
5,<371*<75<$'69.* &'5.DEDW+:**'*)<$0'<
@ Homo sapiens,*+* &+ FKDUQLqUH
6!3 &+ )!$/!$ &+
&+6 *6 OLQNHU OLSRFDOLQHKXPDLQH
>PXWDQW4!+/!4$!,,!54!,<!01!'6!0/!.
5!'.!''!0:!'5!:&!61!.<!)/!+
<!6.!)6!)<!(.!< @ @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD >Homo sapiens9/&/
Homo sapiens,*.9 ,*.- >&'5.DEDW/
5$64'917$9$ &'5.DEDW/6$6)/<6
&'5.DEDW/44+<77337 @ Homo sapiens,*.&
@GLPqUH ELVGLVXOIXUHSURGXLWSDUGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
256
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FLQUHEDIXVSDOID >6!3)!$/!$@LQPXQRJOREXOLQD*NDSSD
TXLPpULFDKXPDQDMus musculusDQWL UHFHSWRU
WLURVLQDSURWHtQDNLQDVDHUE%(5%%+(5
IXVLRQDGDDODVGRVFDGHQDVSHVDGDV
DWUDYpVGHXQFRQHFWRU *6
FRQXQPXWDQWHGHODOLSRFDOLQDKXPDQD OLSRFDOLQD
DVRFLDGDFRQODJHODWLQDVDQHXWUyILOD1*$/RQFRJHQ
SVLGHURFDOLQD GLULJLGRVDO&' PLHPEURGH
ODVXSHUIDPLOLDGHORVUHFHSWRUHVGHOIDFWRUGHQHFURVLV
WXPRUDO71)56)%% UHVLGXRV
LQWHUFDPELDGRV
FDGHQDSHVDGDJDPPDIXVLRQDGDFRQXQHPXWHtQD
GHODOLSRFDOLQD >Homo sapiens9+&+&+
&+ Homo sapiens,*+9 ,*+' ,*+-
>&'5.DEDW+'7<,+ &'5.DEDW+
5,<371*<75<$'69.* &'5.DEDW+
:**'*)<$0'< @ Homo sapiens
,*+* &+ ELVDJUD 6!3
&+ )!$/!$ &+
&+6 *6 FRQHFWRU
OLSRFDOLQDKXPDQD>PXWDQWH4!+/!4$!,
,!54!,<!01!'6!0/!.5!'
.!''!0:!'5!:&!61!.<!)
/!+<!6.!)6!)<!(.!< @
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSD >Homo sapiens9/&/ Homo sapiens
,*.9 ,*.- >&'5.DEDW/
5$64'917$9$ &'5.DEDW/6$6)/<6
&'5.DEDW/44+<77337 @
Homo sapiens,*.& @GtPHUR
ELVGLVXOIXURSURGXFLGRSRUGHODV
FHO~ODVRYiULFDVGHKDPVWHUFKLQRV &+2 JOLFRIRUPD
DOID
inmunomodulador, antineoplásico
257
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FRVLEHOLPDEXP
FRVLEHOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens
&' SURJUDPPHGGHDWKOLJDQG3'/3'/%
KRPRORJ%+ @Homo sapiensPRQRFORQDO
DQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
KLQJH &+ &+'
/ &+6 @
GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo
sapiens >9/$0%'$ Homo sapiens,*/9
,*/- >@
Homo sapiens,*/& @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
FRVLEpOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens
&' OLJDQGGHPRUWSURJUDPPpH3'/3'/
KRPRORJXHGH%%+ @DQWLFRUSVPRQRFORQDO
Homo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
FKDUQLqUH &+ &+
' / &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
ODPEGDHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
@GLPqUH ELVGLVXOIXUH
SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
FRVLEHOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens
&' OLJDQGRGHPXHUWHSURJUDPDGD3'/3'
/KRPyORJRGH%%+ @DQWLFXHUSRPRQRFORQDO
Homo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
ELVDJUD &+ &+
' / &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDODPEGD
Homo sapiens >9/$0%'$ Homo sapiens
,*/9 ,*/- >@
Homo sapiens,*/& @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador, antineoplásico
258
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
GLUORFWRFRJHQXPVDPRSDUYRYHFXP
GLUORFWRFRJHQHVDPRSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV
YHFWRUZLWKDELRHQJLQHHUHGFDSVLGGHULYHGE\'1$
VKXIIOLQJRI$$9FDSVLGVHTXHQFHV $$9%
DYLDQDQGERYLQH$$9 IROORZHGE\in vivo
VHOHFWLRQLQ)DKíí5DJíí,OUJíí )5* PLFH
SDUWLDOO\UHSRSXODWHGZLWKKXPDQKHSDWRF\WHV7KH
YHFWRUKDV$$9JHQRPLFLQYHUWHGWHUPLQDOUHSHDWV
,75 DQGHQFRGHVDKXPDQ%GRPDLQGHOHWHGEORRG
FRDJXODWLRQIDFWRU9,,, K))9,,, XQGHUWKHFRQWURORI
DPRGLILHGWUDQVWK\UHWLQ 775P SURPRWHU
1RWHWKHQXFOHRWLGHVHTXHQFHRIWKHYHFWRULVD
PRGLILFDWLRQRIWKHRQHRIWKHYHFWRURIrovoctocogene
durparvovec (proposed INN: List 120)
gene therapy (hemophilia)
GLUORFWRFRJqQHVDPRSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpUHFRPELQDQWQRQ
UpSOLTXDQWDYHFXQHFDSVLGHREWHQXHSDUELRLQJpQLHULH
GpULYpHGXPpODQJHGHVVpTXHQFHVGHO $'1GH
FDSVLGHVGH$$9 $$9%$$9
DYLDLUHHW$$9ERYLQ VXLYLGHODVpOHFWLRQin vivoFKH]
GHVVRXULV)DKíí5DJíí,OUJíí )5*
SDUWLHOOHPHQWUHSHXSOpVDYHFGHVKpSDWRF\WHV
KXPDLQV/HYHFWHXUFRQWLHQWOHVVpTXHQFHVLQYHUVHV
WHUPLQDOHVUpSpWpHV ,75 GH$$9HWFRGHSRXUOH
IDFWHXUGHFRDJXODWLRQVDQJXLQH9,,,KXPDLQ K)
)9,,, GRQWOHGRPDLQH%DpWpVXSSULPpVRXVOH
FRQWU{OHG XQSURPRWHXUPRGLILpGHODWUDQVWK\UpWLQH
775P
1RWHODVpTXHQFHGHQXFOpRWLGHVGXYHFWHXUHVWXQH
PRGLILFDWLRQGHFHOOHGXYHFWHXUGXrovoctocogène
durparvovec (DCI proposées: Liste 120)
thérapie génique (hémophilie)
259
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
GLUORFWRFRJpQVDPRSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR
UHSOLFDWLYRFRQXQDFiSVLGDELRLQJHQLHUL]DGDPHGLDQWH
ODPH]FODGHVHFXHQFLDVGH'1$GHFiSVLGDVGH
$$9 $$9%$$9DYLDU\$$9
ERYLQR VHJXLGRGHVHOHFFLyQLQYLYRHQUDWRQHV
)DKíí5DJíí,OUJíí )5* SDUFLDOPHQWH
UHSREODGRVFRQKHSDWRFLWRVKXPDQRV(OYHFWRUWLHQH
UHSHWLFLRQHVWHUPLQDOHVLQYHUWLGDV ,75 JHQyPLFDVGH
$$9\FRGLILFDSDUDXQIDFWRUGHFRDJXODFLyQ
VDQJXtQHR9,,,KXPDQR K))9,,, FRQHOGRPLQLR%
GHOHFLRQDGREDMRHOFRQWUROGHXQSURPRWRUGH
WUDQVWLUHWLQDPRGLILFDGR 775P
1RWDODVHFXHQFLDGHQXFOHyWLGRVGHOYHFWRUHVXQD
PRGLILFDFLyQGHODGHOYHFWRUGHrovoctocogén
durparvovec (DCI propuestas: Lista 120)
terapia génica (hemofilia)
GRYDQYHWPDEXP
GRYDQYHWPDE LPPXQRJOREXOLQ*NDSSDDQWL>Felis catus ,/
LQWHUOHXNLQ @IHOLQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQIHOLQL]HG >9+ Homo
sapiens,*+9 ,*+'
,*+- >@ Felis catus
,*+* &+ KLQJH &+
0/!$$ *!$
&+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQIHOLQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ Felis catus
,*.& 1!4 @
GLPHU WULVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 *6FHOO
OLQHJO\FRIRUPDOID
immunomodulator (veterinary use)
GRYDQYHWPDE LPPXQRJOREXOLQH*NDSSDDQWL>Felis catus ,/
LQWHUOHXNLQH @DQWLFRUSVPRQRFORQDOIpOLQLVp
FKDvQHORXUGHJDPPDIpOLQLVpH >9+ Homo
sapiens,*+9 ,*+'
,*+- >@ Felis catus
,*+* &+ FKDUQLqUH
&+0/!$$ *!$
&+ &+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
IpOLQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@
Felis catus ,*.& 1!4
@GLPqUH
WULVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH*6
JO\FRIRUPHDOID
immunomodulateur (usage vétérinaire)
260
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
GRYDQYHWPDE LQPXQRJOREXOLQD*NDSSDDQWL>Felis catus ,/
LQWHUOHXNLQD @DQWLFXHUSRPRQRFORQDOIHOLQL]DGR
FDGHQDSHVDGDJDPPDIHOLQL]DGD >9+ Homo
sapiens,*+9 ,*+'
,*+- >@ Felis catus
,*+* &+ ELVDJUD
&+0/!$$ *!$
&+ &+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
IHOLQL]DGD >9.$33$ Homo sapiens,*.9
,*.- >@
Felis catus ,*.& 1!4
@GtPHUR
WULVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 OtQHDFHOXODU*6JOLFRIRUPD
DOID
inmunomodulador (uso veterinario)
HIEHPDOHQRJUDVWLPXPDOID
HIEHPDOHQRJUDVWLPDOID KXPDQJUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6)
IUDJPHQWIXVHGYLDDSHSWLG\OOLQNHUWRDKXPDQ
LPPXQRJOREXOLQ*)FIUDJPHQWYDULDQWGLPHU
>KXPDQJUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6)
SOXULSRLHWLQ VKRUW>$96(!GHO@LVRIRUP @
>*6*6 *6 OLQNHU @>KXPDQ
LPPXQRJOREXOLQ*)FIUDJPHQW &WHUPLQDO
UHVLGXHV Homo sapiens,*+* QDWXUDO6!$
YDULDQW KLQJH &+ 3!6
&+ &+6 @IXVLRQ
SURWHLQGLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVHKDPVWHURYDU\ &+2 FHOOV
JO\FRIRUPDOID
granulocyte colony stimulating factor
261
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
HIEpPDOpQRJUDVWLPDOID IUDJPHQWGXIDFWHXUGHVWLPXODWLRQGHVFRORQLHVGH
JUDQXORF\WHVKXPDLQ *&6) OLpSDUXQSHSWLGHjXQ
YDULDQWGXIUDJPHQW)FGHO LPPXQRJOREXOLQHKXPDLQH
*GLPqUH
>IDFWHXUKXPDLQGHVWLPXODWLRQGHVFRORQLHVGH
JUDQXORF\WHV *&6)SOXULSRwpWLQH
>$96(!GHO@LVRIRUPHFRXUWH @
>*6*6 *6 OLQNHU @>IUDJPHQW)FGH
O LPPXQRJOREXOLQHKXPDLQH* UpVLGXV&
WHUPLQDX[ Homo sapiens,*+* YDULDQWQDWXUDO
6!$ FKDUQLqUH &+ 3!6
&+ &+6 @SURWpLQHGH
IXVLRQGLPqUH ELVGLVXOIXUHSURGXLW
SDUGHVFHOOXOHVRYDULHQQHVGHKDPVWHUFKLQRLV &+2
JO\FRIRUPHDOID
facteur de stimulation des colonies de granulocytes
HIEHPDOHQRJUDVWLPDOID IUDJPHQWRGHOIDFWRUGHHVWLPXODFLyQGHODVFRORQLDV
GHJUDQXORFLWRVKXPDQR *&6) TXHVHXQHSRUXQ
SpSWLGRDXQDYDULDQWHGHOIUDJPHQW)FGHOD
LQPXQRJOREXOLQDKXPDQD*GtPHUR
>IDFWRUKXPDQRGHHVWLPXODFLyQGHODVFRORQLDVGH
JUDQXORFLWRV *&6)SOXULSR\HWLQD >$96(!GHO@
LVRIRUPDFRUWD @>*6*6 *6 FRQHFWRU
@>IUDJPHQWR)FGHODLQPXQRJOREXOLQDKXPDQD*
UHVLGXR&WHUPLQDO Homo sapiens,*+*
YDULDQWHQDWXUDO6!$ ELVDJUD &+
3!6 &+ &+6
@SURWHtQDGHIXVLyQGtPHUR
ELVGLVXOIXURSURGXFLGRSRUODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
factor estimulante de las colonias de granulocitos
HIPLWHUPDQWXPDOID
HIPLWHUPDQWDOID KXPDQIROOLVWDWLQIUDJPHQWIXVHGYLDDSHSWLG\OOLQNHUWR
DKXPDQLPPXQRJOREXOLQ*)FIUDJPHQWGLPHU
>KXPDQIROOLVWDWLQ )67)6DFWLYLQELQGLQJSURWHLQ
SHSWLGH@>7*OLQNHU @>KXPDQ
LPPXQRJOREXOLQ*)FIUDJPHQW &WHUPLQDO
UHVLGXHV >Homo sapiens,*+* KLQJH
&+ &+ &+6 @
QDWXUDO6!$YDULDQW @IXVLRQSURWHLQGLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH
KDPVWHURYDU\ &+2 FHOOVJO\FRIRUPDOID
anti-transforming growth factor
262
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
HIPLWHUPDQWDOID IUDJPHQWGHODIROOLVWDWLQHKXPDLQHIXVLRQQpHYLDXQ
SHSWLGHjXQIUDJPHQW)FGHO LPPXQRJOREXOLQH
KXPDLQH*GLPqUH
>IROOLVWDWLQHKXPDLQH )67)6SURWpLQHOLDQWO DFWLYLQH
SHSWLGH@>7*OLQNHU @>IUDJPHQW)FGH
O LPPXQRJOREXOLQH*KXPDLQH UpVLGXV&
WHUPLQDX[ >Homo sapiens,*+* FKDUQLqUH
&+ &+ &+6 @
YDULDQWQDWXUHO6!$ @SURWpLQHGHIXVLRQ
GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOID
anti-facteur de croissance transformant
HIPLWHUPDQWDOID IUDJPHQWRGHODIROLVWDWLQDKXPDQDIXVLRQDGDDWUDYpV
GHXQSpSWLGRFRQXQIUDJPHQWR)FGHOD
LQPXQRJOREXOLQDKXPDQD*GtPHUR
>IROLVWDWLQDKXPDQD )67)6SURWHtQDTXHVHXQDDOD
DFWLYLQD SpSWLGR@>7*FRQHFWRU @
>IUDJPHQWR)FGHODLQPXQRJOREXOLQD*KXPDQD
UHVLGXR&WHUPLQDO >Homo sapiens,*+*
ELVDJUD &+ &+
&+6 @ YDULDQWHQDWXUHO6!$ @
SURWHtQDGHIXVLyQGtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
anti-factor de crecimiento transformante
6HTXHQFH 6pTXHQFH 6HFXHQFLD
GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLFKWM 50
IFNGGAPNCI PCKETCENVD CGPGKKCRMN KKNKPRCVCA PDCSNITWKG 100
PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC 150
VVDQTNNAYC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR 200
SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS 250
DEPVCASDNA TYASECAMKE AACSSGVLLE VKHSGSCNSI STGGGVECPP 300
CPAPPVAGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV 350
DGVEVHNAKT KPREEQFNST FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP 400
APIEKTISKT KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV 450
EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH 500
EALHNHYTQK SLSLSPGK 518
'LVXOILGH EULGJH ORFDWLRQ 3RVLWLRQ GH OD SRQW GLVXOIXUH 3RVLFLyQ GHO SXHQWH GLVXOIXUR
LQWUD+ LQWUD+ )67
,J*
LQWHU++
*O\FRV\ODWLRQ VLWHV 6LWHV GH JO\FRV\ODWLRQ 3RVLFLRQHV GH JOLFRVLODFLyQ
$VQ $VQ $VQ
HOH[DFDIWRUXP
HOH[DFDIWRU N GLPHWK\OHS\UD]ROHVXOIRQ\O >
WULIOXRURGLPHWK\OSURSR[\ HS\UD]RO\O@> S
WULPHWK\OS\UUROLGLQ\O@S\ULGLQHFDUER[DPLGH
cystic fibrosis transmembrane regulator (CFTR)
protein modulator
pOH[DFDIWRU N GLPpWK\OHS\UD]ROHVXOIRQ\O >
WULIOXRURGLPpWK\OSURSR[\ HS\UD]RO\O@> S
WULPpWK\OS\UUROLGLQ\O@S\ULGLQHFDUER[DPLGH
modulateur de la protéine régulatrice de la
perméabilité transmembranaire impliquée dans la
mucoviscidose (CFTR)
263
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
HOH[DFDIWRU N GLPHWLOHSLUD]ROVXOIRQLO > WULIOXRUR
GLPHWLOSURSR[L HSLUD]ROLO@> S WULPHWLOSLUUROLGLQ
LO@SLULGLQDFDUER[DPLGD
modulador de la proteína reguladora de la conductancia
transmembrana de la fibrosis quística (CFTR)
&+)126
+
&+
+&
+& 1 2 2 2
6
1 1
+ 1 &+
1 1
&) +&
+&
1
+&
2
HOLYDOGRJHQXPDXWRWHPFHOXP
HOLYDOGRJHQHDXWRWHPFHO DXWRORJRXV&'KHPDWRSRLHWLFVWHPFHOOVWUDQVGXFHGex
vivoZLWKelivaldogene tavalentivec(115)(77)D969*
SVHXGRW\SHGVHOILQDFWLYDWLQJ+,9GHULYHGOHQWLYLUDOYHFWRU
S/%3K$/' HQFRGLQJKXPDQDGUHQROHXNRG\VWURSK\
$/' SURWHLQ $%&'JHQH XQGHUWKHFRQWURORIDPRGLILHG
P\HORSUROLIHUDWLYHVDUFRPDYLUXVSURPRWHU 01'
969* YHVLFXODUVWRPDWLWLVYLUXV*HQYHORSHSURWHLQ
01' P\HORSUROLIHUDWLYHVDUFRPDYLUXVHQKDQFHUZLWK
QHJDWLYHFRQWUROUHJLRQGHOHWHGGOUHYSULPHUELQGLQJVLWH
VXEVWLWXWHG
cell therapy (adrenoleukodystrophy)
pOLYDOGRJqQHDXWRWHPFHO FHOOXOHVVRXFKHVKpPDWRSRwpWLTXHV&'DXWRORJXHV
WUDQVGXLWHVex vivoDYHFO élivaldogène tavalentivecYHFWHXU
OHQWLYLUDOGpULYpGX9,+DXWRLQDFWLYDQW S/%3K$/'
SVHXGRW\Sp969* FRGDQWSRXUODSURWpLQHKXPDLQHGH
O DGUpQROHXFRG\VWURSKLH $/' JqQH$%&' VRXVOH
FRQWU{OHG XQSURPRWHXUGXYLUXVGXVDUFRPH
P\pORSUROLIpUDWLIPRGLILp 01'
969* JO\FRSURWpLQH*GHO HQYHORSSHGXYLUXVGHOD
VWRPDWLWHYpVLFXODLUH
01' DFWLYDWHXUGXYLUXVGXVDUFRPHP\pORSUROLIpUDWLI
GRQWODUpJLRQGHFRQWU{OHQpJDWLIDpWpVXSSULPpHOHVLWHGH
OLDLVRQGHO DPRUFHVXEVWLWXpSDUGOUHY
thérapie cellulaire (adrénoleucodystrophie)
HOLYDOGRJpQDXWRWHPFHO FpOXODVPDGUHKHPDWRSR\pWLFDV&'DXWyORJDV
WUDQVGXFLGDVex vivo FRQelivaldogéne tavalentivec
(115)(77)XQYHFWRUOHQWLYLUDODXWRLQDFWLYDQWHGHULYDGRGHO
9,+\VHXGRWLSDGRFRQ969* S/%3K$/' TXH
FRGLILFDSDUDODSURWHtQDGHODDGUHQROHXFRGLVWURILD $/'
KXPDQD JHQ$%&' EDMRHOFRQWUROGHXQSURPRWRU
PRGLILFDGRGHOYLUXVGHOVDUFRPDPLHORSUROLIHUDWLYR 01'
969* SURWHtQD*GHODHQYXHOWDGHOYLUXVGHOD
HVWRPDWLWLVYHVLFXODU
01' DFWLYDWRUGHOYLUXVGHOVDUFRPDPLHORSUROLIHUDWLYR
FRQODUHJLyQGHFRQWUROQHJDWLYRGHOHFLRQDGD\HOVLWLRGH
XQLyQGHOSULPHUGOUHYVXEVWLWXtGR
terapia celular (adrenoleucodistrofia)
264
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
HOVXEUXWLQLEXP
HOVXEUXWLQLE > S SURSHQR\O SLSHULGLQ\O@HLQGROH
FDUER[DPLGH
Bruton's tyrosine kinase inhibitor
HOVXEUXWLQLE > S SURSpQR\O SLSpULGLQ\O@HLQGROH
FDUER[DPLGH
inhibiteur de la tyrosine kinase de Bruton
HOVXEUXWLQLE > S SURSHQRLO SLSHULGLQLO@HLQGRO
FDUER[DPLGD
inhibidor de la tirosina quinasa de Bruton
&+12
HQDYRJOLIOR]LQXP
HQDYRJOLIOR]LQ S DQK\GURC^FKORUR>
F\FORSURS\OSKHQ\O PHWK\O@GLK\GUREHQ]RIXUDQ
\O`'JOXFLWRO
antidiabetic
pQDYRJOLIOR]LQH S DQK\GURC^FKORUR>
F\FORSURS\OSKpQ\O PpWK\O@GLK\GUREHQ]RIXUDQ
\O`'JOXFLWRO
hypoglycémiant
HQDYRJOLIOR]LQD S DQKLGURC^FORUR>
FLFORSURSLOIHQLO PHWLO@GLKLGUREHQ]RIXUDQLO`'
JOXFLWRO
hipoglucemiante
&+&O2
HQFHOLPDEXP
HQFHOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens/$*
O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ
&' @KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ KLQJH6!3
&+ &+ &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
265
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
KXPDQL]HG >9.$33$ Homo sapiens,*.9'
,*.- >@ Homo sapiens,*.& .P
$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
HQFHOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens/$* DFWLYDWHXUGHV
O\PSKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @DQWLFRUSVPRQRFORQDO
KXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH6!3 &+
&+ &+6 @ GLVXOIXUH
DYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH >9.$33$ Homo sapiens
,*.9' ,*.- >@ Homo sapiens
,*.& .P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
HQFHOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens/$* DFWLYDGRUGHORV
OLQIRFLWRVDFWLYDFLyQGHOLQIRFLWR&' @DQWLFXHUSRPRQRFORQDO
KXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3 &+
&+ &+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDKXPDQL]DGD >9.$33$ Homo sapiens
,*.9' ,*.- >@ Homo sapiens
,*.& .P$ 9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV
FKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
266
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
HQPHWD]REDFWDPXP
HQPHWD]REDFWDP SSR PHWK\O> PHWK\OHWULD]RO
LXP\O PHWK\O@WULR[RȜWKLD
D]DELF\FOR>@KHSWDQHFDUER[\ODWH
beta-lactamase inhibitor
HQPpWD]REDFWDP SSR PpWK\O> PpWK\OHWULD]RO
LXP\O PHWK\O@WULR[RȜWKLD
D]DELF\FOR>@KHSWDQHFDUER[\ODWH
inhibiteur de la bêta-lactamase
HQPHWD]REDFWDP SSR PHWLO> PHWLOHWULD]ROLXP
LO PHWLO@WULR[RȜWLDD]DELFLFOR>@KHSWDQR
FDUER[LODWR
inhibidor de la beta-lactamasa
&+126
HSFRULWDPDEXP
HSFRULWDPDE LPPXQRJOREXOLQ*ODPEGDNDSSDDQWL>Homo
sapiens&'( &'HSVLORQ @DQGDQWL>Homo sapiens
06$ PHPEUDQHVSDQQLQJGRPDLQVVXEIDPLO\$
PHPEHU&' @PRQRFORQDODQWLERG\ELVSHFLILF
JDPPDKHDY\FKDLQFKLPHULFDQWL&'( >9+
Mus musculus ,*+9 ,*+'
,*+- Homo sapiens ,*+9
,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+5
KLQJH &+/!)
/!( '!$ &+(
0 )!/ &+6
.!GHO @ GLVXOILGHZLWK
ODPEGDOLJKWFKDLQFKLPHULF >9/$0%'$ Mus
musculus,*/9 ,*/- Homo
sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
@
JDPPDKHDY\FKDLQHomo sapiensDQWL06$
>9+ Homo sapiens ,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *P*P &+5
KLQJH &+/!)
/!( '!$ &+(
0 .!5 &+6.!GHO
@ GLVXOILGHZLWKNDSSD
OLJKWFKDLQHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 6FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
267
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
pSFRULWDPDE LPPXQRJOREXOLQH*ODPEGDNDSSDDQWL>Homo sapiens&'(
&'HSVLORQ @HWDQWL>Homo sapiens06$ PHPEUHGHOD
VRXVIDPLOOH$jGRPDLQHVWUDQVPHPEUDQDLUHV&' @
DQWLFRUSVPRQRFORQDOELVSpFLILTXH
FKDvQHORXUGHJDPPDFKLPpULTXHDQWL&'( >9+ Mus
musculus ,*+9 ,*+' ,*+-
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
Q*P &+5 FKDUQLqUH
&+/!) /!( '!$ &+
( 0 )!/ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
ODPEGDFKLPpULTXH >9/$0%'$ Mus musculus,*/9
,*/- Homo sapiens,*/9
,*/- >@ Homo sapiens,*/&
@
FKDvQHORXUGHJDPPDHomo sapiensDQWL06$ >9+
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 FKDUQLqUH &+/!)
/!( '!$ &+( 0
.!5 &+6.!GHO @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPH
DOID
immunomodulateur, antinéoplasique
HSFRULWDPDE LQPXQRJOREXOLQD*ODPEGDNDSSDDQWL>Homo sapiens&'(
&'pSVLORQ @\DQWL>Homo sapiens06$ PLHPEURGHODVXE
IDPLOLD$GHGRPLQLRVWUDQVPHPEUDQDULRV&' @DQWLFXHUSR
PRQRFORQDOELHVSHFtILFR
FDGHQDSHVDGDJDPPDTXLPpULFDDQWL&'( >9+ Mus
musculus ,*+9 ,*+' ,*+-
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
Q*P &+5 ELVDJUD &+
/!) /!( '!$ &+(
0 )!/ &+6.!GHO
@ GLVXOIXURFRQODFDGHQDOLJHUDODPEGD
TXLPpULFD >9/$0%'$ Mus musculus,*/9
,*/- Homo sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
@
FDGHQDSHVDGDJDPPDHomo sapiensDQWL06$ >9+
Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *PQ*P &+
5 ELVDJUD &+/!)
/!( '!$ &+( 0
.!5 &+6.!GHO @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens
>9.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV
FKLQRV &+2 OtQHDFHOXODU&+26JOLFRIRUPDDOID
inmunomodulador, antineoplásico
268
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
H]DODGFLJHQXPUHVRSDUYRYHFXP
H]DODGFLJHQHUHVRSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV
VHURW\SH U$$9 YHFWRUHQFRGLQJKXPDQDURPDWLF
/DPLQRDFLGGHFDUER[\ODVH $$'&'23$
GHFDUER[\ODVH''& XQGHUFRQWURORID
F\WRPHJDORYLUXV &09 SURPRWHU
gene therapy (antiparkinsonian)
p]DODGFLJqQHUpVRSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpUHFRPELQDQWGHVpURW\SH
QRQUpSOLTXDQW U$$9 FRGDQWSRXUOD
GpFDUER[\ODVHGHVDFLGHV/DPLQpVDURPDWLTXHV
$$'&'23$GpFDUER[\ODVH''& VRXVOHFRQWU{OH
G XQSURPRWHXUGHF\WRPpJDORYLUXV &09
thérapie génique (antiparkinson)
H]DODGFLJpQUHVRSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR
UHSOLFDWLYRGHOVHURWLSR U$$9 TXHFRGLILFDSDUDOD
/DPLQRiFLGRDURPiWLFRGHVFDUER[LODVD $$'&'23$
GHFDUER[LODVD''& EDMRHOFRQWUROGHXQSURPRWRUGH
FLWRPHJDORYLUXV &09
terapia génica (antiparkinsoniano)
269
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
IDGUDFLFOLEXP
IDGUDFLFOLE RS ^>^> GLPHWK\OS\ULGLQ
\O PHWK\O@DPLQR` SURSDQ\O HSXULQ
\O@DPLQR`SHQWDQRO
cyclin-dependent kinase inhibitor, antineoplastic
IDGUDFLFOLE RS ^>^> GLPpWK\OS\ULGLQ
\O PpWK\O@DPLQR` SURSDQ\O HSXULQ
\O@DPLQR`SHQWDQRO
inhibiteur des kinases dépendantes des cyclines,
antinéoplasique
IDGUDFLFOLE RS ^>^> GLPHWLOSLULGLQLO PHWLO@DPLQR`
SURSDQLO HSXULQLO@DPLQR`SHQWDQRO
inhibidor de las quinasas dependientes de las ciclinas,
antineoplásico
&+12
IHOFLVHWUDJXP
IHOFLVHWUDJ PHWK\O> ^> SURSDQ\O HEHQ]LPLGD]ROH
FDUER[DPLGR@PHWK\O`SLSHULGLQ\O PHWK\O@SLSHULGLQH
FDUER[\ODWH
prokinetic agent
IHOFLVpWUDJ > ^> SURSDQ\O HEHQ]LPLGD]ROH
FDUER[DPLGR@PpWK\O`SLSHULGLQ\O PpWK\O@SLSpULGLQH
FDUER[\ODWHGHPpWK\OH
accélérateur du transit intestinal
IHOFLVHWUDJ > ^> SURSDQLO HEHQ]LPLGD]RO
FDUER[DPLGR@PHWLO`SLSHULGLQLO PHWLO@SLSHULGLQD
FDUER[LODWRGHPHWLOR
estimulante de la motilidad intestinal
&+12
IHOH]RQH[RUXP
IHOH]RQH[RU ^>FKORUR WULIOXRURPHWK\O S\ULGLQ\O@DPLQR`
> GLPHWK\OEXWR[\ PHWK\O@PHWK\OHS\UUROH
GLRQH
antineoplastic
270
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
IpOp]RQH[RU ^>FKORUR WULIOXRURPpWK\O S\ULGLQ\O@DPLQR`>
GLPpWK\OEXWR[\ PpWK\O@PpWK\OHS\UUROHGLRQH
antinéoplasique
IHOH]RQH[RU ^>FORUR WULIOXRURPHWLO SLULGLQLO@DPLQR`>
GLPHWLOEXWR[L PHWLO@PHWLOHSLUUROGLRQD
antineoplásico
&+&O)12
+ 2
&O 1 1
1
&+
)& 2 2
&+
&+
&+
IHUULEHSHFWDV
IHUULFEHSHFWDWH O K\GUR[HWK\O VXEVWLWXWHG aSHUJOXFRVHXQLW DFLG
K\GURO\VHGSRWDWRVWDUFK Įĺ RS 'glucoKHSWRQLF
DFLG aJOXFRVHXQLWV FRPSOH[HVZLWKLURQ ,,, K\GUR[LGH
R[LGHQDQRSDUWLFOHV a)HSHUSDUWLFOH a
antianaemic
EpSHFWDWHIHUULTXH IpFXOHGHSRPPHGHWHUUH Įĺ DFLGH RS 'gluco
KHSWRQLTXH aXQLWpVGHJOXFRVH K\GURO\VpHHQPLOLHX
DFLGHO K\GUR[pWK\O VXEVWLWXpH aSDUXQLWpGH
JOXFRVH FRPSOH[pHDYHFGHVQDQRSDUWLFXOHVG¶K\GUR[\GH
R[\GHGHIHU ,,, a)HSDUSDUWLFXOH a
antianémique
EHSHFWDWRIpUULFR DOPLGyQGHSDWDWD Įĺ iFLGR RS 'glucoKHSWyQLFR
aXQLGDGHVGHJOXFRVD KLGUROL]DGRHQPHGLRiFLGR
O KLGUR[LHWLO VXVWLWXLGR aSRUXQLGDGGHJOXFRVD
FRPSOHMRFRQODVQDQRSDUWtFXODVGHKLGUy[LGRGHKLHUUR ,,,
a)HSRUSDUWtFXOD a
antianémico
)H+2 [^ &+2 P &+2 PQ &+2 `\
P§Q§[§\§
52 52
2 25 25 2 +
+ 2 2 2 2
2+ )H )H
52 25 52 25 2 2
m+n y + x
555 ++&+&+2+ m 555 +++ n
m a n a x a y a
ILDQOLPDEXP
ILDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens /$*
O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ&' @
Homo sapiens PRQRFORQDODQWLERG\
271
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo sapiens ,*+9
,*+' ,*+- >@ Homo sapiens,*+*
&+ KLQJH6!3 &+(!3 /!9
*!$ &+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.- >@ Homo
sapiens ,*.& .P$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
ILDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens /$* DFWLYDWHXUGHV
O\PKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @DQWLFRUSVPRQRFORQDOHomo
sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo sapiens ,*+9
,*+' ,*+- >@ Homo sapiens,*+*
&+ FKDUQLqUH6!3 &+(!3
/!9 *!$ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD Homo sapiens
>9.$33$ Homo sapiens,*.9 ,*.- >@
Homo sapiens ,*.& .P$ 9
@
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
ILDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens /$* DFWLYDGRUGHORV
OLQIRFLWRVOLQIRFLWRDFWLYDFLyQ&' @DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo sapiens ,*+9
,*+' ,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3 &+(!3
/!9 *!$ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDNDSSD Homo sapiens
>9.$33$ Homo sapiens,*.9 ,*.- >@
Homo sapiens ,*.& .P$ 9
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
272
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
ILU]RWHPFHOXP
ILU]RWHPFHO DOORJHQLFKXPDQ&'KHPDWRSRLHWLF
VWHPSURJHQLWRUFHOOV +63&V GHULYHGIURP
JUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6)
PRELOL]HGSHULSKHUDOKHPDWRSRLHWLFFHOOVIURPKXPDQ
OHXNRF\WHDQWLJHQ +/$ PDWFKHGSURVSHFWLYH
WUDQVSODQWRUJDQGRQRUV
cell therapy (transplant)
ILU]RWHPFHO FHOOXOHVVRXFKHVFHOOXOHVSURJpQLWULFHV
KpPDWRSRwpWLTXHV +63&V &'KXPDLQHV
DOORJpQLTXHVGpULYpHVGHFHOOXOHVKpPDWRSRwpWLTXHV
SpULSKpULTXHVPRELOLVpHVSDUOHIDFWHXUVWLPXODQWOHV
FRORQLHVGHJUDQXORF\WHV *&6) GHGRQQHXUV
SURVSHFWLIVSRXUWUDQVSODQWDWLRQG¶RUJDQHV
FRPSDWLEOHVYLVjYLVGHO¶DQWLJqQHOHXFRF\WDLUH
KXPDLQ +/$
thérapie cellulaire (greffe)
ILU]RWHPFHO FpOXODVWURQFDOHVSUHFXUVRUDVKHPDWRSR\pWLFDV
&'KXPDQDVDORJpQLFDVGHULYDGDVGHFpOXODV
KHPDWRSR\pWLFDVSHULIpULFDVPRYLOL]DGDVFRQHOIDFWRU
HVWLPXODGRUGHFRORQLDVGHJUDQXORFLWRV *&6) GH
GRQDQWHVSURVSHFWLYRVSDUDWUDVSODQWHGHyUJDQRV
FRPSDWLEOHVSDUDHODQWtJHQROHXFRFLWDULRKXPDQR
+/$
thérapie cellulaire (transplante)
IOXEUREHQJXDQXP )
IOXEUREHQJXDQH ) N^>EURPR
) IOXRURSURSR[\ SKHQ\O@PHWK\O`JXDQLGLQH
diagnostic imaging agent
IOXEUREHQJXDQH ) N^>EURPR
) IOXRURSURSR[\ SKpQ\O@PpWK\O`JXDQLGLQH
substance à usage diagnostique
IOXEUREHQJXDQR ) N^>EURPR
) IOXRURSURSR[L IHQLO@PHWLO`JXDQLGLQD
agente de diagnóstico
&+%U)12
IRVGHQRSWHULQXP
IRVGHQRSWHULQ DRDRDRDS DPLQRWULK\GUR[\
DDDDRFWDK\GURHȜ
>@GLR[DSKRVSKLQLQR> @S\UDQR>
g@SWHULGLQH H GLRQH
molybdenum cofactor deficiency
273
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
IRVGpQRSWpULQH DRDRDRDS DPLQRWULK\GUR[\
DDDDRFWDK\GURHȜ
>@GLR[DSKRVSKLQLQR> @S\UDQR>
g@SWpULGLQH H GLRQH
déficit à cofacteur en molybdène
IRVGHQRSWHULQD DRDRDRDS DPLQRWULKLGUR[L
DDDDRFWDKLGURHȜ
>@GLR[DIRVILQLQR> @SLUDQR>g@SWHULGLQD
H GLRQD
deficiencia del cofactor molibdeno
&+123
JDWUDOLPDEXP
JDWUDOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&'
&'DQWLJHQ&$03$7+DQWLJHQ&': @
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+. KLQJH
&+ &+' /
&+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQFKLPHULF
>9.$33$ Mus musculus ,*.9
,*.- Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV
JO\FRIRUPDOID
immunomodulator, antineoplastic
JDWUDOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo &' &'
DQWLJqQH&$03$7+DQWLJqQH&': @DQWLFRUSV
PRQRFORQDO
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+.
FKDUQLqUH &+ &+'
/ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
FKLPpULTXH >9.$33$ Mus musculus ,*.9
,*.- Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH
DOID
immunomodulateur, antinéoplasique
274
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JDWUDOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo &' &'
DQWtJHQR&$03$7+DQWtJHQR&': @DQWLFXHUSR
PRQRFORQDO
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
ELVDJUD &+ &+
' / &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
TXLPpULFD >9.$33$ Mus musculus ,*.9
,*.- Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador, antineoplásico
JLURFWRFRJHQXPILWHOSDUYRYHFXP
JLURFWRFRJHQHILWHOSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV
W\SH U$$95HS&DS YHFWRUHQFRGLQJKXPDQ
%GRPDLQGHOHWHGEORRGFRDJXODWLRQIDFWRU9,,, K)
)9,,, XQGHUWKHFRQWURORIDV\QWKHWLFOLYHUVSHFLILF
SURPRWHU
gene therapy (hemophilia)
JLURFWRFRJqQHILWHOSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW
QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXUOH
IDFWHXUGHFRDJXODWLRQVDQJXLQH9,,,KXPDLQ K)
)9,,, GRQWOHGRPDLQH%DpWpVXSSULPpVRXVOH
FRQWU{OHG XQSURPRWHXUV\QWKpWLTXHVSpFLILTXHGXIRLH
thérapie génique (hémophilie)
275
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JLURFWRFRJpQILWHOSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR
UHSOLFDWLYRGHOWLSR U$$95HS&DS TXHFRGLILFD
SDUDHOIDFWRUGHFRDJXODFLyQVDQJXtQHR9,,,KXPDQR K)
)9,,, FRQHOGRPLQLR%GHOHFLRQDGREDMRHOFRQWUROGHXQ
SURPRWRUVLQWpWLFRHVSHFtILFRGHOKtJDGR
terapia génica (hemofilia)
JORILWDPDEXP
JORILWDPDE LPPXQRJOREXOLQ*ODPEGDNDSSDZLWKGRPDLQFURVVRYHU
DQWL>Homo sapiens06$ PHPEUDQHVSDQQLQJ
GRPDLQVVXEIDPLO\$PHPEHU&' @DQGDQWL>Homo
sapiens&'( &'HSVLORQ/HX @PRQRFORQDODQWLERG\
ELVSHFLILFWULYDOHQW
JDPPDODPEGDKHDY\FKDLQDQWL06$DQGDQWL&'(
9+&+9/$0%'$&+&+&+ >KXPDQL]HG
9+DQWL06$ Homo sapiens,*+9
,*+' ,*+- >@ Homo sapiens
,*+* *P &+.!( .!(
. KLQJH
PHUELV WHWUDJO\F\OVHU\O OLQNHU 9/$0''$
DQWL&'( Mus musculus,*/9 ,*/-
Homo sapiens,*/9 ,*/-
>@ PHUELVHU\OOLQNHU
Homo sapiens,*+* *P*P &+.
KLQJH &+/!$
/!$ 3!* &+6!&
' / 7!: &+6
@
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HGDQWL
06$ >KXPDQL]HG9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& (!5 4!.
.P$ 9 @
GLVXOILGHZLWK9+&NDSSDOLJKWFKDLQ
KXPDQL]HGDQWL&'( >KXPDQL]HG9+ Homo
sapiens,*+9 ,*.-
>@ Homo sapiens,*.&
7!6 .P$ 9 @
JDPPDKHDY\FKDLQKXPDQL]HGDQWL06$
>KXPDQL]HG9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *P &+.!( .!(
. KLQJH
&+/!$ /!$ 3!*
&+<!& ' / 7!6
/!$ <!9 &+6
@
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
DQWL06$ >KXPDQL]HG9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& (!5
4!. .P$ 9
@
GLPHU WULVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV
JO\FRIRUPDOID
immunomodulator, antineoplastic
276
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JORILWDPDE LPPXQRJOREXOLQH*ODPEGDNDSSDDYHFGRPDLQHVpFKDQJpVDQWL>Homo
sapiens06$ PHPEUHGHODVRXVIDPLOOH$jGRPDLQHV
WUDQVPHPEUDQDLUHV&' @HWDQWL>Homo sapiens&'( &'HSVLORQ/HX
@DQWLFRUSVPRQRFORQDOELVSpFLILTXHWULYDOHQW
FKDvQHORXUGHJDPPDODPEGDDQWL06$HWDQWL&'( 9+&+9
/$0%'$&+&+&+ >9+DQWL06$KXPDQLVp Homo sapiens
,*+9 ,*+' ,*+- >@ Homo
sapiens,*+* *P &+.!( .!( .
FKDUQLqUH PHUELV WpWUDJO\F\OVpU\O
OLQNHU 9/$0''$DQWL&'( Mus musculus,*/9
,*/- Homo sapiens,*/9 ,*/-
>@ PHUELVpU\OOLQNHU Homo sapiens,*+*
*P*P &+. FKDUQLqUH &+
/!$ /!$ 3!* &+6!&
' / 7!: &+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDDQWL06$KXPDQLVpH
>9.$33$KXPDQLVp Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& (!5
4!. .P$ 9 @
GLVXOIXUHDYHFODFKDvQHOpJqUH9+&NDSSDDQWL&'(
KXPDQLVpH >9+KXPDQLVp Homo sapiens,*+9
,*.- >@ Homo sapiens,*.&
7!6 .P$ 9 @
FKDvQHORXUGHJDPPDDQWL06$KXPDQLVpH >9+KXPDQLVp
Homo sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.!( .!(
. FKDUQLqUH &+/!$
/!$ 3!* &+<!& '
/ 7!6 /!$ <!9 &+6
@
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDDQWL06$KXPDQLVpH
>9.$33$KXPDQLVp Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
(!5 4!. .P$ 9 @
GLPqUH WULVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
JORILWDPDE LQPXQRJOREXOLQD*ODPEGDNDSSDFRQGRPLQLRVFUX]DGRVDQWL>Homo
sapiens06$ PLHPEURGHODVXEIDPLOLD$FRQGRPLQLRV
WUDQVPHPEUDQDULRV&' @\DQWL>Homo sapiens&'( &'pSVLORQ/HX
@DQWLFXHUSRPRQRFORQDOELHVSHFtILFRWULYDOHQWH
FDGHQDSHVDGDJDPPDODPEGDDQWL06$\DQWL&'( 9+&+9
/$0%'$&+&+&+ >9+DQWL06$KXPDQL]DGR Homo
sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.!( .!( .
ELVDJUD FRQHFWRUPHU
ELV WHWUDJOLFLOVHULO 9/$0''$DQWL&'( Mus musculus
,*/9 ,*/- Homo sapiens,*/9
,*/- >@ FRQHFWRUPHUELVHULO Homo
sapiens,*+* *P*P &+. ELVDJUD
&+/!$ /!$ 3!* &+
6!& ' / 7!: &+6
@
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDDQWL06$KXPDQL]DGD
>9.$33$KXPDQL]DGR Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
(!5 4!. .P$ 9 @
277
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
GLVXOIXURFRQODFDGHQDOLJHUD9+&NDSSDDQWL&'(KXPDQL]DGD
>9+KXPDQL]DGR Homo sapiens,*+9 ,*.-
>@ Homo sapiens,*.& 7!6 .P$
9 @
FDGHQDSHVDGDJDPPDDQWL06$KXPDQL]DGD >9+KXPDQL]DGR
Homo sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.!( .!(
. ELVDJUD &+/!$ /!$
3!* &+<!& ' / 7!6
/!$ <!9 &+6 @
( GLVXOIXURFRQODFDGHQDOLJHUDNDSSDDQWL06$KXPDQL]DGD
>9.$33$KXPDQL]DGR Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& (!5
4!. .P$ 9 @
GtPHUR WULVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
278
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JRQWLYLPDEXP
JRQWLYLPDE LPPXQRJOREXOLQVLQJOHFKDLQ9+9+9+DQWL>KXPDQ
UHVSLUDWRU\V\QF\WLDOYLUXV 569 IXVLRQJO\FRSURWHLQ)@
Lama glamaPRQRFORQDODQWLERG\WULYDOHQW
VF9+9+9+FKDLQ >Lama glama9+ Vicugna
pacos,*+9 ,*+' ,*+-
Homo sapiens,*+9 (!'
,*+' ,*+- >@
PHUOLQNHUWULV WHWUDJO\F\OVHU\O Lama
glama9+ Vicugna pacos,*+9 ,*+'
,*+- Homo sapiens,*+9
,*+' ,*+- >@
PHUOLQNHUWULV WHWUDJO\F\OVHU\O
Lama glama9+ Vicugna pacos,*+9
,*+' ,*+- Homo sapiens,*+9
,*+' ,*+- >@
SURGXFHGLQWKH\HDVWPichia pastoris
Komagataella phaffii QRQJO\FRV\ODWHG
immunomodulator, antiviral
JRQWLYLPDE LPPXQRJOREXOLQHFKDvQHXQLTXH9+9+9+DQWL
>JO\FRSURWpLQHGHIXVLRQ)GXYLUXVUHVSLUDWRLUH
V\QF\WLDO 956 KXPDLQ@Lama glamaDQWLFRUSV
PRQRFORQDOWULYDOHQW
VF9+9+9+FKDvQH >Lama glama9+
Vicugna pacos,*+9 ,*+' ,*+-
Homo sapiens,*+9 (!'
,*+' ,*+- >@
PHUOLQNHUWULV WpWUDJO\F\OVpU\O Lama
glama9+ Vicugna pacos,*+9 ,*+'
,*+- Homo sapiens,*+9
,*+' ,*+- >@
PHUOLQNHUWULV WpWUDJO\F\OVpU\O
Lama glama9+ Vicugna pacos,*+9
,*+' ,*+- Homo sapiens,*+9
,*+' ,*+- >@
SURGXLWGDQVODOHYXUHPichia pastoris
Komagataella phaffii QRQJO\FRV\Op
immunomodulateur, antiviral
JRQWLYLPDE LQPXQRJOREXOLQDGHFDGHQD~QLFD9+9+9+DQWL
>JOLFRSURWHtQDGHIXVLyQ)GHOYLUXVUHVSLUDWRULRVLQFLWLDO
956 KXPDQR@Lama glamaDQWLFXHUSRPRQRFORQDO
WULYDOHQWH
VF9+9+9+FDGHQD >Lama glama9+
Vicugna pacos,*+9 ,*+' ,*+-
Homo sapiens,*+9 (!'
,*+' ,*+- >@
FRQHFWRUPHUWULV WHWUDJOLFLOVHULO Lama
glama9+ Vicugna pacos,*+9 ,*+'
,*+- Homo sapiens,*+9
,*+' ,*+- >@
FRQHFWRUPHUWULV WHWUDJOLFLOVHULO
Lama glama9+ Vicugna pacos,*+9
,*+' ,*+- Homo sapiens,*+9
,*+' ,*+- >@
SURGXFLGRHQODOHYDGXUDPichia pastoris
Komagataella phaffii QRJOLFRVLODGR
inmunomodulador, antiviral
279
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JUHPXEDPDEXP
JUHPXEDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Pseudomonas aeruginosa SVO
SRO\VDFFKDULGHV\QWKHVLVORFXVVXUIDFHH[RSRO\VDFFKDULGH DQG
DQWL>Pseudomonas aeruginosa W\SH,,,VHFUHWLRQV\VWHP 7766
76 3FU9SURWHLQ@PRQRFORQDODQWLERG\ELVSHFLILF
JDPPDKHDY\FKDLQ9+&+9+9.$33$&+&+KXPDQL]HG
>9+DQWL3FU9 Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens,*+*
*P &+5 KLQJH
PHUOLQNHU 9+DQWLSV, Homo sapiens,*+9
,*+9 ,*+' ,*+- >@
PHUOLQNHU 9.$33$DQWLSV, Homo
sapiens,*.9 ,*.- >@
PHUOLQNHU Homo sapiens,*+* Q*P
KLQJH &+ &+( 0
&+6 @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQHomo sapiens >9.$33$DQWL3FU9
Homo sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antibacterial
JUpPXEDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Pseudomonas aeruginosa SVO
ORFXVGHV\QWKqVHGHVSRO\VDFFKDULGHVH[RSRO\VDFFKDULGHGH
VXUIDFH @HWDQWL>SURWpLQH3FU9GXV\VWqPHGHVpFUpWLRQW\SH,,,
776676 GH Pseudomonas aeruginosa @DQWLFRUSVPRQRFORQDO
ELVSpFLILTXH
FKDvQHORXUGHJDPPD9+&+9+9.$33$&+&+KXPDQLVpH
>9+DQWL3FU9 Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens,*+*
*P &+5 FKDUQLqUH
PHUOLQNHU 9+DQWLSV, Homo sapiens,*+9
,*+9 ,*+' ,*+- >@
PHUOLQNHU 9.$33$DQWLSV, Homo
sapiens,*.9 ,*.- >@
PHUOLQNHU Homo sapiens,*+* Q*P
FKDUQLqUH &+ &+( 0
&+6 @ GLVXOIXUH
DYHFODFKDvQHOpJqUHNDSSDHomo sapiens >9.$33$DQWL
3FU9 Homo sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@GLPqUH ELVGLVXOIXUHSURGXLW
GDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOID
immunomodulateur, antibactérien
280
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JUHPXEDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Pseudomonas
aeruginosa SVO OXJDUGHVtQWHVLVGHORVSROLVDFiULGRV
H[RSROLVDFiULGRGHVXSHUILFLH @\DQWL>SURWHtQD3FU9
GHOVLVWHPDGHVHFUHFLyQWLSR,,, 776676 GH
Pseudomonas aeruginosa @DQWLFXHUSRPRQRFORQDO
ELHVSHFtILFR
FDGHQDSHVDGDJDPPD9+&+9+9.$33$&+
&+KXPDQL]DGD >9+DQWL3FU9 Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+5 ELVDJUD
FRQHFWRUPHU 9+DQWLSV,
Homo sapiens,*+9 ,*+9
,*+' ,*+- >@
FRQHFWRUPHU 9.$33$DQWLSV,
Homo sapiens,*.9 ,*.-
>@ FRQHFWRUPHU
Homo sapiens,*+* Q*P ELVDJUD
&+ &+( 0
&+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo
sapiens >9.$33$DQWL3FU9 Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV
GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antibacteriano
281
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
LPLIRSODWLQXP
LPLIRSODWLQ GLK\GURJHQ SP > RR F\FORKH[DQH
GLDPLQHțNN@>GLSKRVSKDWR í
țOO@SODWLQDWH í
antineoplastic
LPLIRSODWLQH GLK\GURJqQR SP > RR F\FORKH[DQH
GLDPLQHțNțN@>GLSKRVSKDWR
țOO3@SODWLQDWH
antinéoplasique
LPLIRSODWLQR GLKLGUyJHQR SP > RR FLFORKH[DQR
GLDPLQDțNțN@>GLIRVIDWR țOO3@SODWLQDWR
antineoplásico
&+1233W
LPQRSLWDQWXP
LPQRSLWDQW N^>ELV WULIOXRURPHWK\O SKHQ\O@PHWK\O`NPHWK\O
PHWK\OSKHQ\O PHWK\OSLSHUD]LQ\O S\ULGLQH
FDUER[DPLGH
neurokinin NK1 receptor antagonist
LPQRSLWDQW N^>ELV WULIOXRURPpWK\O SKpQ\O@PpWK\O`NPpWK\O
PpWK\OSKpQ\O PpWK\OSLSpUD]LQ\O S\ULGLQH
FDUER[DPLGH
antagoniste du récepteur NK1 de la neurokinine
LPQRSLWDQW N^>ELV WULIOXRURPHWLO IHQLO@PHWLO`NPHWLO
PHWLOIHQLO PHWLOSLSHUD]LQLO SLULGLQD
FDUER[DPLGD
antagonista del receptor NK1 de neurokinina
&+)12
+& &)
1
1 2
&)
1
1
+& +&
LYDOWLQRVWDWXP
LYDOWLQRVWDW E N> GLPHWK\ODPLQR SURS\O@NK\GUR[\
^> QDSKWKDOHQ\O R[\@PHWK\O`RFWHQHGLDPLGH
histone deacetylase inhibitor, antineoplastic
LYDOWLQRVWDW E N> GLPpWK\ODPLQR SURS\O@NK\GUR[\
^> QDSKWDOpQ\O R[\@PpWK\O`RFWqQHGLDPLGH
inhibiteur de l'histone désacétylase, antinéoplasique
282
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
LYDOWLQRVWDW E N> GLPHWLODPLQR SURSLO@NKLGUR[L
^> QDIWDOHQLO R[L@PHWLO`RFWHQRGLDPLGD
inhibidor de la histona desacetilasa, antineoplásico
&+12
LYX[ROLPDEXP
LYX[ROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
71)56) WXPRUQHFURVLVIDFWRUUHFHSWRU 71)5
VXSHUIDPLO\PHPEHU2;&' @Homo sapiens
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQ Homo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH &+
&+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo
sapiens >9.$33$ Homo sapiens,*.9'
,*.- >@
Homo sapiens ,*.& .P$
9 @
GLPHU
WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 .69FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
LYX[ROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
71)56) PHPEUHGHODVXSHUIDPLOOHGHV
UpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOH$&7
2;&' @DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH
&+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
Homo sapiens >9.$33$ Homo sapiens
,*.9' ,*.- >@
Homo sapiens ,*.& .P$
9 @
GLPqUH
WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH.69
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
283
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
LYX[ROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
71)56) PLHPEURGHODVXSHUIDPLOLDGHORV
UHFHSWRUHVGHOIDFWRUGHQHFURVLVWXPRUDO$&7
2;&' @DQWLFXHUSRPRQRFORQDOHomo
sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD
&+ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
Homo sapiens >9.$33$ Homo sapiens
,*.9' ,*.- >@
Homo sapiens ,*.& .P$
9 @
GtPHUR
WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPD
DOID
inmunomodulador, antineoplásico
L]HQFLWLQLEXP
L]HQFLWLQLE > RsS ^> PHWK\OHS\UD]RO\O DPLQR@
QDSKWK\ULGLQ\O`DPLQR D]DELF\FOR>@RFWDQ
\O@SURSDQHQLWULOH
Janus kinase inhibitor
L]HQFLWLQLE > RsS ^> PpWK\OHS\UD]RO\O DPLQR@
QDSKW\ULGLQ\O`DPLQR D]DELF\FOR>@RFWDQ
\O@SURSDQHQLWULOH
inhibiteur de la kinase de Janus
L]HQFLWLQLE > RsS ^> PHWLOHSLUD]ROLO DPLQR@
QDIWLULGLQLO`DPLQR D]DELFLFOR>@RFWDQ
LO@SURSDQRQLWULOR
inhibidor de la quinasa de Janus
284
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
&+1
OHQDFDSDYLUXP
OHQDFDSDYLU N> S ^>FKORUR PHWKDQHVXOIRQDPLGR
WULIOXRURHWK\O HLQGD]RO\O@> PHWKDQHVXOIRQ\O
PHWK\OEXW\Q\O@S\ULGLQ\O` GLIOXRURSKHQ\O HWK\O@
> ESDR GLIOXRUR WULIOXRURPHWK\O EDWHWUDK\GUR
HF\FORSURSD>@F\FORSHQWD>c@S\UD]RO\O@DFHWDPLGH
antiviral
OpQDFDSDYLU N> S ^>FKORUR PpWKDQHVXOIRQDPLGR
WULIOXRURpWK\O HLQGD]RO\O@> PpWKDQHVXOIRQ\O
PpWK\OEXW\Q\O@S\ULGLQ\O` GLIOXRURSKpQ\O pWK\O@
> ESDR GLIOXRUR WULIOXRURPpWK\O EDWpWUDK\GUR
HF\FORSURSD>@F\FORSHQWD>c@S\UD]RO\O@DFpWDPLGH
antiviral
OHQDFDSDYLU N> S ^>FORUR PHWDQRVXOIRQDPLGR
WULIOXRURHWLO HLQGD]ROLO@> PHWDQRVXOIRQLO PHWLOEXWLQ
LO@SLULGLQLO` GLIOXRURIHQLO HWLO@> ESDR GLIOXRUR
WULIOXRURPHWLO EDWHWUDKLGURH
FLFORSURSD>@FLFORSHQWD>c@SLUD]ROLO@DFHWDPLGD
antiviral
&+&O)126
OHWHWUHVJHQXPDXWROHXFHOXP
OHWHWUHVJHQHDXWROHXFHO $XWRORJRXV&'DQG&'7FHOOVWUDQVGXFHGZLWKDQRQ
UHSOLFDWLQJKXPDQLPPXQRGHILFLHQF\YLUXV +,9 GHULYHGVHOI
LQDFWLYDWLQJ 6,1 YHFWRUWKDWFRPSULVHVD /75 569 58
DQGD 8GHOHWHG/75 85+,9'HOWD /75 HQFRGLQJDQ
DIILQLW\HQKDQFHG1<(62 DXWRLPPXQRJHQLFFDQFHUWHVWLV
DQWLJHQ1<(62&7$*$/DQWLJHQIDPLO\PHPEHU/$*(
VSHFLILF7FHOOUHFHSWRU 7&5 XQGHUWKHFRQWURORIHORQJDWLRQ
IDFWRUDOSKD ()D SURPRWHU7KHYHFWRULVSVHXGRW\SHGZLWK
YHVLFXODUVWRPDWLWLVYLUXVJO\FRSURWHLQ* 969*
5695RXVVDUFRPDYLUXV
cell therapy (antineoplastic)
285
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
OHWHWUHVJpQHDXWROHXFHO /\PSKRF\WHV7&'HW&'DXWRORJXHVWUDQVGXLWVSDUXQ
YHFWHXUDXWRLQDFWLYDQW 6,1 QRQUpSOLTXDQWGpULYpGXYLUXV
GHO LPPXQRGpILFLHQFHQFHKXPDLQH 9,+ FRQWHQDQWXQH
VpTXHQFH/75 WHUPLQDOHORQJXHUpSpWpH HQ 569 58
HWXQHVpTXHQFH/75GRQWOHGRPDLQH8HVWVXSSULPp 85
+,9'HOWD /75 HWTXLFRGHSRXUXQUpFHSWHXUGHV
O\PSKRF\WHV7 7&5 GRQWO DIILQLWpHVWDXJPHQWpHVSpFLILTXH
GX1<(62 DQWLJqQHDXWRLPPXQRJpQLTXHDVVRFLpDX
FDQFHUGXWHVWLFXOH1<(62&7$*$PHPEUHGHOD
IDPLOOHGHO DQWLJqQH//$*( VRXVOHFRQWU{OHG XQ
SURPRWHXUGXIDFWHXUG pORQJDWLRQDOSKD ()D /HYHFWHXU
HVWSVHXGRW\SpDYHFODJO\FRSURWpLQH*GHO HQYHORSSHGHOD
VWRPDWLWHYpVLFXODLUH 969*
569YLUXVGXVDUFRPHGH5RXV
thérapie cellulaire (antinéoplasique)
OHWHWUHVJqQDXWROHXFHO /LQIRFLWRV7&'\&'DXWyORJRVWUDQVGXFLGRVFRQXQ
YHFWRUDXWRLQDFWLYDQWH 6,1 QRUHSOLFDWLYRGHULYDGRGHOYLUXV
GHODLQPXQRGHILFLHQFLDKXPDQD 9,+ TXHFRQWLHQHXQD/75
HQ 569 58 \XQD/75FRQ8GHOHFLRQDGDHQ 8
5+,9'HOWD /75 \TXHFRGLILFDSDUDXQUHFHSWRUGH
OLQIRFLWRV7 7&5 FRQDILQLGDGDXPHQWDGDHVSHFtILFRSDUD
1<(62 DQWtJHQRGHFiQFHUWHVWtFXORVDXWRLQPXQRJpQLFR
1<(62&7$*$PLHPEURGHODIDPLOLDGHDQWtJHQRV/
/$*( EDMRHOFRQWUROGHOSURPRWRUGHOIDFWRUGHHORQJDFLyQ
DOID ()D (OYHFWRUHVWiVHXGRWLSDGRFRQODJOLFRSURWHtQD
*GHOYLUXVGHODHVWRPDWLWLVYHVLFXODU 969*
569YLUXVGHOVDUFRPDGH5RXV
terapia celular (antineoplásico)
OLQSHUOLVLEXP
OLQSHUOLVLE N^>IOXRUR^> K\GUR[\SURSDQ\O SLSHULGLQ
\O@PHWK\O` PRUSKROLQ\O TXLQD]ROLQ\O@PHWKR[\S\ULGLQ
\O`PHWKDQHVXOIRQDPLGH
phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic
OLQSHUOLVLE N^>IOXRUR^> K\GUR[\SURSDQ\O SLSpULGLQ
\O@PpWK\O` PRUSKROLQ\O TXLQD]ROLQ\O@PpWKR[\S\ULGLQ
\O`PpWKDQHVXOIRQDPLGH
inhibiteur de phosphatidylinositol 3-kinase (PI3K),
antinéoplasique
OLQSHUOLVLE N^>IOXRUR^> KLGUR[LSURSDQLO SLSHULGLQLO@PHWLO`
PRUIROLQLO TXLQD]ROLQLO@PHWR[LSLULGLQ
LO`PHWDQRVXOIRQDPLGD
inhibidor de fosfatidilinositol 3-quinasa (PI3K), antineoplásico
&+)126
286
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
ORGDSROLPDEXP
ORGDSROLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens
3'&' SURJUDPPHGFHOOGHDWK3'3'
&' @Homo sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
KLQJH &+/!$ /!(
*!$ $!6 3!6
&+( 0 &+6
@ GLVXOILGHZLWKODPEGDOLJKW
FKDLQHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*/-
>@ Homo sapiens,*/& 7!$
@GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
ORGDSROLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens
3'&' SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH
3'3'&' @DQWLFRUSVPRQRFORQDOHomo
sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
FKDUQLqUH &+/!$ /!(
*!$ $!6 3!6
&+( 0 &+6
@ GLVXOIXUHDYHFODFKDvQH
OpJqUHODPEGDHomo sapiens >9/$0%'$
Homo sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
7!$ @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH
DOID
immunomodulateur, antinéoplasique
ORGDSROLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens
3'&' SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD
3'3'&' @DQWLFXHUSRPRQRFORQDOHomo
sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
ELVDJUD &+/!$ /!(
*!$ $!6 3!6
&+( 0 &+6
@ GLVXOIXURFRQODFDGHQD
OLJHUDODPEGDHomo sapiens >9/$0%'$
Homo sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
7!$ @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
287
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ORPDUGH[DPIHWDPLQXP
ORPDUGH[DPIHWDPLQH S DPLQR FDUEDPLPLGR\ODPLQR N> S
SKHQ\OSURSDQ\O@KH[DQDPLGH
central nervous system stimulant
ORPDUGH[DPIpWDPLQH S DPLQR FDUEDPLPLGR\ODPLQR N> S
SKpQ\OSURSDQ\O@KH[DQDPLGH
stimulant du système nerveux central
ORPDUGH[DPIHWDPLQD S DPLQR FDUEDPLPLGRLODPLQR N> S
IHQLOSURSDQLO@KH[DQDPLGD
estimulante del sistema nervioso central
&+12
ORQRGHOHVWDWXP
ORQRGHOHVWDW DQK\GUR>/DODQ\O/VHU\O/LVROHXF\O/SURO\O/
SURO\O/JOXWDPLQ\O/O\V\O/W\URV\O'SURO\O/SURO\O
S DPLQRGHFDQR\O/ĮJOXWDP\O/WKUHRQLQH@
elastase inhibitor
ORQRGpOHVWDW DQK\GUR>/DODQ\O/VpU\O/LVROHXF\O/SURO\O/
SURO\O/JOXWDPLQ\O/O\V\O/W\URV\O'SURO\O/SURO\O
S DPLQRGpFDQR\O/ĮJOXWDP\O/WKUpRQLQH@
inhibiteur de l'élastase
288
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
ORQRGHOHVWDW DQKLGUR>/DODQLO/VHULO/LVROHXFLO/SUROLO/SUROLO/
JOXWDPLQLO/OLVLO/WLURVLO'SUROLO/SUROLO S
DPLQRGHFDQRLO/ĮJOXWDPLO/WUHRQLQD@
inhibidor de la elastasa
&+12
PDQHOLPDEXP
PDQHOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens
&' SURJUDPPHGGHDWKOLJDQG3'/3'/%
KRPRORJ%+ @Homo sapiensPRQRFORQDO
DQWLERG\
JDPPDKHDY\FKDLQ >9+ Homo sapiens
,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*P*P &+5
KLQJH &+/!$ /!$
&+' / &+6
@ GLVXOILGHZLWKODPEGD
OLJKWFKDLQ >9/$0%'$ Homo sapiens
,*/9 ,*/- >@
Homo sapiens ,*/& @
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 .6FHOOOLQH
JO\FRIRUPDOID
immunomodulator, antineoplastic
PDQpOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens
&' OLJDQGGHPRUWSURJUDPPpH3'/3'/
KRPRORJXHGH%%+ @DQWLFRUSVPRQRFORQDO
Homo sapiens
FKDvQHORXUGHJDPPD >9+ Homo sapiens
,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*P*P &+5
FKDUQLqUH &+/!$ /!$
&+' /
&+6 @ GLVXOIXUHDYHF
ODFKDvQHOpJqUHODPEGD >9/$0%'$ Homo
sapiens,*/9 ,*/-
>@ Homo sapiens ,*/&
@GLPqUH ELVGLVXOIXUH
SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 OLJQpHFHOOXODLUH.6JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
PDQHOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens
&' OLJDQGRGHPXHUWHSURJUDPDGD3'/3'
/KRPyORJRGH%%+ @DQWLFXHUSRPRQRFORQDO
Homo sapiens
289
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FDGHQDSHVDGDJDPPD >9+ Homo sapiens
,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*P*P &+5
ELVDJUD &+/!$ /!$
&+' /
&+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDODPEGD >9/$0%'$ Homo
sapiens,*/9 ,*/-
>@ Homo sapiens ,*/&
@GtPHUR ELVGLVXOIXUR
SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV
&+2 OtQHDFHOXODU.6JOLFRIRUPDDOID
inmunomodulador, antineoplásico
PDYH]HOLPDEXP
PDYH]HOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens /$*
O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ
&' @KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ KLQJH &+
&+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9'
,*.- >@ Homo
sapiens ,*.& .P$ 9
@
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
290
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
PDYp]pOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens /$*
DFWLYDWHXUGHVO\PKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @
DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ FKDUQLqUH
&+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9'
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
PDYH]HOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens /$* DFWLYDGRU
GHORVOLQIRFLWRVOLQIRFLWRDFWLYDFLyQ&' @DQWLFXHUSR
PRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
ELVDJUD &+ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDKXPDQL]DGD >9.$33$ Homo sapiens,*.9'
,*.- >@ Homo
sapiens ,*.& .P$ 9
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
291
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
PHVGRSHWDPXP
PHVGRSHWDP N^>IOXRUR
PHWKDQHVXOIRQ\O SKHQR[\@HWK\O`SURSDQDPLQH
dopamine D3 receptor blocker
PHVGRSpWDP N^>IOXRUR
PpWKDQHVXOIRQ\O SKpQR[\@pWK\O`SURSDQDPLQH
bloqueur des récepteurs à la dopamine D3
PHVGRSHWDP N^>IOXRUR PHWDQRVXOIRQLO IHQR[L@HWLO`SURSDQ
DPLQD
bloqueante del receptor de la dopamina D3
&+)126
PHYRFLFOLEXP
PHYRFLFOLE N> SR ^>FKORUR HLQGRO\O S\ULPLGLQ
\O@DPLQR`PHWK\OF\FORKH[\O@> E
GLPHWK\ODPLQR EXWHQDPLGR@S\ULGLQHFDUER[DPLGH
cyclin-dependent kinase inhibitor, antineoplastic
PpYRFLFOLE N> SR ^>FKORUR HLQGRO\O S\ULPLGLQ
\O@DPLQR`PpWK\OF\FORKH[\O@> E
GLPpWK\ODPLQR EXWpQDPLGR@S\ULGLQHFDUER[DPLGH
inhibiteur des kinases dépendantes des cyclines,
antinéoplasique
PHYRFLFOLE N> SR ^>FORUR HLQGROLO SLULPLGLQ
LO@DPLQR`PHWLOFLFORKH[LO@> E GLPHWLODPLQR EXW
HQDPLGR@SLULGLQDFDUER[DPLGD
inhibidor de las quinasas dependientes de las ciclinas,
antineoplásico
&+&O12
PH]DJLWDPDEXP
PH]DJLWDPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens&'
$'3ULERV\OF\FODVH @PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5
KLQJH &+ &+(
0 &+6 @
GLVXOILGHZLWKODPEGDOLJKWFKDLQKXPDQL]HG
292
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
>9/$0%'$ Homo sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
@GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 .69FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
Pp]DJLWDPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens&' $'3ULERV\O
F\FODVH @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+5
FKDUQLqUH &+ &+(
0 &+6 @ GLVXOIXUH
DYHFODFKDvQHOpJqUHODPEGDKXPDQLVpH >9/$0%'$ Homo
sapiens,*/9 ,*/- >@
Homo sapiens,*/& @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 OLJQpHFHOOXODLUH.69JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
PH]DJLWDPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens&' $'3ULERVLO
FLFODVD @DQWLFXHUSRPRQRFORQDO
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *PQ*P &+5
ELVDJUD &+ &+(
0 &+6 @ GLVXOIXUR
FRQODFDGHQDOLJHUDODPEGDKXPDQL]DGD >9/$0%'$ Homo
sapiens,*/9 ,*/- >@
Homo sapiens,*/& @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV
FKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYGMSWVRQA PGKGLEWVSD 50
ISWNGGKTHY VDSVKGQFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGS 100
LFHDSSGFYF GHWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK 453
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG DNYVSWYQQL PGTAPKLLIY 50
RDSQRPSGVP DRFSGSKSGT SASLAISGLR SEDEADYYCQ SYDSSLSGSV 100
FGGGTKLTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH
/ 9/ 4
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
293
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
PLODWHJUDVWXP
PLODWHJUDVW F\FORSURS\OPHWK\O >
WHWUDPHWK\OF\FORKH[\O SKHQ\O@SLSHUD]LQH
non-steroidal anti-inflammatory
PLODWpJUDVW F\FORSURS\OPpWK\O >
WpWUDPpWK\OF\FORKH[\O SKpQ\O@SLSpUD]LQH
anti-inflammatoire non-stéroïdien
PLODWHJUDVW FLFORSURSLOPHWLO >
WHWUDPHWLOFLFORKH[LO IHQLO@SLSHUD]LQD
antiinflamatorio no esteroideo
&+1
PLSHWUHVJHQXPDXWROHXFHOXP
PLSHWUHVJHQHDXWROHXFHO $XWRORJRXV7FHOOVWUDQVGXFHGZLWKDUHSOLFDWLRQ
LQFRPSHWHQW0RORQH\PXULQHOHXNHPLDYLUXV 0R0/9
DUHWURYLUXV YHFWRUWKDWHQFRGHVD7FHOOUHFHSWRU
7&5 WKDWUHFRJQL]HV1<(62SURWHLQ FDQFHUWHVWLV
DQWLJHQDXWRLPPXQRJHQLFFDQFHUWHVWLVDQWLJHQ1<
(62&7$*$/DQWLJHQIDPLO\PHPEHU/$*(
cell therapy (antineoplastic)
PLSHWUHVJqQHDXWROHXFHO /\PSKRF\WHV7DXWRORJXHVWUDQVGXLWVSDUXQYHFWHXU
GXYLUXVGHODOHXFpPLHPXULQHGH0RORQH\ 0R0/9
XQUHWURYLUXV LQFRPSpWHQWSRXUODUHSOLFDWLRQHW
FRGDQWSRXUXQUpFHSWHXUGHVO\PSKRF\WHV7 7&5
UHFRQQDLVVDQWODSURWpLQH1<(62 DQWLJqQH
DXWRLPPXQRJpQLTXHDVVRFLpDXFDQFHUGXWHVWLFXOH
1<(62&7$*$PHPEUHGHODIDPLOOHGH
O DQWLJqQH//$*(
thérapie cellulaire (antinéoplasique)
PLSHWUHVJpQDXWROHXFHO /LQIRFLWRV7DXWyORJRVWUDQVGXFLGRVFRQXQYHFWRUGHO
YLUXVGHODOHXFHPLDPXULQDGH0RORQH\ 0R0/9 XQ
UHWURYLUXV LQFRPSHWHQWHSDUDUHSOLFDFLyQTXHFRGLILFD
SDUDXQUHFHSWRUGHOLQIRFLWRV7 7&5 TXHUHFRQRFHOD
SURWHtQD1<(62 DQWtJHQRGHFiQFHUWHVWtFXORV
DQWtJHQRDXWRLQPXQRJpQLFRGHFiQFHUWHVWtFXORV1<
(62&7$*$PLHPEURGHODIDPLOLDGH
DQWtJHQRV//$*(
terapia celular (antineoplásico)
PLU]RWDPDEXP
PLU]RWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
&' %+%+%53 @PRQRFORQDO
DQWLERG\
294
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JDPPDKHDY\FKDLQFKLPHULF >9+ Mus
musculus,*+9 ,*+' ,*+-
Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* Y*P!*PQ*P &+
5!. KLQJH &+
/!$ /!$ &+(
0 &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
PLU]RWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&' %+%+%53 @DQWLFRUSV
PRQRFORQDO
FKDvQHORXUGHJDPPDFKLPpULTXH >9+ Mus
musculus,*+9 ,*+' ,*+-
Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* Y*P!*PQ*P &+
5!. FKDUQLqUH
&+/!$ /!$ &+(
0 &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
PLU]RWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
&' %+%+%53 @DQWLFXHUSR
PRQRFORQDO
FDGHQDSHVDGDJDPPDTXLPpULFD >9+ Mus
musculus,*+9 ,*+' ,*+-
Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* Y*P!*PQ*P &+
5!. ELVDJUD &+
/!$ /!$ &+(
0 &+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
KXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV
GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
295
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
PLU]RWDPDEXPFOH]XWRFOD[XP
PLU]RWDPDEFOH]XWRFOD[ LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&' %+%
+%53 @PRQRFORQDODQWLERG\FRQMXJDWHGZLWKFOH]XWRFOD[DQ
LQKLELWRURI%&// %&/OLNH%&/;/
JDPPDKHDY\FKDLQFKLPHULF >9+ Mus musculus,*+9
,*+' ,*+- Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* Y*P!*PQ*P &+5!.
KLQJH &+/!$ /!$
&+( 0 &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOIDFRQMXJDWHGRQDQ
DYHUDJHRIF\VWHLQ\OZLWKFOH]XWRFOD[FRPSULVLQJDFOHDYDEOH
GLSHSWLGH YDOLQHDODQLQH OLQNHU
immunomodulator, antineoplastic
PLU]RWDPDEFOH]XWRFOD[ LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens&' %+%
+%53 @DQWLFRUSVPRQRFORQDOFRQMXJXpDXFOp]XWRFOD[XQ
LQKLELWHXUGH%&// SURWpLQHDSSDUHQWpHDX%&/%&/;/
FKDvQHORXUGHJDPPDFKLPpULTXH >9+ Mus musculus
,*+9 ,*+' ,*+- Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* Y*P!*PQ*P &+5!.
FKDUQLqUH &+/!$
/!$ &+( 0 &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDKXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOIDFRQMXJXp
296
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
VXUF\VWpLQHVHQPR\HQQHDXFOp]XWRFOD[FRPSUHQDQWXQOLQNHU
GLSHSWLGH YDOLQHDODQLQH FOLYDEOH
immunomodulateur, antinéoplasique
PLU]RWDPDEFOH]XWRFOD[ LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&' %+
%+%53 @DQWLFXHUSRPRQRFORQDOFRQMXJDGRFRQ
FOH]XWRFOD[XQLQKLELGRUGH%&// SURWHtQDYLQFXODGDFRQ
%&/%&/;/
FDGHQDSHVDGDJDPPDTXLPpULFD >9+ Mus musculus
,*+9 ,*+' ,*+- Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* Y*P!*PQ*P &+
5!. ELVDJUD &+/!$
/!$ &+( 0
&+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDKXPDQL]DGD >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOIDFRQMXJDGR
FRQUHVWRVGHFLVWHtQDVSRUWpUPLQRPHGLRFRQFOp]XWRFOD[TXH
FRPSUHQGHXQYLQFXODGRUGLSpSWLGR YDOLQDDODQLQD HVFLQGLEOH
inmunomodulador, antineoplásico
297
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
PRERFHUWLQLEXP
PRERFHUWLQLE SURSDQ\O>^>
GLPHWK\ODPLQR HWK\O@ PHWK\O DPLQR`PHWKR[\ SURS
HQDPLGR DQLOLQR@ PHWK\OHLQGRO\O S\ULPLGLQH
FDUER[\ODWH
tyrosine kinase inhibitor, antineoplastic
PRERFHUWLQLE >^> GLPpWK\ODPLQR pWK\O@ PpWK\O DPLQR`PpWKR[\
SURSpQDPLGR DQLOLQR@ PpWK\OHLQGRO
\O S\ULPLGLQHFDUER[\ODWHGHSURSDQ\OH
inhibiteur de la tyrosine kinase, antinéoplasique
PRERFHUWLQLE >^> GLPHWLODPLQR HWLO@ PHWLO DPLQR`PHWR[L
SURSHQDPLGR DQLOLQR@ PHWLOHLQGRO
LO SLULPLGLQDFDUER[LODWRGHSURSDQLOR
inhibidor de la tirosina quinasa, antineoplásico
&+12
2
+&
+ 1 &+
+1 1 1
&+
1 1 2 &+
+& 1 2
&+ &+ 2 &+
PRQRPHWK\OLVIXPDUDV
PRQRPHWK\OIXPDUDWH E PHWKR[\R[REXWHQRLFDFLG
anti-inflammatory
IXPDUDWHGHPRQRPpWK\OH DFLGH E PpWKR[\R[REXWpQRwTXH
anti-inflammatoire
IXPDUDWRGHPRQRPHWLOR iFLGR E PHWR[LR[REXWHQRLFR
antiinflamatorio
&+2
QDUVRSOLPDEXP
QDUVRSOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens0$63
PDQQDQELQGLQJOHFWLQVHULQHSHSWLGDVHPDQQDQ
ELQGLQJOHFWLQVHULQHSURWHDVHPDQQDQELQGLQJOHFWLQ
VHULQHSURWHDVHSVHXGRJHQH0$633 @Homo
sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ KLQJH6!3
&+ &+ &+6
@ GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo
sapiens >9/$0%'$ Homo sapiens,*/9
,*/- >@ Homo
sapiens,*/& @
298
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 6FHOOOLQHJO\FRIRUPDOID
immunomodulator
QDUVRSOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens 0$63 VpULQHSHSWLGDVH
GHODOHFWLQHOLDQWOHPDQQDQHVpULQHSURWpDVHGHODOHFWLQHOLDQWOH
PDQQDQHSVHXGRJqQHGHODSURWpDVHGHODOHFWLQHOLDQWOHPDQQDQH
0$633 @DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH6!3 &+
&+ &+6 @ GLVXOIXUH
DYHFODFKDvQHOpJqUHODPEGDHomo sapiens >9/$0%'$ Homo
sapiens,*/9 ,*/- >@ Homo
sapiens,*/& @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH6JO\FRIRUPHDOID
immunomodulateur
QDUVRSOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens 0$63 VHULQDSHSWLGDVD
GHODOHFWLQDTXHVHXQHDOPDQDQRVHULQDSURWHDVDGHODOHFWLQDXQLGDDO
PDQDQRSVHXGRJHQGHODSURWHDVDGHODOHFWLQDXQLGDDOPDQDQR
0$633 @DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3 &+
&+ &+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDODPEGDHomo sapiens >9/$0%'$ Homo sapiens
,*/9 ,*/- >@ Homo sapiens
,*/& @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV
GHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU6JOLFRIRUPDDOID
inmunomodulador
299
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
QDYDIHQWHUROXP
QDYDIHQWHURO trans>^> ^> R K\GUR[\ K\GUR[\R[R
GLK\GURTXLQROLQ\O HWK\O@DPLQR`PHWK\O H
EHQ]RWULD]RO\O@SURS\O` PHWK\O DPLQR@F\FORKH[\O
K\GUR[\GL WKLRSKHQ\O DFHWDWH
bronchodilator
QDYDIHQWpURO K\GUR[\GL WKLRSKpQ\O DFpWDWHGHtrans>^>
^> R K\GUR[\ K\GUR[\R[R
GLK\GURTXLQROpLQ\O pWK\O@DPLQR`PpWK\O H
EHQ]RWULD]RO\O@SURS\O` PpWK\O DPLQR@F\FORKH[\OH
bronchodilateur
QDYDIHQWHURO KLGUR[LGL WLRIHQLO DFHWDWRGHtrans>^> ^> R
KLGUR[L KLGUR[LR[RGLKLGURTXLQROHLQ
LO HWLO@DPLQR`PHWLO HEHQ]RWULD]RO
LO@SURSLO` PHWLO DPLQR@FLFORKH[LOR
broncodilatador
&+126
QDYRFDIWRUXP
QDYRFDIWRU ^DPLQR> WULIOXRURPHWKR[\ EHQ]HQH
VXOIRQ\O@S\ULGLQ\O`R[DGLD]RO\O PHWKDQRO
cystic fibrosis transmembrane regulator (CFTR)
protein modulator
QDYRFDIWRU ^DPLQR> WULIOXRURPpWKR[\ EHQ]qQH
VXOIRQ\O@S\ULGLQ\O`R[DGLD]RO\O PpWKDQRO
modulateur de la protéine régulatrice de la
perméabilité transmembranaire impliquée dans la
mucoviscidose (CFTR)
QDYRFDIWRU ^DPLQR> WULIOXRURPHWR[L EHQFHQR
VXOIRQLO@SLULGLQLO`R[DGLD]ROLO PHWDQRO
modulador de la proteína reguladora de la
conductancia transmembrana de la fibrosis quística
(CFTR)
&+)126
300
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
QHORQHPGD]XP
QHORQHPGD] K\GUR[\ ^>WHWUDIOXRUR
WULIOXRURPHWK\O SKHQ\O@PHWK\O`DPLQR EHQ]RLFDFLG
N-methyl-D-aspartate (NMDA) receptor antagonist
QpORQHPGD] DFLGHK\GUR[\ ^>WpWUDIOXRUR
WULIOXRURPpWK\O SKpQ\O@PpWK\O`DPLQR EHQ]RwTXH
antagoniste des récepteurs du NMDA
QHORQHPGD] iFLGRKLGUR[L ^>WHWUDIOXRUR
WULIOXRURPHWLO IHQLO@PHWLO`DPLQR EHQ]RLFR
antagonista del receptor de NMDA
&+)12
QHULQGRFLDQLQXP
QHULQGRFLDQLQH ^ E >^ E >GLPHWK\OVXOIR
VXOIREXW\O GLK\GURHLQGRO\OLGHQH@HWK\OLGHQH`
VXOIRSKHQR[\ F\FORKH[HQ\O@HWKHQ\O`
GLPHWK\O VXOIREXW\O HLQGROLXPVXOIRQDWH
fluorescent diagnostic contrast agent
QpULQGRFLDQLQH ^ E >^ E >GLPpWK\OVXOIR
VXOIREXW\O GLK\GURHLQGRO\OLGqQH@pWK\OLGqQH`
VXOIRSKpQR[\ F\FORKH[pQ\O@pWKpQ\O`
GLPpWK\O VXOIREXW\O HLQGROLXPVXOIRQDWH
substance fluorescente à usage diagnostique
QHULQGRFLDQLQD ^ E >^ E >GLPHWLOVXOIR VXOIREXWLO
GLKLGURHLQGROLOLGHQR@HWLOLGHQR`
VXOIRIHQR[L FLFORKH[HQLO@HWHQLO`GLPHWLO
VXOIREXWLO HLQGROLXPVXOIRQDWR
agente de contraste fluorescente de diagnóstico
&+126
QRJDSHQGHNLQXPDOID
QRJDSHQGHNLQDOID KXPDQLQWHUOHXNLQ>DVSDUWLFDFLG@ KXPDQ,/
1!'LVRIRUP SURGXFHGLQ&KLQHVHKDPVWHURYDU\
&+2 FHOOVJO\FRIRUPDOID
interleukin type substance
301
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
QRJDSHQGpNLQHDOID LQWHUOHXNLQHKXPDLQH>DFLGHDVSDUWLTXH@ ,/
KXPDLQHLVRIRUPH1!' SURGXLWSDUGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
dérivé de l'interleukine
QRJDSHQGHNLQDDOID LQWHUOHXNLQDKXPDQD>iFLGRDVSiUWLFR@ ,/KXPDQD
LVRIRUPD1!' SURGXFLGRSRUODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
derivado de la interleukina
QXPLGDUJLVWDWXP
QXPLGDUJLVWDW RS DPLQR> S DPLQRSURSDQR\O@
ERURQRSURS\O S\UUROLGLQHFDUER[\OLFDFLG
arginase inhibitor, antineoplastic
QXPLGDUJLVWDW DFLGH RS DPLQR> S DPLQRSURSDQR\O@
ERURQRSURS\O S\UUROLGLQHFDUER[\OLTXH
inhibiteur de l'arginase, antinéoplasique
QXPLGDUJLVWDW iFLGR RS DPLQR> S DPLQRSURSDQRLO@
ERURQRSURSLO SLUUROLGLQDFDUER[tOLFR
inhibidor de la arginasa, antineoplásico
&+%12
QXUXOLPDEXP
QXUXOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&7/$
F\WRWR[LF7O\PSKRF\WHDVVRFLDWHGSURWHLQ&7/$
&' @Homo sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
*P &+.!5 KLQJH
&+ &+' / &+6
*!GHO.!GHO @ GLVXOILGHZLWKNDSSD
OLJKWFKDLQHomo sapiens >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 .6FHOOOLQH
JO\FRIRUPDOID
immunomodulator, antineoplastic
302
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
QXUXOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens&7/$
SURWpLQHDVVRFLpHDX[O\PSKRF\WHV7F\WRWR[LTXHV&7/$
&' @DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
*P &+.!5 FKDUQLqUH
&+ &+' /
&+6*!GHO.!GHO @ GLVXOIXUHDYHFOD
FKDvQHOpJqUHNDSSDHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 OLJQpHFHOOXODLUH.6JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
QXUXOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&7/$
SURWHtQDDVRFLDGDFRQOLQIRFLWRV7FLWRWy[LFDV&7/$
&' @DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
*P &+.!5 ELVDJUD
&+ &+' / &+6
*!GHO.!GHO @ GLVXOIXURFRQODFDGHQD
OLJHUDNDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV
FKLQRV &+2 OtQHDFHOXODU.6JOLFRIRUPDDOID
inmunomodulador, antineoplásico
303
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
REDILVWDWXP
REDILVWDW > IOXRUREHQ]HQHVXOIRQ\O
GLD]DELF\FOR>@RFWDQ\O@ HWULD]RO
\O PHWKDQRQH
aldo-keto reductase AKR1C3 inhibitor
REDILVWDW > IOXRUREHQ]qQHVXOIRQ\O
GLD]DELF\FOR>@RFWDQ\O@ HWULD]RO
\O PpWKDQRQH
inhibiteur de l'aldo-cétoréductase AKR1C3
REDILVWDW > IOXRUREHQFHQRVXOIRQLO
GLD]DELFLFOR>@RFWDQLO@ HWULD]ROLO PHWDQRQD
inhibidor de la aldo-ceto reductasa AKR1C3
&+)126
RGHVLYLPDEXP
RGHVLYLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Zaire ebolavirus =DLUH
(ERODYLUXV (%29 HQYHORSHJO\FRSURWHLQ *3 @Homo
sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+. KLQJH
&+ &+' /
&+6 @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antiviral
RGpVLYLPDE LPPXQRJOREXOLQH*NDSSDDQWL>JO\FRSURWpLQH
G HQYHORSSH *3 GHZaire ebolaviruV YLUXV(EROD=DwUH
(%29 @DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+. FKDUQLqUH
&+ &+' /
&+6 @ GLVXOIXUH
DYHFODFKDvQHOpJqUHNDSSDHomo sapiens >9
.$33$ Homo sapiens ,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antiviral
304
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
RGHVLYLPDE LQPXQRJOREXOLQD*NDSSDDQWL>JOLFRSURWHtQDGH
HQYROWXUD *3 GHZaire ebolaviruV YLUXV(EROD=DwUH
(%29 @DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *P &+.
ELVDJUD &+ &+
' / &+6
@ GLVXOIXURFRQODFDGHQDOLJHUDNDSSD
Homo sapiens >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV
GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antiviral
RGURQH[WDPDEXP
RGURQH[WDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
06$ PHPEUDQHVSDQQLQJGRPDLQVVXEIDPLO\$
PHPEHU&' @DQGDQWL>Homo sapiens&'(
&'HSVLORQ @Homo sapiensPRQRFORQDODQWLERG\
ELVSHFLILF
JDPPDKHDY\FKDLQHomo sapiensDQWL06$
>9+ Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH6!3
&+() !3 /!9
*!$ &+ &+6
@ GLVXOILGHZLWKNDSSDOLJKW
FKDLQHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
305
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JDPPDKHDY\FKDLQHomo sapiensDQWL&'(
>9+ Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
KLQJH6!3 ´´ &+()
!3 /!9 *!$ ´´ &+
+!5 <!) ´´ &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
Homo sapiens >9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUP
DOID
immunomodulator, antineoplastic
RGURQH[WDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens06$
PHPEUHGHODVRXVIDPLOOH$jGRPDLQHV
WUDQVPHPEUDQDLUHV&' @HWDQWL>Homo sapiens&'(
&'HSVLORQ @DQWLFRUSVPRQRFORQDOHomo sapiens
ELVSpFLILTXH
FKDvQHORXUGHJDPPDHomo sapiensDQWL06$
>9+ Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
FKDUQLqUH6!3 &+
() !3 /!9 *!$
&+ &+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens ¶
¶ >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @
FKDvQHORXUGHJDPPDHomo sapiensDQWL&'(
>9+ Homo sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
FKDUQLqUH6!3 &+
() !3 /!9 *!$
&++!5 <!) &+6
@ GLVXOIXUHDYHFODFKDvQH
OpJqUHNDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
RGURQH[WDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens06$
PLHPEURGHODVXEIDPLOLD$GHGRPLQLRV
WUDQVPHPEUDQDULRV&' @\DQWL>Homo sapiens&'(
&'pSVLORQ @DQWLFXHUSRPRQRFORQDOHomo sapiens
ELHVSHFtILFR
FDGHQDSHVDGDJDPPDHomo sapiensDQWL06$
>9+ Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
ELVDJUD6!3 &+
() !3 /!9 *!$
&+ &+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens ¶¶
>9.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @
306
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FDGHQDSHVDGDJDPPDHomo sapiensDQWL&'(
>9+ Homo sapiens ,*+9
,*+' ,*+- >@ Homo
sapiens,*+* &+ ELVDJUD
6!3 &+() !3
/!9 *!$ &++!5
<!) &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL&'
EVQLVESGGG LVQPGRSLRL SCVASGFTFN DYAMHWVRQA PGKGLEWVSV 50
ISWNSDSIGY ADSVKGRFTI SRDNAKNSLY LQMHSLRAED TALYYCAKDN 100
HYGSGSYYYY QYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPP VAGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300
QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350
EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450
LGK 453
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL&'
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYTMHWVRQA PGKGLEWVSG 50
ISWNSGSIGY ADSVKGRFTI SRDNAKKSLY LQMNSLRAED TALYYCAKDN 100
SGYGHYYYGM DVWGQGTTVT VASASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNRFTQ KSLSLSLGK 449
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG 50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQH YINWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
RODIHUWLQLEXP
RODIHUWLQLE N> ^GLIOXRUR> K\GUR[\HWK\O SLSHUD]LQ
\O@DQLOLQR`TXLQD]ROLQ\O SKHQ\O@SURSHQDPLGH
tyrosine kinase inhibitor, antineoplastic
RODIHUWLQLE N> ^GLIOXRUR> K\GUR[\pWK\O SLSpUD]LQ
\O@DQLOLQR`TXLQD]ROLQ\O SKpQ\O@SURSpQDPLGH
inhibiteur de la tyrosine kinase, antinéoplasique
307
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
RODIHUWLQLE N> ^GLIOXRUR> KLGUR[LHWLO SLSHUD]LQ
LO@DQLOLQR`TXLQD]ROLQLO IHQLO@SURSHQDPLGD
inhibidor de la tirosina quinasa, antineoplásico
&+)12
ROLWUHVJHQXPDXWROHXFHOXP
ROLWUHVJHQHDXWROHXFHO DXWRORJRXV&'DQG&'7FHOOVWUDQVGXFHGZLWKD
QRQUHSOLFDWLQJKXPDQLPPXQRGHILFLHQF\YLUXV +,9
GHULYHGVHOILQDFWLYDWLQJ 6,1 YHFWRUWKDWFRPSULVHVD
/75 569 58 DQGD 8GHOHWHG/75 85+,9
'HOWD /75 HQFRGLQJD0$*($ 0$*(IDPLO\
PHPEHU$0$*(DQWLJHQPHODQRPDDQWLJHQIDPLO\
$ VSHFLILF7FHOOUHFHSWRU 7&5 XQGHUWKHFRQWURORI
HORQJDWLRQIDFWRUDOSKD ()D SURPRWHU7KHYHFWRULV
SVHXGRW\SHGZLWKYHVLFXODUVWRPDWLWLVYLUXVJO\FRSURWHLQ*
969*
5695RXVVDUFRPDYLUXV
cell therapy (antineoplastic)
ROLWUHVJqQHDXWROHXFHO O\PSKRF\WHV7&'HW&'DXWRORJXHVWUDQVGXLWVSDU
XQYHFWHXUDXWRLQDFWLYDQW 6,1 QRQUpSOLTXDQWGpULYpGX
YLUXVGHO LPPXQRGpILFLHQFHQFHKXPDLQH 9,+ FRQWHQDQW
XQHVpTXHQFH/75 WHUPLQDOHORQJXHUpSpWpH HQ
569 58 HWXQHVpTXHQFH/75GRQWOHGRPDLQH8
HVWVXSSULPp 859,+'HOWD /75 HWTXLFRGHSRXU
XQUpFHSWHXUGHVO\PSKRF\WHV7 7&5 VSpFLILTXHGX
0$*($ PHPEUH$GHODIDPLOOH0$*(DQWLJqQH
0$*(IDPLOOHGHVDQWLJHQVGHPpODQRPH$ VRXV
OHFRQWU{OHG XQSURPRWHXUGXIDFWHXUG pORQJDWLRQDOSKD
()D /HYHFWHXUHVWSVHXGRW\SpDYHFODJO\FRSURWpLQH*
GHO HQYHORSSHGHODVWRPDWLWHYpVLFXODLUH 969*
569YLUXVGXVDUFRPHGH5RXV
thérapie cellulaire (antinéoplasique)
ROLWUHVJpQDXWROHXFHO OLQIRFLWRV7&'\&'DXWyORJRVWUDQVGXFLGRVFRQXQ
YHFWRUDXWRLQDFWLYDQWH 6,1 QRUHSOLFDWLYRGHULYDGRGHO
YLUXVGHODLQPXQRGHILFLHQFLDKXPDQD 9,+ TXHFRQWLHQH
XQD/75HQ 569 58 \XQD/75FRQ8
GHOHFLRQDGDHQ 85+,9'HOWD /75 \TXHFRGLILFD
SDUDXQUHFHSWRUGHOLQIRFLWRV7 7&5 HVSHFtILFRSDUD
0$*($ PLHPEUR$GHODIDPLOLD0$*(DQWtJHQR
0$*(IDPLOLDGHDQWtJHQRVGHPHODQRPD$ EDMR
HOFRQWUROGHOSURPRWRUGHOIDFWRUGHHORQJDFLyQDOID
()D (OYHFWRUHVWiVHXGRWLSDGRFRQODJOLFRSURWHtQD*
GHOYLUXVGHODHVWRPDWLWLVYHVLFXODU 969*
569YLUXVGHOVDUFRPDGH5RXV
terapia celular (antineoplásico)
308
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
ROSDVLUDQXP
ROSDVLUDQ allPambo O^ SS > DFHWDPLGRGHR[\ȕ'
JDODFWRS\UDQRV\O R[\@ELV> ^> DFHWDPLGRGHR[\ȕ
'JDODFWRS\UDQRV\O R[\@HWKR[\`HWK\O FDUEDPR\O@K\GUR[\
WULR[RVXOIDQ\OLGHQHRFWDR[D
WULD]DȜSKRVSKDQRQDWULDFRQWDQ\O` OPHWK\OP
WKLRF\WLG\O\O ĺ OPHWK\ODGHQ\O\O ĺ O
PHWK\OJXDQ\O\O ĺ OPHWK\OF\WLG\O\O ĺ O
PHWK\OF\WLG\O\O ĺ OPHWK\OF\WLG\O\O ĺ O
PHWK\OF\WLG\O\O ĺ OPHWK\OXULG\O\O ĺ GHR[\
IOXRURXULG\O\O ĺ GHR[\ IOXRURDGHQ\O\O ĺ GHR[\
IOXRURXULG\O\O ĺ OPHWK\OXULG\O\O ĺ O
PHWK\OJXDQ\O\O ĺ OPHWK\OXULG\O\O ĺ O
PHWK\OXULG\O\O ĺ OPHWK\ODGHQ\O\O ĺ O
PHWK\OXULG\O\O ĺ OPHWK\ODGHQ\O\O ĺ O
PHWK\OF\WLG\O\O ĺ OPHWK\OPWKLRJXDQ\O\O ĺ
GHR[\DGHQRVLQHGXSOH[ZLWKallPambo OPHWK\OP
WKLRJXDQ\O\O ĺ GHR[\ IOXRURPWKLRXULG\O\O ĺ
OPHWK\OF\WLG\O\O ĺ GHR[\ IOXRURJXDQ\O\O ĺ O
PHWK\OJXDQ\O\O ĺ GHR[\ IOXRURJXDQ\O\O ĺ O
PHWK\OJXDQ\O\O ĺ GHR[\ IOXRURDGHQ\O\O ĺ O
PHWK\ODGHQ\O\O ĺ GHR[\ IOXRURXULG\O\O ĺ O
PHWK\ODGHQ\O\O ĺ OPHWK\ODGHQ\O\O ĺ O
PHWK\OF\WLG\O\O ĺ OPHWK\ODGHQ\O\O ĺ O
PHWK\ODGHQ\O\O ĺ GHR[\ IOXRURXULG\O\O ĺ O
PHWK\ODGHQ\O\O ĺ GHR[\ IOXRURXULG\O\O ĺ O
PHWK\OPWKLRJXDQ\O\O ĺ GHR[\ IOXRURPWKLRF\WLG\O\O
ĺ OPHWK\OXULGLQH
antiatherosclerosis
ROSDVLUDQ toutPambo O^ SS > DFpWDPLGRGpVR[\ȕ'
JDODFWRS\UDQRV\O R[\@ELV> ^> DFpWDPLGRGpVR[\ȕ
'JDODFWRS\UDQRV\O R[\@pWKR[\`pWK\O FDUEDPR\O@K\GUR[\
WULR[RVXOIDQ\OLGqQHRFWDR[D
WULD]DȜSKRVSKDQRQDWULDFRQWDQ\O` OPpWK\OP
WKLRF\WLG\O\O ĺ OPpWK\ODGpQ\O\O ĺ O
PpWK\OJXDQ\O\O ĺ OPpWK\OF\WLG\O\O ĺ O
PpWK\OF\WLG\O\O ĺ OPpWK\OF\WLG\O\O ĺ O
PpWK\OF\WLG\O\O ĺ OPpWK\OXULG\O\O ĺ GpVR[\
IOXRURXULG\O\O ĺ GpVR[\ IOXRURDGpQ\O\O ĺ
GpVR[\ IOXRURXULG\O\O ĺ OPpWK\OXULG\O\O ĺ O
PpWK\OJXDQ\O\O ĺ OPpWK\OXULG\O\O ĺ O
PpWK\OXULG\O\O ĺ OPpWK\ODGpQ\O\O ĺ O
PpWK\OXULG\O\O ĺ OPpWK\ODGpQ\O\O ĺ O
PpWK\OF\WLG\O\O ĺ OPpWK\OPWKLRJXDQ\O\O ĺ
GpVR[\DGpQRVLQHGXSOH[DYHFtoutPambo OPpWK\OP
WKLRJXDQ\O\O ĺ GpVR[\ IOXRURPWKLRXULG\O\O ĺ
OPpWK\OF\WLG\O\O ĺ GpVR[\ IOXRURJXDQ\O\O ĺ
OPpWK\OJXDQ\O\O ĺ GpVR[\ IOXRURJXDQ\O\O ĺ
OPpWK\OJXDQ\O\O ĺ GpVR[\ IOXRURDGpQ\O\O ĺ
OPpWK\ODGpQ\O\O ĺ GpVR[\ IOXRURXULG\O\O ĺ
OPpWK\ODGpQ\O\O ĺ OPpWK\ODGpQ\O\O ĺ O
PpWK\OF\WLG\O\O ĺ OPpWK\ODGpQ\O\O ĺ O
PpWK\ODGpQ\O\O ĺ GpVR[\ IOXRURXULG\O\O ĺ O
PpWK\ODGpQ\O\O ĺ GpVR[\ IOXRURXULG\O\O ĺ O
PpWK\OPWKLRJXDQ\O\O ĺ GpVR[\ IOXRURPWKLRF\WLG\O\O
ĺ OPpWK\OXULGLQH
antiathérosclérose
309
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ROSDVLUiQ todoPambo O^ SS > DFHWDPLGRGHVR[Lȕ'
JDODFWRSLUDQRVLO R[L@ELV> ^> DFHWDPLGRGHVR[Lȕ'
JDODFWRSLUDQRVLO R[L@HWR[L`HWLO FDUEDPRLO@KLGUR[LWULR[R
VXOIDQLOLGHQRRFWDR[DWULD]DȜ
IRVIDQRQDWULDFRQWDQLO` OPHWLOPWLRFLWLGLOLO ĺ O
PHWLODGHQLOLO ĺ OPHWLOJXDQLOLO ĺ OPHWLOFLWLGLOLO ĺ
OPHWLOFLWLGLOLO ĺ OPHWLOFLWLGLOLO ĺ OPHWLOFLWLGLOLO
ĺ OPHWLOXULGLOLO ĺ GHVR[L IOXRURXULGLOLO ĺ
GHVR[L IOXRURDGHQLOLO ĺ GHVR[L IOXRURXULGLOLO ĺ O
PHWLOXULGLOLO ĺ OPHWLOJXDQLOLO ĺ OPHWLOXULGLOLO ĺ
OPHWLOXULGLOLO ĺ OPHWLODGHQLOLO ĺ OPHWLOXULGLOLO
ĺ OPHWLODGHQLOLO ĺ OPHWLOFLWLGLOLO ĺ OPHWLOP
WLRJXDQLOLO ĺ GHVR[LDGHQRVLQDG~SOH[FRQtodoPambo O
PHWLOPWLRJXDQLOLO ĺ GHVR[L IOXRURPWLRXULGLOLO ĺ O
PHWLOFLWLGLOLO ĺ GHVR[L IOXRURJXDQLOLO ĺ OPHWLOJXDQLOLO
ĺ GHVR[L IOXRURJXDQLOLO ĺ OPHWLOJXDQLOLO ĺ
GHVR[L IOXRURDGHQLOLO ĺ OPHWLODGHQLOLO ĺ GHVR[L
IOXRURXULGLOLO ĺ OPHWLODGHQLOLO ĺ OPHWLODGHQLOLO ĺ
OPHWLOFLWLGLOLO ĺ OPHWLODGHQLOLO ĺ OPHWLODGHQLOLO
ĺ GHVR[L IOXRURXULGLOLO ĺ OPHWLODGHQLOLO ĺ
GHVR[L IOXRURXULGLOLO ĺ OPHWLOPWLRJXDQLOLO ĺ GHVR[L
IOXRURPWLRFLWLGLOLO ĺ OPHWLOXULGLQD
antiateroesclerosis
&+)1236
RPLGXELFHOXP
RPLGXELFHO DOORJHQHLFKXPDQXPELOLFDOFRUGEORRGGHULYHGKHPDWRSRLHWLF&'
SURJHQLWRUFHOOVex-vivoH[SDQGHGLQWKHSUHVHQFHRIQLFRWLQDPLGH
DQGF\WRNLQHV
cell therapy (stem cell transplantation)
RPLGXELFHO FHOOXOHVSURJpQLWULFHVKpPDWRSRwpWLTXHV&'KXPDLQHV
DOORJpQLTXHVGpULYpHVGXVDQJGHFRUGRQRPELOLFDOHQFXOWXUH
G¶H[SDQVLRQex vivoHQSUpVHQFHGHQLFRWLQDPLGHHWGHF\WRNLQHV
thérapie cellulaire (greffe de cellules souches)
RPLGXELFHO FpOXODVSURJHQLWRUDVKHPDWRSR\pWLFDV&'DORJpQLFDVKXPDQDV
GHULYDGDVGHVDQJUHGHFRUGyQXPELOLFDOH[SDQGLGDVex vivoHQ
SUHVHQFLDGHQLFRWLQDPLGD \FLWRFLQDV
terapia celular (transplante de células madres
310
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
RQYDQVHUWLEXP
RQYDQVHUWLE K\GUR[\HWK\O > PHWK\OSLSHUD]LQ\O
WULIOXRURPHWKR[\ DQLOLQR@GLK\GURHS\UD]ROR>
h@TXLQD]ROLQHFDUER[DPLGH
antineoplastic
RQYDQVHUWLE K\GUR[\pWK\O > PpWK\OSLSpUD]LQ\O
WULIOXRURPpWKR[\ DQLOLQR@GLK\GURHS\UD]ROR>
h@TXLQD]ROLQHFDUER[DPLGH
antinéoplasique
RQYDQVHUWLE KLGUR[LHWLO > PHWLOSLSHUD]LQLO
WULIOXRURPHWR[L DQLOLQR@GLKLGURHSLUD]ROR>
h@TXLQD]ROLQDFDUER[DPLGD
antineoplásico
&+)12
RULVPLODVWXP
RULVPLODVW GLFKORUR^> GLIOXRURPHWKR[\ GLR[R Ȝ
VSLUR>>@EHQ]RGLR[ROH WKLDQ@\O@
R[RHWK\O`S\ULGLQHR[LGH
phosphodiesterase IV inhibitor
RULVPLODVW R[\GHGHGLFKORUR^> GLIOXRURPpWKR[\
GLR[R ȜVSLUR>>@EHQ]RGLR[ROH WKLDQ@\O@
R[RpWK\O`S\ULGLQH
inhibiteur de la phosphodiestérase IV
RULVPLODVW y[LGRGHGLFORUR^> GLIOXRURPHWR[L
GLR[R ȜVSLUR>>@EHQ]RGLR[RO WLDQ@LO@
R[RHWLO`SLULGLQD
inhibidor de la fosfodiesterasa IV
&+&O)126
RWHQDSUR[HVXOXP
RWHQDSUR[HVXO FDUEDPRWKLR\OSKHQ\O S PHWKR[\QDSKWKDOHQ
\O SURSDQRDWH
non-steroidal anti-inflammatory
311
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
RWpQDSUR[pVXO S PpWKR[\QDSKWDOpQ\O SURSDQRDWHGH
FDUEDPRWKLR\OSKpQ\OH
anti-inflammatoire non-stéroïdien
RWHQDSUR[HVXO S PHWR[LQDIWDOHQLO SURSDQRDWRGH
FDUEDPRWLRLOIHQLOR
antiinflamatorio no esteroideo
&+126
SDFPLOLPDEXP
SDFPLOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &'
SURJUDPPHGFHOOGHDWKOLJDQG%+%+
3'/3'/3'&'/%KRPRORJ%
KRPRORJXH @Homo sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH6!3
&+ &+ &+6
.!GHO @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQHomo sapiens >1WHUPLQDO
UHJLRQ PHUOLQNHU SURWHDVH
FOHDYDEOHUHJLRQ PHUOLQNHU 9
.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 GHULYHG
FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
SDFPLOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&' OLJDQGGHPRUWSURJUDPPpH%+%+
3'/3'/3'&'/KRPRORJXHGH% @
DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH6!3
&+ &+ &+6
.!GHO @ GLVXOIXUHDYHFOD
FKDvQHOpJqUHNDSSDHomo sapiens >UpJLRQ
1WHUPLQDOH PHUOLQNHU UpJLRQ
FOLYDEOHSDUGHVSURWpDVHV PHUOLQNHU
9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPqUH ELVGLVXOIXUH
SURGXLWHGDQVXQHOLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH
DOID
immunomodulateur, antinéoplasique
312
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
SDFPLOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
&' OLJDQRGHPXHUWHSURJUDPDGD%+%
+3'/3'/3'&'/KRPyORJRGH% @
DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3
&+ &+ &+6
.!GHO @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDHomo sapiens >UHJLyQ
1WHUPLQDO FRQHFWRUPHU UHJLyQ
HVFLQGLEOHSRUODVSURWHDVDV FRQHFWRUPHU
9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@GtPHUR
ELVGLVXOIXURSURGXFLGRHQXQDOtQHDFHOXODUGHULYDGD
GHODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS 50
IWRNGIVTVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS 100
AAFDYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG 442
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
QGQSGSGIAL CPSHFCQLPQ TGGGSSGGSG GSGGISSGLL SGRSDNHGGS 50
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA 100
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ DNGYPSTFGG 150
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 200
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 250
LSSPVTKSFN RGEC 264
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWUD/ 1WHUPLQDO UHJLRQ
,QWHU+/ &+ &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
SDOWXVRWLQXP
SDOWXVRWLQH > DPLQRSLSHULGLQ\O
GLIOXRURSKHQ\O TXLQROLQ\O@K\GUR[\EHQ]RQLWULOH
somatostatin receptor agonist
SDOWXVRWLQH > DPLQRSLSpULGLQ\O
GLIOXRURSKpQ\O TXLQROpLQ\O@K\GUR[\EHQ]RQLWULOH
agoniste des récepteurs de la somatostatine
SDOWXVRWLQD > DPLQRSLSHULGLQLO
GLIOXRURIHQLO TXLQROHLQLO@KLGUR[LEHQ]RQLWULOR
agonista de los receptores de la somatostatina
313
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
&+)12
SDPXIHWLQLEXP
SDPXIHWLQLE IOXRUR
^> SKHQ\ODFHW\O FDUEDPRWKLR\O@DPLQR`SKHQR[\
PHWKR[\NPHWK\OTXLQROLQHFDUER[DPLGH
tyrosine kinase inhibitor, antineoplastic
SDPXIpWLQLE IOXRUR
^> SKpQ\ODFpW\O FDUEDPRWKLR\O@DPLQR`SKpQR[\
PpWKR[\NPpWK\OTXLQROpLQHFDUER[DPLGH
inhibiteur de la tyrosine kinase, antinéoplasique
SDPXIHWLQLE IOXRUR^> IHQLODFHWLO FDUEDPRWLRLO@DPLQR`IHQR[L
PHWR[LNPHWLOTXLQROHtQDFDUER[DPLGD
inhibidor de la tirosina quinasa, antineoplásico
&+)126
SDWULWXPDEXPGHUX[WHFDQXP
SDWULWXPDEGHUX[WHFDQ LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
(5%% UHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%
+(5 @Homo sapiensPRQRFORQDODQWLERG\
FRQMXJDWHGWRGHUX[WHFDQFRPSULVLQJDOLQNHUDQGD
FDPSWRWKHFLQGHULYDWLYH
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
KLQJH &+ &+
( 0 &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @
314
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 FHOOOLQHJO\FRIRUP
DOIDFRQMXJDWHGRQDQDYHUDJHRIF\VWHLQ\OWR
GHUX[WHFDQFRPSULVLQJDOLQNHUDQGDFDPSWRWKHFLQ
GHULYDWLYH
)RUWKHderuxtecanSDUWSOHDVHUHIHUWRWKHSURS,11/LVW
SXEOLVKHGLQthe WHO Drug Information, Vol.30, No.4, 2016.
immunomodulator, antineoplastic
SDWULWXPDEGpUX[WHFDQ LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
(5%% UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE%
+(5 @DQWLFRUSVPRQRFORQDOHomo sapiens,
FRQMXJXpDXGpUX[WpFDQFRPSUHQDQWXQOLQNHUHWXQ
GpULYpGHODFDPSWRWKpFLQH
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
FKDUQLqUH &+
&+( 0 &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOIDFRQMXJXpVXUXQHPR\HQQHGH
F\VWpLQ\ODXGpUX[WpFDQFRPSUHQDQWXQOLQNHUHWXQ
GpULYpGHODFDPSWRWKpFLQH
3RXUODSDUWLHdéruxtécanYHXLOOH]YRXVUpIpUHUjOD/LVWH
GHV'&,SURSSXEOLpHGDQVOHWHO Drug Information, Vol.30,
No.4, 2016.
immunomodulateur, antinéoplasique
SDWULWXPDEGHUX[WHFiQ LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
(5%% UHFHSWRUWLURVLQDSURWHtQDNLQDVDHUE%
+(5 @DQWLFXHUSRPRQRFORQDOHomo sapiens,
FRQMXJDGRFRQGHUX[WHFiQTXHFRPSUHQGHXQ
FRQHFWRU\XQGHULYDGRGHODFDPSWRWHFLQD
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
ELVDJUD &+
&+( 0 &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOIDFRQMXJDGRFRQUHVWRVFLVWHLQLOSRU
WpUPLQRPHGLRFRQGHUX[WHFiQTXHFRPSUHQGHXQ
FRQHFWRU\XQGHULYDGRGHODFDPSRWHFLQD
3DUDODIUDFFLyQderuxtecánVHSXHGHUHIHULUDOD/LVWDGH
'&,SURSSXEOLFDGDHQHOWHO Drug Information, Vol.30,
No.4, 2016.
inmunomodulador, antineoplásico
315
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE 50
INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100
TWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP 50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1RQH RI WKH IRXU LQWHUFKDLQ GLVXOILGH EULGJHV LV SUHVHQW DQ DYHUDJH RI F\VWHLQ\O
EHLQJ FRQMXJDWHG HDFK YLD D WKLRHWKHU ERQG WR D GUXJ OLQNHU
$XFXQ GHV TXDWUH SRQWV GLVXOIXUHV LQWHUFKDvQHV HVW SUpVHQW F\VWpLQ\O HQ PR\HQQH
pWDQW FKDFXQ FRQMXJXp YLD XQH OLDLVRQ WKLRpWKHU j XQ OLQNHUSULQFLSH DFWLI
1LQJXQR GH ORV FXDWUR SXHQWHV GLVXOIXUR LQWHUFDWHQDULRV HVWD SUHVHQWH XQD PHGLD
GH FLVWHLQLO HVWi FRQMXJDGD D FRQHFWRUHV GH SULQFLSLR DFWLYR
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
3RWHQWLDO PRGLILHG UHVLGXHV UpVLGXV PRGLILpV SRWHQWLHOV UHVWRV PRGLILFDGRV SRWHQFLDOHV
2 2
+
*O\ *O\ 3KH *O\ 1 2 2
1+
+
1 2
&
2
2 1
1 &2+ 2+
+ +&
6 &+
2
+ 1+ )
SD[DOLVLEXP
SD[DOLVLE >GLPHWK\O PRUSKROLQ\O GLK\GURH
>@R[D]LQR>e@SXULQ\O@S\ULPLGLQDPLQH
phosphatidylinositol 3-kinase (PI3K) inhibitor,
antineoplastic
SD[DOLVLE >GLPpWK\O PRUSKROLQ\O GLK\GURH
>@R[D]LQR>e@SXULQ\O@S\ULPLGLQDPLQH
inhibiteur de phosphatidylinositol 3-kinase (PI3K),
antinéoplasique
SD[DOLVLE >GLPHWLO PRUIROLQLO GLKLGURH
>@R[D]LQR>e@SXULQLO@SLULPLGLQDPLQD
inhibidor de fosfatidilinositol 3-quinasa (PI3K),
antineoplásico
316
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
&+12
SHWRVHPWDPDEXP
SHWRVHPWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens (*)5 HSLGHUPDO
JURZWKIDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%
(5%%+(5+(5(5%% @DQGDQWL>Homo sapiens /*5
OHXFLQHULFKUHSHDWFRQWDLQLQJ*SURWHLQFRXSOHGUHFHSWRU*
SURWHLQFRXSOHGUHFHSWRU*35*35 @Homo sapiens
PRQRFORQDODQWLERG\ELVSHFLILF
JDPPDKHDY\FKDLQHomo sapiens DQWL(*)5 >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 KLQJH
&+ &+/!' ( 0 /!(
&+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@
JDPPDKHDY\FKDLQHomo sapiens DQWL/*5 >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 KLQJH
&+ &+/!. ( 0 7!.
&+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
SpWRVHPWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(*)5 UpFHSWHXU
GXIDFWHXUGHFURLVVDQFHpSLGHUPLTXHUpFHSWHXUW\URVLQHSURWpLQH
NLQDVHHUE(5%%+(5+(5(5%% @HWDQWL>Homo
sapiens /*5 UpFHSWHXUjUpSpWLWLRQVULFKHVHQOHXFLQHFRXSOpj
ODSURWpLQH*UpFHSWHXUFRXSOpjODSURWpLQH**35
*35 @DQWLFRUSVPRQRFORQDOHomo sapiens,ELVSpFLILTXH
FKDvQHORXUGHJDPPDHomo sapiensDQWL(*)5 >9+
Homo sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 FKDUQLqUH
&+ &+/!' ( 0
/!( &+6.!GHO @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens >9
.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P$
9 @
317
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FKDvQHORXUGHJDPPDHomo sapiensDQWL/*5
>9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5
FKDUQLqUH &+
&+/!. ( 0 7!.
&+6.!GHO @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
SHWRVHPWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(*)5
UHFHSWRUGHOIDFWRUGHFUHFLPLHQWRHSLGpUPLFR
UHFHSWRUWLURVLQDSURWHtQDNLQDVDHUE(5%%+(5
+(5(5%% @\DQWL>Homo sapiens /*5 UHFHSWRU
GHDUHSHWLFLRQHVULFDVHQOHXFLQDDFRSODGDDOD
SURWHtQD*UHFHSWRUDFRSODGRDODSURWHtQD*
*35*35 @DQWLFXHUSRPRQRFORQDOHomo
sapiens,ELHVSHFtILFR
FDGHQDSHVDGDJDPPDHomo sapiensDQWL/*5
>9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5
ELVDJUD &+
&+/!. ( 0 7!.
&+6.!GHO @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @
FDGHQDSHVDGDJDPPDHomo sapiensDQWL(*)5
>9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* *PQ*P &+5
ELVDJUD &+
&+/!' ( 0 /!(
&+6.!GHO @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2
JOLFRIRUPDDOID
inmunomodulador, antineoplásico
318
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL(*)5
QVQLVQSGSE LKKPGASVKI SCKASGYDFT NYAMNWVRQA PGHGLEWMGW 50
INANTGDPTY AQGFTGRFVF SLDTSVSTAY LQISSLKAED SAVYYCTRER 100
FLEWLHFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTDPPSREE MTKNQVSLTC EVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL/*5
EVQLVQSGSK LKKPGASVKV SCKASGYTFT SYTMNWVRQA PGQGLEWMGW 50
INTDTGDPTY AQGFTGRFVF SLDTSVSTAF LQINSLKAED TAVYYCARGD 100
CDSTSCYRYS YGYEDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT KPPSREEMTK NQVSLKCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPG 456
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA 50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD&'5 &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
'HIXFRV\ODWHG ! FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2
ELDQWHQQDLUHV FRPSOH[HV GpIXFRV\OpV ! JOLFDQRV GH WLSR &+2 ELDQWHQDULRV
FRPSOHMRV GHIXFRVLODGRV !
SLPLWHVSLEXP
SLPLWHVSLE HWK\O^> PHWK\OHS\UD]RO\O HLPLGD]RO
\O@ SURSDQ\O HS\UD]ROR>b@S\ULGLQ
\O`EHQ]DPLGH
antineoplastic
SLPLWHVSLE pWK\O^> PpWK\OHS\UD]RO\O HLPLGD]RO
\O@ SURSDQ\O HS\UD]ROR>b@S\ULGLQ
\O`EHQ]DPLGH
antinéoplasique
SLPLWHVSLE HWLO^> PHWLOHSLUD]ROLO HLPLGD]ROLO@
SURSDQLO HSLUD]ROR>b@SLULGLQLO`EHQ]DPLGD
antineoplásico
&+12
319
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
SUDOX]DWDPDEXP
SUDOX]DWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&'
DFWLYDWHGOHXFRF\WHFHOODGKHVLRQPROHFXOH$/&$0 @
KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* Y*P!*PQ*P &+
. KLQJH &+ &+
( 0 &+6.!GHO
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>1WHUPLQDOUHJLRQ PHUOLQNHU
SURWHDVHFOHDYDEOHUHJLRQ PHUOLQNHU 9
.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU
2YDU\ &+2 GHULYHGFHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
SUDOX]DWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &'
PROpFXOHG DGKpVLRQFHOOXODLUHGHOHXFRF\WHVDFWLYpH
$/&$0 @DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* Y*P!*PQ*P
&+. FKDUQLqUH &+
&+( 0 &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDKXPDQLVpH >UpJLRQ1WHUPLQDOH PHU
OLQNHU UpJLRQFOLYDEOHSDUGHVSURWpDVHV
PHUOLQNHU 9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWHGDQVXQH
OLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
SUDOX]DWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &'
PROpFXODGHDGKHVLyQFHOXODUGHOHXFRFLWRVDFWLYDGRV
$/&$0 @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
Q*P &+. ELVDJUD
&+ &+( 0 &+6
.!GHO @ GLVXOIXURFRQODFDGHQD
OLJHUDNDSSDKXPDQL]DGD >UHJLyQ1WHUPLQDO
FRQHFWRUPHU UHJLyQHVFLQGLEOHSRUODVSURWHDVDV
FRQHFWRUPHU 9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@GtPHUR ELVGLVXOIXUR
SURGXFLGRHQXQDOtQHDFHOXODUGHULYDGDGHODVFpOXODVRYiULFDV
GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
320
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
SUDOX]DWDPDEXPUDYWDQVLQXP
SUDOX]DWDPDEUDYWDQVLQH LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&'
DFWLYDWHGOHXFRF\WHFHOODGKHVLRQPROHFXOH$/&$0 @
KXPDQL]HGPRQRFORQDODQWLERG\FRQMXJDWHGWR
PD\WDQVLQRLG'0
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*PQ*P &+.
KLQJH &+ &+(
0 &+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>1WHUPLQDOUHJLRQ PHUOLQNHU
SURWHDVHFOHDYDEOHUHJLRQ PHUOLQNHU
9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens,*.& .P$ 9
@GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 GHULYHGFHOOOLQHJO\FRIRUPDOIDFRQMXJDWHGRQ
DQDYHUDJHRIWRO\V\OWRPD\WDQVLQRLG'0>N
GHDFHW\ON PHUFDSWRPHWK\OR[RSHQW\O
PD\WDQVLQH@YLDWKHUHGXFLEOH63'%OLQNHU>N
VXFFLQLPLG\O S\ULG\OGLWKLR EXWDQRDWH@
)RUWKHravtansine SDUWSOHDVHUHIHUWRWKHGRFXPHQW"INN for
pharmaceutical substances: Names for radicals, groups and
others"*
immunomodulator, antineoplastic
SUDOX]DWDPDEUDYWDQVLQH LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&' PROpFXOHG DGKpVLRQFHOOXODLUHGHOHXFRF\WHV
DFWLYpH$/&$0 @DQWLFRUSVPRQRFORQDOKXPDQLVp
FRQMXJXpDXPD\WDQVLQRwGH'0
321
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*PQ*P &+.
FKDUQLqUH &+ &+(
0 &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >UpJLRQ1WHUPLQDOH
PHUOLQNHU UpJLRQFOLYDEOHSDUGHVSURWpDVHV
PHUOLQNHU 9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWHGDQVXQH
OLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOIDFRQMXJXp
VXURXO\V\OHQPR\HQQHDXPD\WDQVLQRwGH'0
>N GpDFpW\ON PHUFDSWRPpWK\OR[RSHQW\O
PD\WDQVLQH@YLDOHOLQNHU63'%UpGXFWLEOH>
S\ULG\OGLWKLR EXWDQRDWHGHNVXFFLQLPLG\OH@
3RXUODSDUWLHravtansineYHXLOOH]YRXVUpIpUHUDXGRFXPHQW
"INN for pharmaceutical substances: Names for radicals,
groups and others"*.
immunomodulateur, antinéoplasique
SUDOX]DWDPDEUDYWDQVLQD LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
&' PROpFXODGHDGKHVLyQFHOXODUGHOHXFRFLWRV
DFWLYDGRV$/&$0 @DQWLFXHUSRPRQRFORQDO
KXPDQL]DGRFRQMXJDGRFRQPDLWDQVLQRLGH'0
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* Y*P!*PQ*P &+.
ELVDJUD &+
&+( 0 &+6.!GHO
@ GLVXOIXURFRQODFDGHQD
OLJHUDNDSSDKXPDQL]DGD >UHJLyQ1WHUPLQDO
FRQHFWRUPHU UHJLyQHVFLQGLEOHSRU
ODVSURWHDVDV FRQHFWRPHU 9
.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GtPHUR ELVGLVXOIXUR
SURGXFLGRHQXQDOtQHDFHOXODUGHULYDGDGHODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
FRQMXJDGRHQRUHVLGXRVOLVLOSRUWpUPLQRPHGLR
FRQHOPDLWDQVLQRLGH'0>N GHDFHWLON
PHUFDSWRPHWLOR[RSHQWLO PDLWDQVLQD@PHGLDQWHHO
HVSDFLDGRU63'%UHGXFLEOH> SLULGLOGLWLR EXWDQRDWR
GHNVXFFLQLPLGLOR@
3DUDODIUDFFLyQravtansineVHSXHGHUHIHULUVHDOGRFXPHQWR
"INN for pharmaceutical substances: Names for radicals,
groups and others"*.
inmunomodulador, antineoplásico
322
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QITLKESGPT LVKPTQTLTL TCTFSGFSLS TYGMGVGWIR QPPGKALEWL 50
ANIWWSEDKH YSPSLKSRLT ITKDTSKNQV VLTITNVDPV DTATYYCVQI 100
DYGNDYAFTY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
QGQSGQGLCH PAVLSAWESC SSGGGSSGGS AVGLLAPPGG LSGRSDNHGG 50
SDIVMTQSPL SLPVTPGEPA SISCRSSKSL LHSNGITYLY WYLQKPGQSP 100
QLLIYQMSNL ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCAQNLEL 150
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 200
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 250
EVTHQGLSSP VTKSFNRGEC 270
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWUD/ 1WHUPLQDO UHJLRQ
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
)RU WKH ravtansine SDUW SOHDVH UHIHU WR WKH GRFXPHQW INN for pharmaceutical substances: Names for radicals,
groups and others"
3RXU OD SDUWLH ravtansine, YHXLOOH] YRXV UpIpUHU DX GRFXPHQW INN for pharmaceutical substances: Names for
radicals, groups and others
3DUD OD IUDFFLyQ ravtansina, VH SXHGHQ GLULJLU DO GRFXPHQWR INN for pharmaceutical substances: Names for
radicals, groups and others
SUHJDEDOLQXPDUHQDFDUELOXP
SUHJDEDOLQDUHQDFDUELO S PHWK\O^> ^ R >
PHWK\OSURSDQR\O R[\@HWKR[\`FDUERQ\O DPLQR@PHWK\O`
KH[DQRLFDFLG
gabamimetic
SUpJDEDOLQHDUpQDFDUELO DFLGH S PpWK\O^> ^ R >
PpWK\OSURSDQR\O R[\@pWKR[\`FDUERQ\O DPLQR@PpWK\O`
KH[DQRwTXH
gabamimétique
SUHJDEDOLQDDUHQDFDUELOR iFLGR S PHWLO^> ^ R >
PHWLOSURSDQRLO R[L@HWR[L`FDUERQLO DPLQR@PHWLO`
KH[DQRLFR
gabamimético
&+12
UDOPLWDURQWXP
UDOPLWDURQW HWK\OPHWK\ON^> S PRUSKROLQ\O@SKHQ\O`H
S\UD]ROHFDUER[DPLGH
neuroleptic
323
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
UDOPLWDURQW pWK\OPpWK\ON^> S PRUSKROLQ\O@SKpQ\O`H
S\UD]ROHFDUER[DPLGH
neuroleptique
UDOPLWDURQW HWLOPHWLON^> S PRUIROLQLO@IHQLO`HSLUD]RO
FDUER[DPLGD
neuroléptico
&+12
UHEDPLSLGXPPRIHWLOXP
UHEDPLSLGHPRIHWLO rac PRUSKROLQ\O HWK\O R
FKORUREHQ]DPLGR R[RGLK\GURTXLQROLQ
\O SURSDQRDWH
antiulcer
UpEDPLSLGHPRIpWLO rac R FKORUREHQ]DPLGR R[R
GLK\GURTXLQROpLQ\O SURSDQRDWHGH PRUSKROLQ
\O pWK\OH
antiulcéreux
UHEDPLSLGDGHPRIHWLOR rac R FORUREHQ]DPLGR R[R
GLKLGURTXLQROHLQLO SURSDQRDWRGH PRUIROLQLO HWLOR
antiulceroso
&+&O12
UHPHVWHPFHOXP
UHPHVWHPFHO KXPDQFXOWXUHH[SDQGHGDOORJHQHLFDGKHUHQW
PHVHQFK\PDOOLNHVWURPDOFHOOVGHULYHGIURPERQH
PDUURZRIKXPDQOHXNRF\WHDQWLJHQ +/$ ±XQPDWFKHG
KHDOWK\DGXOWGRQRUV&HOOVH[SUHVVFHOOVXUIDFH
PDUNHUV&'&'&'&'&'&'
&'&'D&'DQG&'DQGVHFUHWH
LQWHUOHXNLQ ,/ LQWHUOHXNLQ ,/ YDVFXODU
HQGRWKHOLDOJURZWKIDFWRU 9(*) SURVWDJODQGLQ(
3*( VWURPDOGHULYHGIDFWRU 6') LQGROHDPLQH
GLR[\JHQDVH ,'2 DQGNHUDWLQRF\WHJURZWKIDFWRU
.*) 7KHFHOOVDUHQHJDWLYHIRU&'&'&'
&'&'DQG+/$FODVV,,KLVWRFRPSDWLELOLW\
DQWLJHQJDPPDFKDLQ +/$'5 PDUNHUV
cell therapy (acute graft versus host disease)
324
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
UpPHVWHPFHO FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PH
KXPDLQHVDOORJpQLTXHVGpULYpHVGHODPRHOOH
RVVHXVHG¶XQGRQQHXUDGXOWHVDLQLQFRPSDWLEOHSRXU
O¶DQWLJqQHOHXFRF\WDLUHKXPDLQ +/$ HQFXOWXUH
G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV
H[SULPHQWjOHXUVXUIDFHOHVPDUTXHXUV&'&'
&'&'&'&'&'&'D&'
DQG&'HWVHFUqWHQWO¶LQWHUOHXNLQH ,/
O¶LQWHUOHXNLQH ,/ IDFWHXUGHFURLVVDQFHGH
O¶HQGRWKpOLXPYDVFXODLUH 9(*) SURVWDJODQGLQH(
3*( IDFWHXUGpULYpGXSDUHQFK\PH 6')
LQGROHDPLQHGLR[\JHQDVH ,'2 HWOHIDFWHXUGH
FURLVVDQFHGHVNpUDWLQRF\WHV/HVFHOOXOHVVRQW
QpJDWLYHVSRXU&'&'&'&'&'HWOD
FKDvQHJDPPDGHO¶DQWLJqQHPDMHXU
G¶KLVWRFRPSDWLELOLWp &0+ GHFODVVH,, +/$'5
thérapie cellulaire (maladie aiguë du greffon contre
l'hôte)
UHPHVWHPFHO FpOXODVHVWURPDOHVSDUHFLGDVDPHVHQTXLPDOHV
DORJpQLFDVKXPDQDVDGKHUHQWHV\H[SDQGLGDVHQ
FXOWLYRGHULYDGDVGHODPpGXODyVHDGHGRQDQWHV
DGXOWRVVDQRVQRFRPSDWLEOHVSDUDHODQWtJHQR
OHXFRFLWDULRKXPDQR +/$ /DVFpOXODVH[SUHVDQORV
PDUFDGRUHVGHVXSHUILFLH&'&'&'&'
&'&'&'D&'\&'\VHFUHWDQ
LQWHUOHXNLQD ,/ LQWHUOHXNLQD ,/ IDFWRUGH
FUHFLPLHQWRGHOHQGRWHOLRYDVFXODU 9(*)
SURVWDJODQGLQD( 3*( IDFWRUGHULYDGRGHOHVWURPD
6') LQGROHDPLQDGLR[LJHQDVD ,'2 \IDFWRU
GHFUHFLPLHQWRGHTXHUDWLQRFLWRV .*) /DVFpOXODV
VRQQHJDWLYDVSDUDORVPDUFDGRUHV&'&'
&'&'&'\ODFDGHQDJDPPDGHODQWtJHQR
GHKLVWRFRPSDWLELOLGDGGH+/$FODVH,, +/$'5
terapia celular (enfermedad aguda de injerto contra
huésped)
UHPLEUXWLQLEXP
UHPLEUXWLQLE N ^DPLQR> NPHWK\OSURS
HQDPLGR HWKR[\@S\ULPLGLQ\O`IOXRUR
PHWK\OSKHQ\O F\FORSURS\OIOXRUREHQ]DPLGH
Bruton's tyrosine kinase inhibitor
UpPLEUXWLQLE N ^DPLQR> NPpWK\OSURS
pQDPLGR pWKR[\@S\ULPLGLQ\O`IOXRUR
PpWK\OSKpQ\O F\FORSURS\OIOXRUREHQ]DPLGH
inhibiteur de la tyrosine kinase de Bruton
UHPLEUXWLQLE N ^DPLQR> NPHWLOSURS
HQDPLGR HWR[L@SLULPLGLQLO`IOXRURPHWLOIHQLO
FLFORSURSLOIOXRUREHQ]DPLGD
inhibidor de la tirosina quinasa de Bruton
325
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
&+)12
UHWLIDQOLPDEXP
UHWLIDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
3'&' SURJUDPPHGFHOOGHDWK3'3'
&' @ PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ KLQJH6!3
&+ &+ &+6.!GHO
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
FKLPHULF ¶¶ >9.$33$ Mus musculus,*.9
,*.- Homo sapiens,*.9'
,*.- >@
Homo sapiens,*.& .P$
9 @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
UpWLIDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
3'&' SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH
3'3'&' @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ FKDUQLqUH6!3
&+ &+ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQH
OpJqUHNDSSDFKLPpULTXH ¶¶ >9.$33$ Mus
musculus,*.9 ,*.- Homo
sapiens,*.9' ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
UHWLIDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
3'&' SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD
3'3'&' @ DQWLFXHUSRPRQRFORQDO
326
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3
&+ &+ &+6
.!GHO @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDTXLPpULFD ¶¶ >9.$33$
Mus musculus,*.9 ,*.-
Homo sapiens,*.9'
,*.- >@ Homo sapiens
,*.& .P$ 9
@GtPHUR ELVGLVXOIXUR
SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV
&+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
ULO]DEUXWLQLEXP
ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPHWK\OR[R
R[D S\UD]ROR>d@S\ULPLGLQD SLSHUD]LQD
SLSHULGLQD R[HWDQD
GLEHQ]HQDXQGHFDSKDQHQHFDUERQLWULOH
Bruton's tyrosine kinase inhibitor
ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPpWK\OR[R
R[D S\UD]ROR>d@S\ULPLGLQD SLSpUD]LQD
SLSpULGLQD R[pWDQD
GLEHQ]pQDXQGpFDSKDQqQHFDUERQLWULOH
inhibiteur de la tyrosine kinase de Bruton
327
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPHWLOR[RR[D
SLUD]ROR>d@SLULPLGLQD SLSHUD]LQD
SLSHULGLQD R[HWDQD
GLEHQFHQDXQGHFDIDQHQRFDUERQLWULOR
inhibidor de la tirosina quinasa de Bruton
&+)12
ULPWX]DOFDSXP
ULPWX]DOFDS N GLIOXRURF\FORKH[\O PHWK\OHS\UD]RO
\O PRUSKROLQ\O S\ULPLGLQDPLQH
modulator of small-conductance calcium-activated
potassium channels
ULPWX]DOFDS N GLIOXRURF\FORKH[\O PpWK\OHS\UD]RO
\O PRUSKROLQ\O S\ULPLGLQDPLQH
modulateur des canaux potassiques actives par le
calcium de petite conductance
ULPWX]DOFDS N GLIOXRURFLFORKH[LO PHWLOHSLUD]ROLO
PRUIROLQLO SLULPLGLQDPLQD
modulador de los canales de potasio activados por
calcio de pequeña conductancia
&+)12
ULWOHFLWLQLEXP
ULWOHFLWLQLE ^ SR PHWK\O> HS\UUROR>d@S\ULPLGLQ
\O DPLQR@SLSHULGLQ\O`SURSHQRQH
Janus kinase inhibitor
ULWOpFLWLQLE ^ SR PpWK\O> HS\UUROR>d@S\ULPLGLQ
\O DPLQR@SLSpULGLQ\O`SURSpQRQH
inhibiteur de la kinase de Janus
328
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
ULWOHFLWLQLE ^ SR PHWLO> HSLUUROR>d@SLULPLGLQ
LO DPLQR@SLSHULGLQLO`SURSHQRQD
inhibidor de la quinasa de Janus
&+12
URSRFDPSWLGXP
URSRFDPSWLGH DQWLEDFWHULDOSHSWLGH// KXPDQ
/OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKHQ\ODODQ\O/
SKHQ\ODODQ\O/DUJLQ\O/O\V\O/VHU\O/O\V\O/Į
JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/
SKHQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/
JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/
SKHQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/
YDO\O/SURO\O/DUJLQ\O/WKUHRQ\O/ĮJOXWDP\O/VHULQH
antimicrobial, immunomodulator
URSRFDPSWLGH SHSWLGHDQWLEDFWpULHQ// KXPDLQ
/OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKpQ\ODODQ\O/
SKpQ\ODODQ\O/DUJLQ\O/O\V\O/VpU\O/O\V\O/Į
JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/
SKpQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/
JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/
SKpQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/
YDO\O/SURO\O/DUJLQ\O/WKUpRQ\O/ĮJOXWDP\O/VpULQH
antimicrobien, immunomodulateur
URSRFDPSWLGD SpSWLGRDQWLEDFWHULDO// KXPDQR
/OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKHQ\ODODQ\O/
SKHQ\ODODQ\O/DUJLQ\O/O\V\O/VHU\O/O\V\O/Į
JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/
SKHQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/
JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/
SKHQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/
YDO\O/SURO\O/DUJLQ\O/WKUHRQ\O/ĮJOXWDP\O/VHULQD
antimicrobiano, inmunomodulador
&+12
URYDOHXFHOXP
URYDOHXFHO KXPDQFXOWXUHHQULFKHGH[SDQGHGDXWRORJRXV(SVWHLQ
%DUUYLUXVVSHFLILFF\WRWR[LF7FHOOV (%9&7/ GHULYHG
IURPSHULSKHUDOEORRGPRQRQXFOHDUFHOOV 3%0&V IRU
FHOOEDVHGWKHUDS\&HOOVDUHJHQHUDWHGE\FRFXOWXUH
ZLWKJDPPDLUUDGLDWHGDXWRORJRXVO\PSKREODVWRLGFHOO
OLQHV /&/ DQGLQWHUOHXNLQ ,/ VWLPXODWLRQ
cell therapy (antineoplastic)
329
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
URYDOHXFHO O\PSKRF\WHV7F\WRWR[LTXHVVSpFLILTXHVGXYLUXVG¶(SVWHLQ%DUU
(%9&7/ KXPDLQVDXWRORJXHVHQFXOWXUHG¶H[SDQVLRQHQULFKLH
GpULYpVGHVFHOOXOHVPRQRQXFOpHVGXVDQJSpULSKpULTXH 3%0&V
SRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHVVRQWJpQpUpHVSDUFRFXOWXUH
DYHFGHVOLJQpHVFHOOXODLUHVO\PSKREODVWRwGHV /&/ DXWRORJXHV
LUUDGLpHVSDUGHVUD\RQVJDPPDHWXQHVWLPXODWLRQSDULQWHUOHXNLQH
,/
thérapie cellulaire (antinéoplasique)
URYDOHXFHO OLQIRFLWRV7FLWRWy[LFRVHVSHFtILFRVGHOYLUXVGH(SVWHLQ%DUU (%9
&7/ DXWyORJRVKXPDQRVH[SDQGLGRVHQULTXHFLGRVHQFXOWLYR
GHULYDGRVGHFpOXODVPRQRQXFOHDUHVGHVDQJUHSHULIpULFD 3%0&V
SDUDWHUDSLDFHOXODU/DVFpOXODVVHJHQHUDQPHGLDQWHFRFXOWLYRFRQ
OtQHDVFHOXODUHVOLQIREODVWRLGHVDXWyORJDVLUUDGLDGDVFRQUDGLDFLyQ
JDPPD\HVWLPXODFLyQFRQLQWHUOHXNLQD ,/
terapia celular (antineoplásico)
VDPRWROLVLEXP
VDPRWROLVLE > K\GUR[\SURSDQ\O S\ULGLQ\O@> S PHWKR[\SURS\O@
PHWK\OGLK\GURHLPLGD]R>c@TXLQROLQRQH
phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic
VDPRWROLVLE > K\GUR[\SURSDQ\O S\ULGLQ\O@> S PpWKR[\SURS\O@
PpWK\OGLK\GURHLPLGD]R>c@TXLQROpLQRQH
inhibiteur de phosphatidylinositol 3-kinase (PI3K), antinéoplasique
VDPRWROLVLE > KLGUR[LSURSDQLO SLULGLQLO@> S PHWR[LSURSLO@PHWLO
GLKLGURHLPLGD]R>c@TXLQROHLQRQD
inhibidor de fosfatidilinositol 3-quinasa (PI3K), antineoplásico
&+12
VDVDQOLPDEXP
VDVDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens3'&'
SURJUDPPHGFHOOGHDWK3'3'&' @KXPDQL]HG
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ KLQJH6!3
&+ &+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG >9
.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P$
9 @
GLPHU ELVGLVXOILGHSURGXFHGLQDJOXWDPLQH
V\QWKHWDVHNQRFNRXW&KLQHVH+DPVWHU2YDU\ &+2 EDVHG
H[SUHVVLRQV\VWHP &+2.69*6.2 JO\FRIRUPDOID
immunomodulator, antineoplastic
330
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
VDVDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens3'&'
SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH3'3'
&' @DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ FKDUQLqUH
6!3 &+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQH
OpJqUHNDSSDKXPDQLVpH >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@GLPqUH ELVGLVXOIXUHSURGXLW
GDQVXQV\VWqPHG H[SUHVVLRQEDVpVXUGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JOXWDPLQHV\QWKpWDVH
NQRFNRXW &+2.69*6.2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
VDVDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens3'&'
SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD3'3'
&' @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
ELVDJUD6!3 &+ &+
&+6 @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDKXPDQL]DGD >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQXQVLVWHPDGHH[SUHVLyQEDVDGRHQ
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOXWDPLQD
VLQWHWDVDNQRFNRXW &+2.69*6.2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWINWVRQA PGQGLEWMGN 50
IYPGSSLTNY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARLS 100
TGTFAYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIVMTQSPDS LAVSLGERAT INCKSSQSLW DSGNQKNFLT WYQQKPGQPP 50
KLLIYWTSYR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYFY 100
PHTFGGGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
331
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
VHSRIDUVHQXP
VHSRIDUVHQ allPambo OPHWK\OPWKLRJXDQ\O\O ĺ OPHWK\OP
WKLRJXDQ\O\O ĺ OPHWK\OPWKLRXULG\O\O ĺ O
PHWK\OPWKLRJXDQ\O\O ĺ OPHWK\OPWKLRJXDQ\O\O
ĺ OPHWK\OPWKLRDGHQ\O\O ĺ OPHWK\OP
WKLRXULG\O\O ĺ OPHWK\OPWKLRF\WLG\O\O ĺ O
PHWK\OPWKLRDGHQ\O\O ĺ OPHWK\OPWKLRF\WLG\O\O
ĺ OPHWK\OPWKLRJXDQ\O\O ĺ OPHWK\OP
WKLRDGHQ\O\O ĺ OPHWK\OPWKLRJXDQ\O\O ĺ O
PHWK\OPWKLRXULG\O\O ĺ OPHWK\OPWKLRXULG\O\O ĺ
OPHWK\OPWKLRF\WLG\O\O ĺ OPHWK\ODGHQRVLQH
promotion of functional centrosomal protein (Cep290)
synthesis
VpSRIDUVHQ toutPambo OPpWK\OPWKLRJXDQ\O\O ĺ OPpWK\OP
WKLRJXDQ\O\O ĺ OPpWK\OPWKLRXULG\O\O ĺ O
PpWK\OPWKLRJXDQ\O\O ĺ OPpWK\OPWKLRJXDQ\O\O
ĺ OPpWK\OPWKLRDGpQ\O\O ĺ OPpWK\OP
WKLRXULG\O\O ĺ OPpWK\OPWKLRF\WLG\O\O ĺ O
PpWK\OPWKLRDGpQ\O\O ĺ OPpWK\OPWKLRF\WLG\O\O
ĺ OPpWK\OPWKLRJXDQ\O\O ĺ OPpWK\OP
WKLRDGpQ\O\O ĺ OPpWK\OPWKLRJXDQ\O\O ĺ O
PpWK\OPWKLRXULG\O\O ĺ OPpWK\OPWKLRXULG\O\O ĺ
OPpWK\OPWKLRF\WLG\O\O ĺ OPpWK\ODGpQRVLQH
stimulation de la synthèse de la protéine centrosomale
(Cep290) fonctionnelle
VHSRIDUVpQ todoPambo OPHWLOPWLRJXDQLOLO ĺ OPHWLOP
WLRJXDQLOLO ĺ OPHWLOPWLRXULGLOLO ĺ OPHWLOP
WLRJXDQLOLO ĺ OPHWLOPWLRJXDQLOLO ĺ OPHWLOP
WLRDGHQLOLO ĺ OPHWLOPWLRXULGLOLO ĺ OPHWLOP
WLRFLWLGLOLO ĺ OPHWLOPWLRDGHQLOLO ĺ OPHWLOP
WLRFLWLGLOLO ĺ OPHWLOPWLRJXDQLOLO ĺ OPHWLOP
WLRDGHQLOLO ĺ OPHWLOPWLRJXDQLOLO ĺ OPHWLOP
WLRXULGLOLO ĺ OPHWLOPWLRXULGLOLO ĺ OPHWLOP
WLRFLWLGLOLO ĺ OPHWLODGHQRVLQD
estimulación de la síntesis de proteína centrosomal (Cep290)
funcional
&+1236
VHUSOXOLPDEXP
VHUSOXOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens3'&'
SURJUDPPHGFHOOGHDWK3'3'&' @KXPDQL]HG
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
KLQJH6!3 &+ &+
&+6 @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQKXPDQL]HG >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$ 9
@
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
332
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
VHUSOXOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens3'&' SURWpLQH
GHPRUWFHOOXODLUHSURJUDPPpH3'3'&' @DQWLFRUSV
PRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDHomo sapiens >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ FKDUQLqUH6!3
&+ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
VHUSOXOLPDE PXQRJOREXOLQD*NDSSDDQWL>Homo sapiens3'&' SURWHtQD
GHPXHUWHFHOXODUSURJUDPDGD3'3'&' @DQWLFXHUSR
PRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDHomo sapiens >9+ Homo
sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ ELVDJUD
6!3 &+ &+ &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDKXPDQL]DGD >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QVQLVESGGG LVKPGGSLRL SCAASGFTFS NYGMSWIRQA PGKGLEWVST 50
ISGGGSNIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCVSYY 100
YGIDFWGQGT SVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK 443
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPSS LSASVGDRVT ITCKASQDVT TAVAWYQQKP GKAPKLLIYW 50
ASTRHTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYTIPWTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K
1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH
+ 9+ 4
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
333
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
VHWDPHYHWFHOXP
VHWDPHYHWFHO FDQLQHFXOWXUHH[SDQGHGDGLSRVHGHULYHGDOORJHQHLF
PHVHQFK\PDOOLNHVWURPDOFHOOVIRUFHOOEDVHGWKHUDS\
&HOOVH[SUHVVFHOOVXUIDFHPDUNHUV&'DQG&' WK\
PHPEUDQHJO\FRSURWHLQ DQGVHFUHWHLQWHUOHXNLQ ,/
PRQRF\WHFKHPRWDFWLFSURWHLQ 0&3&&PRWLI
FKHPRNLQH KHSDWRF\WHJURZWKIDFWRU +*)VFDWWHU
IDFWRU6)KHSDWRSRHLWLQ$ PHWDOORSURWHLQDVHLQKLELWRU
7,03 &;&PRWLIFKHPRNLQH &;&/N'D
LQWHUIHURQJDPPDLQGXFHGSURWHLQ,3 LQWHUOHXNLQ
UHFHSWRUDQWDJRQLVWSURWHLQ ,/51,/UD DQG
LQGROHDPLQHGLR[\JHQDVH ,'2,'2 7KHFHOOV
DUHQHJDWLYHIRU&'&'DQGIRUWKHPDMRU
KLVWRFRPSDWLELOLW\FRPSOH[ 0+& FODVV,,PDUNHUV
cell therapy (veterinary use)
VpWDPpYHWFHO FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PHFDQLQHV
DOORJpQLTXHVGpULYpHVGHWLVVXVDGLSHX[HQFXOWXUH
G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV
H[SHULPHQWOHVPDUTXHXUVGHVXUIDFH&'HW&'
JO\FRSURWpLQHPHPEUDQDLUHWK\ HWVHFUqWHQWGH
O¶LQWHUOHXNLQH ,/ SURWpLQHFKLPLRDWWUDFWLYHGX
PRQRF\WH 0&3FKLPLRNLQHGHPRWLI&& IDFWHXU
GHFURLVVDQFHGHO KpSDWRF\WH +*)IDFWHXUGLVSHUVDQW
6)KpSDWRSRwpWLQH$ LQKLELWHXUGHPHWDOORSURWHLQDVH
7,03 FKLPLRNLQHGHPRWLI&;&
&;&/SURWpLQHGHN'DLQGXLWHSDUO¶LQWHUIpURQ
JDPPD,3 SURWpLQHDQWDJRQLVWHGXUpFHSWHXUGH
O¶LQWHUOHXNLQH ,/51,/UD HWO¶LQGROHDPLQH
GLR[\JpQDVH ,'2,'2 /HVFHOOXOHVVRQWQpJDWLYHV
SRXUOHVPDUTXHXUV&'&'HWO¶DQWLJqQHPDMHXU
G¶KLVWRFRPSDWLELOLWp &0+ GHFODVVH,,
thérapie cellulaire (usage vétérinaire)
VHWDPHYHWFHO FpOXODVHVWURPDOHVSDUHFLGDVDPHVHQTXLPDOHV
DORJpQLFDVGHSHUURGHULYDGDVGHWHMLGRDGLSRVR\
H[SDQGLGDVHQFXOWLYRSDUDWHUDSLDFHOXODU/DVFpOXODV
H[SUHVDQORVPDUFDGRUHVGHVXSHUILFLH&'\&'
JOLFRSURWHtQDGHPHPEUDQDWK\ \VHFUHWDQ
LQWHUOHXNLQD ,/ SURWHtQDTXLPLRWiFWLFDGHPRQRFLWRV
0&3TXLPRTXLQDFRQPRWLYR&& IDFWRUGH
FUHFLPLHQWRGHKHSDWRFLWRV +*)IDFWRUGLVSHUVDQWH
6)KHSDWRSR\HWLQD$ LQKLELGRUGHPHWDORSURWHLQDVD
7,03 TXLPRTXLQDFRQPRWLYR&;& &;&/
SURWHtQDGHN'DLQGXFWRUDGHLQWHUIHUyQJDPPD,3
SURWHtQDDQWDJRQLVWDGHOUHFHSWRUGHLQWHUOHXNLQD
,/51,/UD HLQGROHDPLQDGLR[LJHQDVD ,'2
,'2 /DVFpOXODVVRQQHJDWLYDVSDUDORVPDUFDGRUHV
&'&'\HODQWtJHQRSULQFLSDOGH
KLVWRFRPSDWLELOLGDG 0+& GHFODVH,,
terapia celular (uso veterinario)
VLPOXNDIXVSXPDOID
VLPOXNDIXVSDOID LPPXQRJOREXOLQ*NDSSD DQWL KXPDQVHSUDVH
VXUIDFHH[SUHVVHGSURWHDVHILEUREODVWDFWLYDWLRQSURWHLQ
DOSKD)$3ĮSURO\OHQGRSHSWLGDVH)$3 HQJLQHHUHG
KXPDQPRQRFORQDODQWLERG\ IXVHGWRRQHLQWHUOHXNLQ
,/ FKDLQKHWHURGLPHU
334
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
JDPPDKHDY\FKDLQ >Homo sapiens9+ Homo
sapiens,*+9 ,*+' ,*+- >&'5.DEDW+
6<$06 &'5.DEDW+$,,*6*$67<<$'69.*
&'5.DEDW+*:)**)1< @ Homo
sapiens,*+* &+ KLQJH &+
/!$/!$3!* &+ <!&7!6
/!$<!9 &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQ >9.$33$
Homo sapiens,*.9 ,*.- >&'5.DEDW/
5$6469766</$ &'5.DEDW/>@9*655$7
&'5.DEDW/>@44*,0/337 @ Homo
sapiens,*.& @
JDPPDKHDY\FKDLQIXVHGWR,/ >Homo sapiens
9+ Homo sapiens,*+9 ,*+' ,*+-
>&'5.DEDW+6<$06 &'5.DEDW+
$,,*6*$67<<$'69.* &'5.DEDW+
*:)**)1< @ Homo sapiens,*+*
&+ KLQJH &+ /!$/!$
3!* &+ 6!&7!: &+6
.GHO *6 OLQNHU
Homo sapiens,/ 3U 7!$ )!$
<!$ /!* &!$ @
GLVXOILGHZLWKNDSSDOLJKWFKDLQ >9.$33$
Homo sapiens,*.9 ,*.- >&'5.DEDW/
5$6469766</$ &'5.DEDW/9*655$7
&'5.DEDW/44*,0/337 @
Homo sapiens,*.& @GLPHU
WULVGLVXOILGHSURGXFHGLQ&KLQHVHKDPVWHU
RYDU\ &+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
VLPOXNDIXVSDOID LPPXQRJOREXOLQH*NDSSDDQWL>VpSUDVHKXPDLQH SURWpDVH
H[SULPpHjODVXUIDFHSURWpLQHDOSKDG DFWLYDWLRQGHV
ILEUREODVWHV)$3ĮSURO\OHQGRSHSWLGDVH)$3 @DQWLFRUSV
PRQRFORQDOKXPDLQLVVXGHO LQJpQpUHULH IXVLRQQpHjXQH
FKDvQHGHO LQWHUOHXNLQHKXPDLQH ,/ KpWpURGLPqUH
FKDvQHORXUGHJDPPD >Homo sapiens9+ Homo
sapiens,*+9 ,*+' ,*+- >&'5.DEDW+
6<$06 &'5.DEDW+$,,*6*$67<<$'69.*
&'5.DEDW+*:)**)1< @ Homo
sapiens,*+* &+ FKDUQLqUH &+
/!$/!$3!* &+ <!&7!6
/!$<!9 &+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD >9.$33$
Homo sapiens,*.9 ,*.- >&'5.DEDW/
5$6469766</$ &'5.DEDW/>@9*655$7
&'5.DEDW/>@44*,0/337 @ Homo
sapiens,*.& @
FKDvQHORXUGHJDPPDIXVLRQQpjO ,/ >Homo
sapiens9+ Homo sapiens,*+9 ,*+' ,*+-
>&'5.DEDW+6<$06 &'5.DEDW+
$,,*6*$67<<$'69.* &'5.DEDW+
*:)**)1< @ Homo sapiens,*+*
&+ FKDUQLqUH &+ /!$/!$
3!* &+ 6!&7!: &+6
.GHO *6 OLQNHU
Homo sapiens,/ 3U 7!$ )!$
<!$ /!* &!$ @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
335
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
>9.$33$ Homo sapiens,*.9 ,*.-
>&'5.DEDW/5$6469766</$
&'5.DEDW/9*655$7 &'5.DEDW/
44*,0/337 @ Homo sapiens
,*.& @GLPqUH
WULVGLVXOIXUHSURGXLWSDUGHVFHOOXOHV
RYDULHQQHVGHKDPVWHUFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
VLPOXNDIXVSDOID LQPXQRJOREXOLQD*NDSSDDQWL>VHSUDVDKXPDQD
SURWHDVDH[SUHVDGDHQODVXSHUILFHSURWHtQDDOIDGH
DFWLYDFLyQGHORVILEUREODVWRV)$3ĮSUROLO
HQGRSHSWLGDVD)$3 @DQWLFXHUSRPRQRFORQDOKXPDQR
UHDOL]DGRDWUDYpVGH,QJHQLHUD IXVLRQDGDFRQXQD
FDGHQDGHODLQHUOHXNLQDKXPDQD ,/
KHWHURGtPHUR
FDGHQDSHVDGDJDPPD >Homo sapiens9+
Homo sapiens,*+9 ,*+' ,*+-
>&'5.DEDW+6<$06 &'5.DEDW+
$,,*6*$67<<$'69.* &'5.DEDW+
*:)**)1< @ Homo sapiens
,*+* &+ ELVDJUD &+
/!$/!$3!* &+ <!&
7!6/!$<!9 &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSD >9.$33$ Homo sapiens,*.9
,*.- >&'5.DEDW/5$6469766</$
&'5.DEDW/>@9*655$7
&'5.DEDW/>@44*,0/337 @
Homo sapiens,*.& @
FDGHQDSHVDGDJDPPDIXVLRQDGDDO,/
>Homo sapiens9+ Homo sapiens,*+9
,*+' ,*+- >&'5.DEDW+6<$06
&'5.DEDW+$,,*6*$67<<$'69.*
&'5.DEDW+*:)**)1< @
Homo sapiens,*+* &+ ELVDJUD
&+ /!$/!$3!*
&+ 6!&7!: &+6
.GHO *6 OLQNHU
Homo sapiens,/ 3U 7!$ )!$
<!$ /!* &!$
@ GLVXOIXURFRQODFDGHQD
OLJHUDNDSSD >9.$33$ Homo sapiens
,*.9 ,*.- >&'5.DEDW/
5$6469766</$ &'5.DEDW/
9*655$7 &'5.DEDW/44*,0/337
@ Homo sapiens,*.&
@GtPHUR
WULVGLVXOIXURSURGXFLGRSRUODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
336
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
6HTXHQFH 6pTXHQFH 6HFXHQFLD
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL)$3
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50
IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100
FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVCT 350
LPPSRDELTK NQVSLSCAVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLVSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN 50
VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 215
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL)$3 IXVHG ZLWK ,/
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50
IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100
FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVYT 350
LPPCRDELTK NQVSLWCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGGGGG 450
SGGGGSGGGG SAPASSSTKK TQLQLEHLLL DLQMILNGIN NYKNPKLTRM 500
LTAKFAMPKK ATELKHLQCL EEELKPLEEV LNGAQSKNFH LRPRDLISNI 550
NVIVLELKGS ETTFMCEYAD ETATIVEFLN RWITFAQSII STLT 694
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN 50
VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 215
'LVXOILGH EULGJH ORFDWLRQ 3RVLWLRQ GH OD SRQW GLVXOIXUH 3RVLFLyQ GHO SXHQWH GLVXOIXUR
LQWUD+ ,J*
,/
LQWUD/
LQWHU+/
LQWHU++
*O\FRV\ODWLRQ VLWHV 6LWHV GH JO\FRV\ODWLRQ 3RVLFLRQHV GH JOLFRVLODFLyQ
1 1
VLQEDJOXVWDWXP
VLQEDJOXVWDW SRRS K\GUR[\PHWK\O SHQW\OSLSHULGLQH
WULRO
ceramide glucosyltransferase inhibitor
VLQEDJOXVWDW SRRS K\GUR[\PpWK\O SHQW\OSLSpULGLQH
WULRO
inhibiteur de la céramide glucosyltransférase
VLQEDJOXVWDW SRRS KLGUR[LPHWLO SHQWLOSLSHULGLQD
WULRO
inhibidor de la ceramida glucosiltransferasa
&+12
337
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
VRQHORNLPDEXP
VRQHORNLPDE LPPXQRJOREXOLQVLQJOHFKDLQ9+9+ 9+DQWL>Homo sapiens
,/$ LQWHUOHXNLQ$,/$ DQGHomo sapiens,/)
LQWHUOHXNLQ),/) @DQGDQWL>Homo sapiens$/%
DOEXPLQKXPDQVHUXPDOEXPLQ+$6 @KXPDQL]HGLama
glamaPRQRFORQDODQWLERG\ELVSHFLILFWULYDOHQW
VF9+9+ 9+ >KXPDQL]HG9+DQWL,/) Vicugna
pacos,*+9 ,*+' ,*+- Homo
sapiens,*+9 ,*+' ,*+-
>@ PHUOLQNHU WHWUDJO\F\OVHU\OWULJO\F\OVHU\O
KXPDQL]HG9+ DQWL$/% Homo sapiens,*+9
,*+' ,*+- :!6 *
>@ PHUOLQNHU WHWUDJO\F\OVHU\O
WULJO\F\OVHU\O KXPDQL]HG9+DQWL,/$DQGDQWL
,/) Vicugna pacos,*+9 ,*+'
,*+- Homo sapiens,*+9
,*+' ,*+- >@ SURGXFHGLQ
WKH\HDVWPichia pastoris Komagataella phaffii QRQ
JO\FRV\ODWHG
immunomodulator
VRQpORNLPDE LPPXQRJOREXOLQHFKDvQHXQLTXH9+9+ 9+DQWL>Homo
sapiens,/$ LQWHUOHXNLQH$,/$ HWHomo sapiens
,/) LQWHUOHXNLQH),/) @HWDQWL>Homo sapiens$/%
DOEXPLQHVpUXPDOEXPLQHKXPDLQH6$+ @DQWLFRUSV
PRQRFORQDOLama glamaKXPDQLVpELVSpFLILTXHWULYDOHQW
VF9+9+ 9+ >9+FKLPpULTXHDQWL,/) Vicugna
pacos,*+9 ,*+' ,*+- Homo
sapiens,*+9 ,*+' ,*+-
>@ PHUOLQNHU WpWUDJO\F\OVpU\OWULJO\F\OVpU\O
9+ KXPDQLVpDQWL$/% Homo sapiens,*+9
,*+' ,*+- :!6 *
>@ PHUOLQNHU WpWUDJO\F\OVpU\O
WULJO\F\OVpU\O 9+FKLPpULTXHDQWL,/$DQGDQWL
,/) Vicugna pacos,*+9 ,*+'
,*+- Homo sapiens,*+9
,*+' ,*+- >@ SURGXLWGDQVOD
OHYXUHPichia pastoris Komagataella phaffii QRQJO\FRV\Op
immunomodulateur
VRQHORNLPDE LQPXQRJOREXOLQDFDGHQD~QLFD9+9+ 9+DQWL>Homo
sapiens,/$ LQWHUOHXNLQD$,/$ \Homo sapiens
,/) LQWHUOHXNLQD),/) @\DQWL>Homo sapiens$/%
DOE~PLQDDOE~PLQDVpULFDKXPDQD6$+ @DQWLFXHUSR
PRQRFORQDOLama glamaKXPDQL]DGRELHVSHFtILFRWULYDOHQWH
VF9+9+ 9+ >9+TXLPpULFRDQWL,/) Vicugna
pacos,*+9 ,*+' ,*+- Homo
sapiens,*+9 ,*+' ,*+-
>@ FRQHFWRUPHU WHWUDJOLFLOVHULOWULJOLFLOVHULO
9+ KXPDQL]DGRDQWL$/% Homo sapiens,*+9
,*+' ,*+- :!6 *
>@ FRQHFWRPHU WHWUDJOLFLOVHULO
WULJOLFLOVHULO 9+TXLPpULFRDQWL,/$\DQWL,/)
Vicugna pacos,*+9 ,*+' ,*+-
Homo sapiens,*+9 ,*+'
,*+- >@ SURGXFLGRHQOD
OHYDGXUDPichia pastoris Komagataella phaffii QRJOLFRVLODGR
inmunomodulador
338
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
VRYDWHOWLGXP
VRYDWHOWLGH N FDUER[\SURSDQR\O HQGRWKHOLQ KXPDQ SHSWLGH
>.!(&!$&!$@
N FDUER[\SURSDQR\O /ĮDVSDUW\O/ĮJOXWDP\O/ĮJOXWDP\O/
DODQ\O/YDO\O/W\URV\O/SKHQ\ODODQ\O/DODQ\O/KLVWLG\O/OHXF\O
/ĮDVSDUW\O/LVROHXF\O/LVROHXF\O/WU\SWRSKDQ
endothelin receptor agonist
VRYDWHOWLGH N FDUER[\SURSDQR\O HQGRWKpOLQH KXPDLQH SHSWLGH
>.!(&!$&!$@
N FDUER[\SURSDQR\O /ĮDVSDUW\O/ĮJOXWDP\O/ĮJOXWDP\O/
DODQ\O/YDO\O/W\URV\O/SKpQ\ODODQ\O/DODQ\O/KLVWLG\O/OHXF\O
/ĮDVSDUW\O/LVROHXF\O/LVROHXF\O/WU\SWRSKDQH
antagoniste du récepteur de l'endothéline
VRYDWHOWLGD N FDUER[LSURSDQRLO HQGRWHOLQD KXPDQD SpSWLGR
>.!(&!$&!$@
N FDUER[LSURSDQRLO /ĮDVSDUWLO/ĮJOXWDPLO/ĮJOXWDPLO/
DODQLO/YDOLO/WLURVLO/IHQLODODQLO/DODQLO/KLVWLGLO/OHXFLO/Į
DVSDUWLO/LVROHXFLO/LVROHXFLO/WULSWyIDQR
antagonista del receptor de la endotelina
&+12
VWDSXOGHQFHOXP
VWDSXOGHQFHO KXPDQDXWRORJRXVPRQRF\WHGHULYHGGHQGULWLFFHOOV 0R'&V
JHQHUDWHGex-vivoIURPSDWLHQW¶VSHULSKHUDOEORRGPRQRQXFOHDU
FHOOV 3%0&V IRUFHOOEDVHGWKHUDS\7KHFHOOVDUHGLIIHUHQWLDWHG
IURPDXWRORJRXVDGKHUHQWPRQRF\WHVE\FXOWXULQJLQWKH
SUHVHQFHRILQWHUOHXNLQ ,/ DQGJUDQXORF\WHPDFURSKDJH
FRORQ\VWLPXODWLQJIDFWRU *0&6) DQGSXOVHGZLWKDNLOOHG
KXPDQSURVWDWHDGHQRFDUFLQRPDFHOOOLQH
cell therapy (antineoplastic)
VWDSXOGHQFHO FHOOXOHVGHQGULWLTXHVDXWRORJXHVKXPDLQHVGpULYpHVGHV
PRQRF\WHVJpQpUpHVex vivojSDUWLUGHFHOOXOHVPRQRQXFOpHV
GXVDQJSpULSKpULTXHGHVSDWLHQWVSRXUWKpUDSLHFHOOXODLUH/HV
FHOOXOHVVHGLIIpUHQFLHQWjSDUWLUGHVPRQRF\WHVDGKpUHQWV
DXWRORJXHVSDUFXOWXUHHQSUpVHQFHG¶LQWHUOHXNLQH ,/ HWGX
IDFWHXUVWLPXODQWOHVFRORQLHVGHJUDQXORF\WHVHWGH
PDFURSKDJHV *0&6) HWSXOVpHVSDUGHVFHOOXOHVWXpHVG¶XQH
OLJQpHFHOOXODLUHKXPDLQHG¶DGpQRFDUFLQRPHGHODSURVWDWH
thérapie cellulaire (antinéoplasique)
339
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
HVWDSXOGHQFHO FpOXODVGHQWUtWLFDVDXWyORJDVKXPDQDVGHULYDGDVGH
PRQRFLWRVJHQHUDGDVex vivoDSDUWLUGHFpOXODV
PRQRQXFOHDUHVGHVDQJUHSHULIpULFDGHSDFLHQWHV
SDUDWHUDSLDFHOXODU/DVFpOXODVVHGLIHUHQFLDQDSDUWLU
GHPRQRFLWRVDGKHUHQWHVDXWyORJRVPHGLDQWHFXOWLYR
HQSUHVHQFLDGHLQOHUOHXFLQD ,/ \IDFWRU
HVWLPXODGRUGHFRORQLDVGHJUDQXORFLWRV\PDFUyIDJRV
*0&6) \SXOVDGDVFRQFpOXODVPDWDGDVGHXQD
OtQHDFHOXODUGHDGHQRFDUFLQRPDSURVWiWLFRKXPDQD
terapia celular (antineoplásico)
VXYRGLUVHQXP
VXYRGLUVHQ >allPS S @ GHR[\ IOXRURPWKLRXULG\O\O ĺ
GHR[\ IOXRURPWKLRF\WLG\O\O ĺ GHR[\
IOXRURPWKLRDGHQ\O\O ĺ GHR[\ IOXRURP
WKLRDGHQ\O\O ĺ GHR[\ IOXRURPWKLRJXDQ\O\O
ĺ GHR[\ IOXRURPWKLRJXDQ\O\O ĺ O
PHWK\ODGHQ\O\O ĺ GHR[\ IOXRURP
WKLRDGHQ\O\O ĺ OPHWK\OJXDQ\O\O ĺ O
PHWK\OPWKLRDGHQ\O\O ĺ GHR[\ IOXRURP
WKLRXULG\O\O ĺ OPHWK\OJXDQ\O\O ĺ O
PHWK\OJXDQ\O\O ĺ GHR[\ IOXRURP
WKLRF\WLG\O\O ĺ GHR[\ IOXRURPWKLRDGHQ\O\O
ĺ GHR[\ IOXRURPWKLRXULG\O\O ĺ
GHR[\ IOXRURPWKLRXULG\O\O ĺ GHR[\
IOXRURPWKLRXULG\O\O ĺ GHR[\ IOXRURP
WKLRF\WLG\O\O ĺ GHR[\ IOXRURXULGLQH
promotion of functional dystrophin synthesis
VXYRGLUVHQ >toutPS S @ GpVR[\ IOXRURPWKLRXULG\O\O ĺ
GpVR[\ IOXRURPWKLRF\WLG\O\O ĺ GpVR[\
IOXRURPWKLRDGpQ\O\O ĺ GpVR[\ IOXRURP
WKLRDGpQ\O\O ĺ GpVR[\ IOXRURPWKLRJXDQ\O\O
ĺ GpVR[\ IOXRURPWKLRJXDQ\O\O ĺ O
PpWK\ODGpQ\O\O ĺ GpVR[\ IOXRURP
WKLRDGpQ\O\O ĺ OPpWK\OJXDQ\O\O ĺ O
PpWK\OPWKLRDGpQ\O\O ĺ GpVR[\ IOXRURP
WKLRXULG\O\O ĺ OPpWK\OJXDQ\O\O ĺ O
PpWK\OJXDQ\O\O ĺ GpVR[\ IOXRURP
WKLRF\WLG\O\O ĺ GpVR[\ IOXRURPWKLRDGpQ\O\O
ĺ GpVR[\ IOXRURPWKLRXULG\O\O ĺ
GpVR[\ IOXRURPWKLRXULG\O\O ĺ GpVR[\
IOXRURPWKLRXULG\O\O ĺ GpVR[\ IOXRURP
WKLRF\WLG\O\O ĺ GpVR[\ IOXRURXULGLQH
stimulation de la synthèse de dystrophine fonctionnelle
VXYRGLUVpQ >todoPS S @ GHVR[L IOXRURPWLRXULGLOLO ĺ
GHVR[L IOXRURPWLRFLWLGLOLO ĺ GHVR[L IOXRUR
PWLRDGHQLOLO ĺ GHVR[L IOXRURPWLRDGHQLOLO
ĺ GHVR[L IOXRURPWLRJXDQLOLO ĺ
GHVR[L IOXRURPWLRJXDQLOLO ĺ OPHWLODGHQLOLO
ĺ GHVR[L IOXRURPWLRDGHQLOLO ĺ O
PHWLOJXDQLOLO ĺ OPHWLOPWLRDGHQLOLO ĺ
GHVR[L IOXRURPWLRXULGLOLO ĺ OPHWLOJXDQLOLO
ĺ OPHWLOJXDQLOLO ĺ GHVR[L IOXRURP
340
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
WLRFLWLGLOLO ĺ GHVR[L IOXRURPWLRDGHQLOLO
ĺ GHVR[L IOXRURPWLRXULGLOLO ĺ
GHVR[L IOXRURPWLRXULGLOLO ĺ GHVR[L IOXRUR
PWLRXULGLOLO ĺ GHVR[L IOXRURPWLRFLWLGLOLO
ĺ GHVR[L IOXRURXULGLQD
estimulación de la síntesis de distrofina funcional
&+)1236
WDIROHFLPDEXP
WDIROHFLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
3&6. SURSURWHLQFRQYHUWDVHVXEWLOLVLQNH[LQW\SH
QHXUDODSRSWRVLVUHJXODWHGFRQYHUWDVH1$5&
1$5&SURSURWHLQHFRQYHUWDVH3& @Homo
sapiensPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH &+
&+ &+6.!GHO
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @GLPHU
WHWUDNLVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 6FHOOOLQHJO\FRIRUP
DOID
antihypercholesterolemic
WDIROpFLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
3&6. SURSURWpLQHFRQYHUWDVHVXEWLOLVLQHNH[LQHW\SH
FRQYHUWDVHUpJXOpHSDUO DSRSWRVHQHXURQDOH
1$5&1$5&SURSURWpLQHFRQYHUWDVH3& @
DQWLFRUSVPRQRFORQDOHomo sapiens
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH
&+ &+ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @GLPqUH
WpWUDNLVGLVXOIXUH
SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV
FKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPHDOID
antihypercholestérolémique
341
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
WDIROHFLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
3&6. SURSURWHtQDFRQYHUWDVDVXEWLOLVLQDNH[LQDWLSR
FRQYHUWDVDUHJXODGDSRUODDSRSWRVDQHXURQDO
1$5&1$5&SURSURWHtQDFRQYHUWDVD3& @
DQWLFXHUSRPRQRFORQDOHomo sapiens
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD
&+ &+ &+6.!GHO
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDHomo sapiens >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @GtPHUR
WHWUDNLVGLVXOIXUR
SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV
&+2 OtQHDFHOXODU&+26JOLFRIRUPDDOID
antihipercolesterolémico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
QLQLQESGPG LVKPSETLSL TCTVSGGSIS SASYYWSWIR QPPGKGLEWI 50
GSINYRGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
NSGVVPAAGP NWFGPWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTFRVVSV LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G 451
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RRNWFTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K K K
1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH
+ 9+ 4
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
WDOTXHWDPDEXP
WDOTXHWDPDE LPPXQRJOREXOLQ*NDSSD*ODPEGDDQWL>Homo
sapiens*35&' *SURWHLQFRXSOHGUHFHSWRUFODVV&
JURXSPHPEHU' @DQGDQWL>Homo sapiens&'(
&'HSVLORQ/HX @KXPDQL]HGDQGFKLPHULF
PRQRFORQDODQWLERG\ELVSHFLILF
JDPPDKHDY\FKDLQKXPDQL]HGDQWL*35&'
>9+ Homo sapiens,*+9
,*+' ,*+- >@ Homo
sapiens,*+* &+ KLQJH6!3
&+)!$ /!$
&+ &+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
342
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
DQWL*35&' >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.& .P
$ 9 @
JDPPDKHDY\FKDLQFKLPHULFDQWL&'( >9+ Mus musculus
,*+9 Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens,*+* &+
KLQJH6!3 &+)!$ /!$
&+)!/ 5!. &+6
@ GLVXOILGHZLWKODPEGDOLJKWFKDLQKXPDQL]HG
DQWL&'( >9/$0%'$ Homo sapiens,*/9
,*/- >@ Homo sapiens,*/&
@
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU
2YDU\ &+2 .FHOOOLQHJO\FRIRUPDOID
immunomodulator, antineoplastic
WDOTXpWDPDE LPPXQRJOREXOLQH*NDSSD*ODPEGDDQWL>Homo sapiens *35&'
PHPEUH'GXJURXSHGHODFODVVH&GXUpFHSWHXUFRXSOpDX[SURWpLQHV
* @HWDQWL>Homo sapiens&'( &'HSVLORQ/HX @DQWLFRUSV
PRQRFORQDOKXPDQLVpHWFKLPpULTXHELVSpFLILTXH
FKDvQHORXUGHJDPPDDQWL*35&'KXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ FKDUQLqUH6!3
&+)!$ /!$ &+
&+6 @ GLVXOIXUHDYHFODFKDvQH
OpJqUHNDSSDDQWL*35&'KXPDQLVpH >9.$33$ Homo sapiens
,*.9 ,*.- >@ Homo sapiens
,*.& .P$ 9 @
FKDvQHORXUGHJDPPDDQWL&'FKLPpULTXH >9+ Mus musculus
,*+9 Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens,*+* &+
FKDUQLqUH6!3 &+)!$
/!$ &+)!/ 5!. &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHODPEGD
DQWL&'(KXPDQLVpH >9/$0%'$ Homo sapiens,*/9
,*/- >@ Homo sapiens,*/&
@GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH.
JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
WDOTXHWDPDE LQPXQRJOREXOLQD*NDSSD*ODPEGDDQWL>Homo sapiens *35&'
PLHPEUR'GHOJUXSRGHODFODVH&GHOUHFHSWRUDFRSODGRFRQSURWHtQDV
* @\DQWL>Homo sapiens&'( &'pSVLORQ/HX @DQWLFXHUSR
PRQRFORQDOKXPDQL]DGR\TXLPpULFRELHVSHFtILFR
FDGHQDSHVDGDJDPPDDQWL*35&'KXPDQL]DGD >9+ Homo
sapiens,*+9 ,*+' ,*+- >@
Homo sapiens,*+* &+ ELVDJUD6!3
&+)!$ /!$ &+
&+6 @ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDDQWL*35&'KXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@ Homo sapiens
,*.& .P$ 9 @
FDGHQDSHVDGDJDPPDDQWL&'TXLPpULFD >9+ Mus musculus
,*+9 Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens,*+* &+
ELVDJUD6!3 &+)!$
/!$ &+)!/ 5!. &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
343
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ODPEGDDQWL&'(KXPDQL]DGD >9/$0%'$
Homo sapiens,*/9 ,*/-
>@ Homo sapiens,*/&
@GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 OtQHDFHOXODU.JOLFRIRUPD
DOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL*35&'
QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL 50
INPYNSDTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARVA 100
LRVALDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EAAGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK 445
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD DQWL*35&'
DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS 50
ASYRYSGVPS RFSGSGSGTE FTLTISNLQP EDFATYYCQQ YNRYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD DQWL&'(
EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR 50
IRSKYNNYAT YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR 100
HGNFGNSYVS WFAYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFL LYSKLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
GK 452
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD DQWL&'(
QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI 50
GGTNKRAPGT PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS 215
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ &+ &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
WDQLPLODVWXP
WDQLPLODVW GLFKORUR> S > F\FORSURS\OPHWKR[\
GLIOXRURPHWKR[\ SKHQ\O@^> F\FORSURS\OPHWKR[\
PHWKDQHVXOIRQDPLGR EHQ]R\O@R[\`HWK\O@S\ULGLQH
R[LGH
phosphodiesterase IV inhibitor
WDQLPLODVW R[\GHGHGLFKORUR> S >
F\FORSURS\OPpWKR[\ GLIOXRURPpWKR[\ SKpQ\O@^>
F\FORSURS\OPpWKR[\
PpWKDQHVXOIRQDPLGR EHQ]R\O@R[\`pWK\O@S\ULGLQH
inhibiteur de la phosphodiestérase IV
344
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
WDQLPLODVW y[LGRGHGLFORUR> S > FLFORSURSLOPHWR[L
GLIOXRURPHWR[L IHQLO@^> FLFORSURSLOPHWR[L
PHWDQRVXOIRQDPLGR EHQ]RLO@R[L`HWLO@SLULGLQD
inhibidor de la fosfodiesterasa IV
&+&O)126
WDSRWRFOD[XP
WDSRWRFOD[ SRRSESR FKORURPHWKR[\
GLPHWK\O GLK\GURHH HȜWKLD
D]DVSLUR> >@EHQ]R[D]HSLQD
F\FOREXWDQDF\FORGRGHFDSKDQHQH
QDSKWKDOHQH@WULRQH
antineoplastic
WDSRWRFOD[ SRRSESR FKORURPpWKR[\
GLPpWK\O GLK\GURHH HȜWKLD
D]DVSLUR> >@EHQ]R[D]pSLQD
F\FOREXWDQDF\FORGRGpFDSKDQqQH QDSKWDOqQH@
WULRQH
antinéoplasique
WDSRWRFOD[ SRRSESR FORURPHWR[L
GLPHWLO GLKLGURHH HȜWLD
D]DVSLUR> >@EHQ]R[D]HSLQD
FLFOREXWDQDFLFORGRGHFDIDQHQR QDIWDOHQR@
WULRQD
antineoplásico
&+&O126
345
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
WHEURFDEWDJHQXPDXWROHXFHOXP
WHEURFDEWDJHQHDXWROHXFHO DXWRORJRXV7FHOOVWUDQVGXFHGZLWKDUHSOLFDWLRQ
LQFRPSHWHQW0RORQH\PXULQHOHXNHPLDYLUXV 0R0/9
DUHWURYLUXV YHFWRUWKDWHQFRGHVDFKLPHULFDQWLJHQ
UHFHSWRU &$5 WDUJHWLQJKXPDQ%O\PSKRF\WHDQWLJHQ
&' &'PROHFXOH%/\PSKRF\WH6XUIDFH$QWLJHQ
%7&HOO6XUIDFH$QWLJHQ/HX&9,'
cell therapy (antineoplastic)
WpEURFDEWDJqQHDXWROHXFHO O\PSKRF\WHV7DXWRORJXHVWUDQVGXLWVSDUXQYHFWHXUGX
YLUXVGHODOHXFpPLHPXULQHGH0RORQH\ 0R0/9 XQ
UHWURYLUXV LQFRPSpWHQWSRXUODUHSOLFDWLRQHWFRGDQW
SRXUXQUpFHSWHXUDQWLJpQLTXHFKLPpULTXH &$5 GLULJp
FRQWUHO DQWLJqQH&'GHVO\PSKRF\WHV%KXPDLQV
PROHFXOH&'DQWLJqQHGHVXUIDFH%GHV
O\PSKRF\WHV%DQWLJqQHGHVXUIDFH/HXGHV
O\PSKRF\WHV7&9,'
thérapie cellulaire (antinéoplasique)
WHEURFDEWDJpQDXWROHXFHO OLQIRFLWRV7DXWyORJRVWUDQVGXFLGRVFRQXQYHFWRUGHO
YLUXVGHODOHXFHPLDPXULQDGH0RORQH\ 0R0/9 XQ
UHWURYLUXV LQFRPSHWHQWHSDUDUHSOLFDFLyQTXHFRGLILFD
SDUDXQUHFHSWRUGHDQWtJHQRVTXLPpULFR &$5
GLULJLGRDODQWtJHQRGHOLQIRFLWRV%KXPDQRV&'
PROpFXOD&'DQWtJHQR%GHVXSHUILFLHGH
OLQIRFLWRV%DQWtJHQRGHVXSHUILFLHGHOLQIRFLWRV7/HX
&9,'
terapia celular (antineoplásico)
WLOYHVWDPDEXP
WLOYHVWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens$;/
$;/UHFHSWRUW\URVLQHNLQDVHW\URVLQHSURWHLQNLQDVH
UHFHSWRU8)2 @KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*PQ*P &+5!.
KLQJH &+ &+(
0 &+6
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
KXPDQL]HG >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @GLPHU
ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
WLOYHVWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens $;/
UpFHSWHXUW\URVLQHNLQDVH$;/UpFHSWHXUW\URVLQH
SURWpLQHNLQDVH8)2 @DQWLFRUSVPRQRFORQDO
KXPDQLVp
346
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y
*P!*PQ*P &+5!.
FKDUQLqUH &+ &+
( 0 &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
WLOYHVWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens $;/
UHFHSWRUWLURVLQDNLQDVD$;/UHFHSWRUWLURVLQD
SURWHtQDNLQDVD8)2 @DQWLFXHUSRPRQRFORQDO
KXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* Y*P!*PQ*P &+5!.
ELVDJUD &+
&+( 0 &+6
@ GLVXOIXURFRQODFDGHQD
OLJHUDNDSSDKXPDQL]DGD >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @GtPHUR
ELVGLVXOIXURSURGXFLGRHQODVFpOXODV
RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
347
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
WLQODUHEDQWXP
WLQODUHEDQW ^>GLIOXRUR
WULIOXRURPHWK\O SKHQ\O@SLSHULGLQHFDUERQ\O`
WHWUDK\GURHS\UD]ROR>c@S\ULGLQ\O HWKDQRQH
retinol binding protein-4 antagonist
WLQODUpEDQW ^>GLIOXRUR
WULIOXRURPpWK\O SKpQ\O@SLSpULGLQHFDUERQ\O`
WpWUDK\GURHS\UD]ROR>c@S\ULGLQ\O pWKDQRQH
antagoniste de la protéine 4 se liant au rétinol
WLQODUHEDQW ^>GLIOXRUR WULIOXRURPHWLO IHQLO@SLSHULGLQD
FDUERQLO`WHWUDKLGURHSLUD]ROR>c@SLULGLQ
LO HWDQRQD
antagonista de la proteína 4 de unión a retinol
&+)12
WLQXULOLPDEXP
WLQXULOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
&($&$0 FDUFLQRHPEU\RQLFDQWLJHQUHODWHGFHOO
DGKHVLRQPROHFXOH&'F @KXPDQL]HGPRQRFORQDO
DQWLERG\
JDPPDKHDY\FKDLQHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ KLQJH &+
&+ &+6.!GHO
@ GLVXOILGHZLWKNDSSDOLJKWFKDLQ
KXPDQL]HG >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens,*.& .P$
9 @
GLPHU
WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\
&+2 FHOOVJO\FRIRUPDOID
immunomodulator, antineoplastic
WLQXULOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
&($&$0 PROpFXOHG DGKpVLRQFHOOXODLUH
DSSDUHQWpHjO DQWLJqQHFDUFLQRHPEU\RQQDLUH
&'F @DQWLFRUSVPRQRFORQDOKXPDQLVp
348
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FKDvQHORXUGHJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ FKDUQLqUH
&+ &+ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDKXPDQLVpH >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @
GLPqUH
WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV
GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
WLQXULOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
&($&$0 PROpFXODGHDGKHVLyQFHOXODU
UHODFLRQDGDFRQHODQWtJHQRFDUFLQRHPEULRQDULR
&'F @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDHomo sapiens >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD
&+ &+ &+6.!GHO
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDKXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @
GtPHUR
WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH
KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
349
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
WROXGHVYHQODID[LQXP
WROXGHVYHQODID[LQH rac> R GLPHWK\ODPLQR
K\GUR[\F\FORKH[\O HWK\O@SKHQ\OPHWK\OEHQ]RDWH
antidepressant
WROXGHVYHQODID[LQH PpWK\OEHQ]RDWHGHrac> R GLPpWK\ODPLQR
K\GUR[\F\FORKH[\O pWK\O@SKpQ\OH
antidépresseur
WROXGHVYHQODID[LQD PHWLOEHQ]RDWRGHrac> R GLPHWLODPLQR
KLGUR[LFLFORKH[LO HWLO@IHQLOR
antidepresivo
&+12
WRPLQHUVHQXP
WRPLQHUVHQ allPambo O PHWKR[\HWK\O PHWK\OPWKLRF\WLG\O\O
ĺ O PHWKR[\HWK\O PHWK\OXULG\O\O ĺ
O PHWKR[\HWK\O PHWK\OF\WLG\O\O ĺ O
PHWKR[\HWK\O DGHQ\O\O ĺ O PHWKR[\HWK\O P
WKLRJXDQ\O\O ĺ PWKLRWK\PLG\O\O ĺ GHR[\P
WKLRDGHQ\O\O ĺ GHR[\PWKLRDGHQ\O\O ĺ
GHR[\PHWK\OPWKLRF\WLG\O\O ĺ GHR[\P
WKLRDGHQ\O\O ĺ PWKLRWK\PLG\O\O ĺ P
WKLRWK\PLG\O\O ĺ GHR[\PWKLRJXDQ\O\O ĺ
GHR[\PWKLRDGHQ\O\O ĺ GHR[\PHWK\OP
WKLRF\WLG\O\O ĺ O PHWKR[\HWK\O DGHQ\O\O ĺ
O PHWKR[\HWK\O PHWK\OF\WLG\O\O ĺ O
PHWKR[\HWK\O PHWK\OF\WLG\O\O ĺ O
PHWKR[\HWK\O PWKLRDGHQ\O\O ĺ O
PHWKR[\HWK\O PHWK\OF\WLGLQH
reduction of abnormal huntingtin synthesis
WRPLQHUVHQ toutPambo O PpWKR[\pWK\O PpWK\OP
WKLRF\WLG\O\O ĺ O PpWKR[\pWK\O
PpWK\OXULG\O\O ĺ O PpWKR[\pWK\O
PpWK\OF\WLG\O\O ĺ O PpWKR[\pWK\O DGpQ\O\O
ĺ O PpWKR[\pWK\O PWKLRJXDQ\O\O ĺ P
WKLRWK\PLG\O\O ĺ GpVR[\PWKLRDGpQ\O\O ĺ
GpVR[\PWKLRDGpQ\O\O ĺ GpVR[\PpWK\OP
WKLRF\WLG\O\O ĺ GpVR[\PWKLRDGpQ\O\O ĺ P
WKLRWK\PLG\O\O ĺ PWKLRWK\PLG\O\O ĺ GpVR[\
PWKLRJXDQ\O\O ĺ GpVR[\PWKLRDGpQ\O\O ĺ
GpVR[\PpWK\OPWKLRF\WLG\O\O ĺ O
PpWKR[\pWK\O DGpQ\O\O ĺ O PpWKR[\pWK\O
PpWK\OF\WLG\O\O ĺ O PpWKR[\pWK\O
PpWK\OF\WLG\O\O ĺ O PpWKR[\pWK\O P
WKLRDGpQ\O\O ĺ O PpWKR[\pWK\O
PpWK\OF\WLGLQH
réduction de la synthèse de huntingtine anormale
350
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
WRPLQHUVpQ todoPambo O PHWR[LHWLO PHWLOPWLRFLWLGLOLO
ĺ O PHWR[LHWLO PHWLOXULGLOLO ĺ O
PHWR[LHWLO PHWLOFLWLGLOLO ĺ O
PHWR[LHWLO DGHQLOLO ĺ O PHWR[LHWLO P
WLRJXDQLOLO ĺ PWLRWLPLGLOLO ĺ GHVR[LP
WLRDGHQLOLO ĺ GHVR[LPWLRDGHQLOLO ĺ
GHVR[LPHWLOPWLRFLWLGLOLO ĺ GHVR[LP
WLRDGHQLOLO ĺ PWLRWLPLGLOLO ĺ PWLRWLPLGLOLO
ĺ GHVR[LPWLRJXDQLOLO ĺ GHVR[LP
WLRDGHQLOLO ĺ GHVR[LPHWLOPWLRFLWLGLOLO ĺ
O PHWR[LHWLO DGHQLOLO ĺ O PHWR[LHWLO
PHWLOFLWLGLOLO ĺ O PHWR[LHWLO PHWLOFLWLGLOLO
ĺ O PHWR[LHWLO PWLRDGHQLOLO ĺ O
PHWR[LHWLO PHWLOFLWLGLQD
reducción de la síntesis de huntingtina anormale
&+1236
WUD]SLUREHQXP
WUD]SLUREHQ ^>F\FORKH[\OR[R R[RSKHQ\OEXW\O
WULD]DVSLUR>@GHFDQ\O@PHWK\O`EHQ]RLFDFLG
prokinetic agent
WUD]SLUREqQH DFLGH^>F\FORKH[\OR[R R[RSKpQ\OEXW\O
WULD]DVSLUR>@GpFDQ\O@PpWK\O`EHQ]RwTXH
accélérateur du transit intestinal
WUD]SLUREpQ iFLGR^>FLFORKH[LOR[R R[RIHQLOEXWLO
WULD]DVSLUR>@GHFDQLO@PHWLO`EHQ]RLFR
estimulante de la motilidad intestinal
&+12
WUHSURVWLQLOXPSDOPLWLOXP
WUHSURVWLQLOSDOPLWLO KH[DGHF\O ^ RRDSDS K\GUR[\> S
K\GUR[\RFW\O@DDKH[DK\GURH
F\FORSHQWD>b@QDSKWKDOHQ\O`R[\ DFHWDWH
vasodilator
351
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
WUpSURVWLQLOSDOPLWLO ^ RRDSDS K\GUR[\> S K\GUR[\RFW\O@
DDKH[DK\GURHF\FORSHQWD>b@QDSKWDOpQ
\O`R[\ DFpWDWHGHKH[DGpF\OH
vasodilatateur
WUHSURVWLQLOSDOPLWLOR ^ RRDSDS KLGUR[L> S KLGUR[LRFWLO@
DDKH[DKLGURHFLFORSHQWD>b@QDIWDOHQ
LO`R[L DFHWDWRGHKH[DGHFLOR
vasodilatador
&+2
YHOVHFRUDWXP
YHOVHFRUDW ^> RS GLIOXRURSURSDQDPLGR
GLK\GUREHQ]RGLR[LQ\O SURSR[\@HLQGD]RO
\O`N> R R[RODQ\O@EHQ]DPLGH
glucocorticoid receptor agonist, anti-inflammatory
YHOVpFRUDW ^> RS GLIOXRURSURSDQDPLGR
GLK\GUREHQ]RGLR[LQ\O SURSR[\@HLQGD]RO
\O`N> R R[RODQ\O@EHQ]DPLGH
agoniste des récepteurs glucocorticoids, anti-
inflamamtoire
YHOVHFRUDW ^> RS GLIOXRURSURSDQDPLGR
GLKLGUREHQ]RGLR[LQLO SURSR[L@HLQGD]ROLO`
N> R R[RODQLO@EHQ]DPLGD
agonista de los receptores glucocorticoides,
antiinflamatorio
&+)12
YHYHULPHUXP
YHYHULPHU SRO\>NNGL SURSHQ\O HWKDQHGLDPLQHco
NNGL SURSHQ\O SURSDQHGLDPLQHcoSURS
HQDPLQH § @SURGXFHGE\FURVVOLQNLQJRI
SRO\>NNGL SURSHQ\O SURSDQHGLDPLQH co
SURSHQDPLQH § @ZLWKGLFKORURHWKDQH
PRO DQGQHXWUDOL]DWLRQ
hydrochloric acid binding polymer
352
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
YpYpULPqUH SRO\>NNGL SURSpQ\O pWKDQHGLDPLQHco
NNGL SURSpQ\O SURSDQHGLDPLQHcoSURS
pQDPLQH § @SURGXLWSDUUpWLFXODWLRQGH
SRO\>NNGL SURSpQ\O SURSDQHGLDPLQH co
SURSpQDPLQH § @DYHFOHGLFKORURpWKDQH
PRO HWQHXWUDOLVDWLRQ
polymère liant l'acide chlorhydrique
YHYHUtPHUR SROL>NNGL SURSHQLO HWDQRGLDPLQDco
NNGL SURSHQLO SURSDQRGLDPLQDcoSURS
HQDPLQD § @SURGXFLGRSRUHQWUHFUX]DPLHQWR
GHSROL>NNGL SURSHQLO SURSDQRGLDPLQD
coSURSHQDPLQD § @FRQGLFORURHWDQR
PRO \QHXWUDOL]DFLyQ
polímero de unión al ácido clorhídrico
> &+1 a &+1 a
&+1 a@QQ
YLERVWROLPDEXP
YLERVWROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 7,*,7
7FHOOLPPXQRUHFHSWRUZLWK,JGRPDLQDQG,7,09VHW
,JPHPEHU96,*9VHWDQGWUDQVPHPEUDQH
PHPEHU9670 @KXPDQL]HGPRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*P &+. KLQJH
&+ &+' /
&+6 @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPHU ELVGLVXOILGH
SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV
JO\FRIRUPDOID
immunomodulator, antineoplastic
YLERVWROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 7,*,7
LPPXQRUpFHSWHXUGHVO\PSKRF\WHV7DYHFGRPDLQH,J
HW,7,0PHPEUHGHO ,J9VHW96,*PHPEUHGH
O ,J9VHWHWUpJLRQWUDQVPHPEUDQH9670 @
DQWLFRUSVPRQRFORQDOKXPDQLVp
353
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
&+. FKDUQLqUH &+
&+' / &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUH
NDSSDKXPDQLVpH >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens ,*.& .P$ 9
@
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH
DOID
immunomodulateur, antinéoplasique
YLERVWROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 7,*,7
LQPXQRUHFHSWRUGHORVOLQIRFLWRV7FRQGRPLQLR,JH,7,0
PLHPEURGHOD,J9VHW96,*PLHPEURGHOD,J9VHW\
UHJLyQWUDQVPHPEUDQD9670 @DQWLFXHUSRPRQRFORQDO
KXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P
&+. ELVDJUD &+
&+' / &+6
@ GLVXOIXURFRQODFDGHQDOLJHUD
NDSSDKXPDQL]DGD >9.$33$ Homo sapiens
,*.9 ,*.- >@
Homo sapiens ,*.& .P$ 9
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLVQSGAE VKKPGSSVKV SCKASGYTFS SYVMHWVRQA PGQGLEWIGY 50
IDPYNDGAKY AQKFQGRVTL TSDKSTSTAY MELSSLRSED TAVYYCARGG 100
PYGWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPSS LSASVGDRVT ITCRASEHIY SYLSWYQQKP GKVPKLLIYN 50
AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQH HFGSPLTFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
&WHUPLQDO O\VLQH FOLSSLQJ
+ &+6 .
354
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
YXSDQRUVHQXP
YXSDQRUVHQ allPambo O > DFHWDPLGRGHR[\ȕ'
JDODFWRS\UDQRV\O R[\@ELV^> ^> DFHWDPLGRGHR[\
ȕ'JDODFWRS\UDQRV\O R[\@KH[\O`DPLQR R[RSURSR[\@PHWK\O`
K\GUR[\WHWUDR[RGLR[DWULD]DȜ
SKRVSKDRFWDFRVDQ\O O PHWKR[\HWK\O PWKLRJXDQ\O\O
ĺ O PHWKR[\HWK\O JXDQ\O\O ĺ O
PHWKR[\HWK\O DGHQ\O\O ĺ O PHWKR[\HWK\O
PHWK\OF\WLG\O\O ĺ O PHWKR[\HWK\O DGHQ\O\O ĺ
PWKLRWK\PLG\O\O ĺ PWKLRWK\PLG\O\O ĺ GHR[\P
WKLRJXDQ\O\O ĺ GHR[\PHWK\OPWKLRF\WLG\O\O ĺ
GHR[\PHWK\OPWKLRF\WLG\O\O ĺ GHR[\P
WKLRDGHQ\O\O ĺ GHR[\PWKLRJXDQ\O\O ĺ P
WKLRWK\PLG\O\O ĺ GHR[\PWKLRDGHQ\O\O ĺ
GHR[\PWKLRDGHQ\O\O ĺ O PHWKR[\HWK\O
PHWK\OXULG\O\O ĺ O PHWKR[\HWK\O PHWK\OF\WLG\O\O
ĺ O PHWKR[\HWK\O PWKLRJXDQ\O\O ĺ O
PHWKR[\HWK\O PHWK\OPWKLRF\WLG\O\O ĺ O
PHWKR[\HWK\O DGHQRVLQH
antihyperlipidaemic
YXSDQRUVHQ toutPambo O > DFpWDPLGRGpVR[\ȕ'
JDODFWRS\UDQRV\O R[\@ELV^> ^> DFpWDPLGR
GpVR[\ȕ'JDODFWRS\UDQRV\O R[\@KH[\O`DPLQR
R[RSURSR[\@PpWK\O`K\GUR[\WpWUDR[RGLR[D
WULD]DȜSKRVSKDRFWDFRVDQ\O O
PpWKR[\pWK\O PWKLRJXDQ\O\O ĺ O
PpWKR[\pWK\O JXDQ\O\O ĺ O PpWKR[\pWK\O DGpQ\O\O
ĺ O PpWKR[\pWK\O PpWK\OF\WLG\O\O ĺ O
PpWKR[\pWK\O DGpQ\O\O ĺ PWKLRWK\PLG\O\O ĺ P
WKLRWK\PLG\O\O ĺ GpVR[\PWKLRJXDQ\O\O ĺ
GpVR[\PpWK\OPWKLRF\WLG\O\O ĺ GpVR[\PpWK\OP
WKLRF\WLG\O\O ĺ GpVR[\PWKLRDGpQ\O\O ĺ
GpVR[\PWKLRJXDQ\O\O ĺ PWKLRWK\PLG\O\O ĺ
GpVR[\PWKLRDGpQ\O\O ĺ GpVR[\PWKLRDGpQ\O\O
ĺ O PpWKR[\pWK\O PpWK\OXULG\O\O ĺ O
PpWKR[\pWK\O PpWK\OF\WLG\O\O ĺ O PpWKR[\pWK\O
PWKLRJXDQ\O\O ĺ O PpWKR[\pWK\O PpWK\OP
WKLRF\WLG\O\O ĺ O PpWKR[\pWK\O DGpQRVLQH
antihyperlipidémiant
YXSDQRUVpQ todoPambo O > DFHWDPLGRGHVR[Lȕ'
JDODFWRSLUDQRVLO R[L@ELV^> ^> DFHWDPLGRGHVR[Lȕ
'JDODFWRSLUDQRVLO R[L@KH[LO`DPLQR R[RSURSR[L@PHWLO`
KLGUR[LWHWUDR[RGLR[DWULD]DȜ
IRVIDRFWDFRVDQLO O PHWR[LHWLO PWLRJXDQLOLO ĺ
O PHWR[LHWLO JXDQLOLO ĺ O PHWR[LHWLO DGHQLOLO
ĺ O PHWR[LHWLO PHWLOFLWLGLOLO ĺ O
PHWR[LHWLO DGHQLOLO ĺ PWLRWLPLGLOLO ĺ PWLRWLPLGLOLO
ĺ GHVR[LPWLRJXDQLOLO ĺ GHVR[LPHWLOP
WLRFLWLGLOLO ĺ GHVR[LPHWLOPWLRFLWLGLOLO ĺ
GHVR[LPWLRDGHQLOLO ĺ GHVR[LPWLRJXDQLOLO ĺ P
WLRWLPLGLOLO ĺ GHVR[LPWLRDGHQLOLO ĺ GHVR[LP
WLRDGHQLOLO ĺ O PHWR[LHWLO PHWLOXULGLOLO ĺ O
PHWR[LHWLO PHWLOFLWLGLOLO ĺ O PHWR[LHWLO P
WLRJXDQLOLO ĺ O PHWR[LHWLO PHWLOPWLRFLWLGLOLO
ĺ O PHWR[LHWLO DGHQRVLQD
antihiperlipémico
355
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
&+1236
[LOLHUWLQLEXP
[LOLHUWLQLE DRDR N> HWK\Q\ODQLOLQR PHWKR[\TXLQD]ROLQ
\O@PHWK\OKH[DK\GURS\UUROR>b@S\UUROH H
FDUER[DPLGH
tyrosine kinase inhibitor, antineoplastic
[LOLHUWLQLE DRDR N> pWK\Q\ODQLOLQR PpWKR[\TXLQD]ROLQ
\O@PpWK\OKH[DK\GURS\UUROR>b@S\UUROH H
FDUER[DPLGH
inhibiteur de la tyrosine kinase, antinéoplasique
[LOLHUWLQLE DRDR N> HWLQLODQLOLQR PHWR[LTXLQD]ROLQLO@
PHWLOKH[DKLGURSLUUROR>b@SLUURO H FDUER[DPLGD
inhibidor de la tirosina quinasa, antineoplásico
&+12
&+
2 1
2
+ 1
1 1
+ &+
+1
1 +
&+
]DJRWHQHPDEXP
]DJRWHQHPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens0$37
PLFURWXEXOHDVVRFLDWHGSURWHLQWDXWDX @KXPDQL]HG
PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* &+
KLQJH6!3 &+
&+ &+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9
@GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 *6FHOOOLQHJO\FRIRUPDOID
immunomodulator (Alzheimer's disease)
356
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
]DJRWpQpPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
0$37 SURWpLQHWDXDVVRFLpHDX[PLFURWXEXOHVWDX @
DQWLFRUSVPRQRFORQDOKXPDQLVp
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
&+ FKDUQLqUH6!3
&+ &+ &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQH
OpJqUHNDSSDKXPDQLVpH >9.$33$ Homo
sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH
FHOOXODLUH*6JO\FRIRUPHDOID
immunomodulateur (maladie d'Alzheimer)
]DJRWHQHPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens0$37
SURWHtQDWDXDVRFLDGDDORVPLFURW~EXORVWDX @
DQWLFXHUSRPRQRFORQDOKXPDQL]DGR
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* &+ ELVDJUD6!3
&+ &+ &+6
.!GHO @ GLVXOIXURFRQOD
FDGHQDOLJHUDNDSSDKXPDQL]DGD >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD
FHOXODU*6JOLFRIRUPDDOID
inmunomodulador (enfermedad de Alzheimer)
357
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
]DQLGDWDPDEXP
]DQLGDWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens (5%%
HSLGHUPDOJURZWKIDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQ
NLQDVHHUE%(*)5+(5+(5SFHUE%1(8
&' @KXPDQL]HGPRQRFORQDODQWLERG\ELSDUDWRSLF
WDUJHWLQJWZRGLIIHUHQWQRQRYHUODSSLQJHSLWRSHVRQ(5%%
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo sapiens
,*+9 ,*+' ,*+- >@
Homo sapiens,*+* *P &+.
KLQJH &+ &+7!9
/!< ' / )!$
<!9 &+6.!GHO @
GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG >9
.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P
$ 9 @
JDPPDKHDY\FKDLQ9.$33$9+&+&+KXPDQL]HG
>9.$33$ Homo sapiens,*.9
,*.- >@ PHUOLQNHU
9+ Homo sapiens,*+9 ,*+' ,*+-
>@ GLDODQ\O Homo
sapiens,*+* KLQJH&!6 &+
&+7!9 ' / 7!/
.!/ 7!: &+6.!GHO
@
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 JO\FRIRUPDOID
immunomodulator, antineoplastic
]DQLGDWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(5%%
UpFHSWHXUGXIDFWHXUGHFURLVVDQFHpSLGHUPLTXH
UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE%(*)5+(5
+(5SFHUE%1(8&' @DQWLFRUSV
PRQRFORQDOKXPDQLVpELSDUDWRSLTXH FLEODQWGHX[
pSLWRSHVGLIIpUHQWVQRQFKHYDXFKDQWVVXU(5%%
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P &+
FKDUQLqUH &+
&+7!9 /!< ' /
)!$ <!9 &+6.!GHO
@ GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD
KXPDQLVpH >9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens
,*.& .P$ 9 @
FKDvQHORXUGHJDPPD9.$33$9+&+&+KXPDQLVpH
>9.$33$ Homo sapiens,*.9
,*.- >@ PHUOLQNHU
9+ Homo sapiens,*+9 ,*+'
,*+- >@ GLDODQ\O
Homo sapiens,*+* FKDUQLqUH&!6
&+ &+7!9 ' /
7!/ .!/ 7!:
&+6.!GHO @GLPqUH
ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID
immunomodulateur, antinéoplasique
358
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
]DQLGDWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(5%%
UHFHSWRUGHOIDFWRUGHFUHFLPLHQWRHSLGpUPLFRUHFHSWRU
WLURVLQDSURWHtQDNLQDVDHUE%(*)5+(5+(5
SFHUE%1(8&' @DQWLFXHUSRPRQRFORQDO
KXPDQL]DGRELSDUDWySLFR FX\DGLDQDVRQGRVHStWRSRV
GLIHUHQWHVQRVRODSDEOHVHQ(5%%
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* *P &+
ELVDJUD &+ &+
7!9 /!< ' / )!$
<!9 &+6.!GHO @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo sapiens,*.&
.P$ 9 @
FDGHQDSHVDGDJDPPD9.$33$9+&+&+KXPDQL]DGD
>9.$33$ Homo sapiens,*.9
,*.- >@ FRQHFWRUPHU
9+ Homo sapiens,*+9 ,*+'
,*+- >@ GLDODQLO
Homo sapiens,*+* ELVDJUD&!6
&+ &+7!9 ' / 7!/
.!/ 7!: &+6.!GHO
@
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID
inmunomodulador, antineoplásico
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
GEVQLVESGG GLVQPGGSLR LSCAASGFTF ADYTMDWVRQ APGKGLEWVG 50
DVNPNSGGSI YNQRFKGRFT FSVDRSKNTL YLQMNSLRAE DTAVYYCARN 100
LGPSFYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYVYPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFALV SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
GDIQMTQSPS SLSASVGDRV TITCRASQDV NTAVAWYQQK PGKAPKLLIY 50
SASFLYSGVP SRFSGSRSGT DFTLTISSLQ PEDFATYYCQ QHYTTPPTFG 100
QGTKVEIKGG SGGGSGGGSG GGSGGGSGEV QLVESGGGLV QPGGSLRLSC 150
AASGFNIKDT YIHWVRQAPG KGLEWVARIY PTNGYTRYAD SVKGRFTISA 200
DTSKNTAYLQ MNSLRAEDTA VYYCSRWGGD GFYAMDYWGQ GTLVTVSSAA 250
EPKSSDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD 300
VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 350
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYVLPPSR DELTKNQVSL 400
LCLVKGFYPS DIAVEWESNG QPENNYLTWP PVLDSDGSFF LYSKLTVDKS 450
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G 481
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
GDIQMTQSPS SLSASVGDRV TITCKASQDV SIGVAWYQQK PGKAPKLLIY 50
SASYRYTGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QYYIYPATFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 215
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
359
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
]HOPLQHPDEXP
]HOPLQHPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens
$'&<$35 DGHQ\ODWHF\FODVHDFWLYDWLQJSRO\SHSWLGH
$'&<$3 W\SH,UHFHSWRUSLWXLWDU\DGHQ\ODWHF\FODVH
DFWLYDWLQJSRO\SHSWLGH 3$&$3 W\SH,UHFHSWRU3$&
3$&5 @PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
Q*P &+. KLQJH
&+1!* &+( 0
&+6 @ GLVXOILGH
ZLWKNDSSDOLJKWFKDLQKXPDQL]HG >9.$33$ Homo
sapiens,*.9 ,*.- >@
Homo sapiens,*.& .P$
9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ&KLQHVH
+DPVWHU2YDU\ &+2 FHOOOLQHQRQJO\FRV\ODWHG
immunomodulator
]HOPLQpPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens
$'&<$35 UpFHSWHXUGHW\SH,GXSRO\SHSWLGHDFWLYDQW
O DGpQ\ODWHF\FODVH $'&<$3 UpFHSWHXUGHW\SH,GX
SRO\SHSWLGHDFWLYDQWO DGpQ\ODWHF\FODVHSLWXLWDLUH 3$&$3
3$&3$&5 @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
Q*P &+. FKDUQLqUH
&+1!* &+( 0
&+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH
>9.$33$ Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.&
.P$ 9 @
GLPqUH ELVGLVXOIXUHSURGXLWGDQVGHV
FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 QRQ
JO\FRV\Op
immunomodulateur
]HOPLQHPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens
$'&<$35 UHFHSWRUGHWLSR,GHSROLSpSWLGRDFWLYDGRUGH
ODDGHQLODWRFLFODVD $'&<$3 UHFHSWRUGHWLSR,GH
SROLSpSWLGRDFWLYDGRUGHODDGHQLODWRFLFODVDSLWXLWDULD
3$&$3 3$&3$&5 @DQWLFXHUSRPRQRFORQDO
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+* Y*P!*P
Q*P &+. ELVDJUD
&+1!* &+( 0
&+6 @ GLVXOIXUR
FRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQODV
FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 QRJOLFRVLODGR
inmunomodulador
360
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
]HOTXLVWLQHOXP
]HOTXLVWLQHO tertEXW\O S > SR DPLQRK\GUR[\
R[REXWDQ\O@R[RGLD]DVSLUR>@RFWDQH
FDUER[\ODWH
N-methyl-D-aspartate (NMDA) receptor partial agonist
]HOTXLVWLQHO S > SR DPLQRK\GUR[\R[REXWDQ\O@
R[RGLD]DVSLUR>@RFWDQHFDUER[\ODWHGHtert
EXW\OH
agoniste partiel des récepteurs du NMDA
]HOTXLVWLQHO S > SR DPLQRKLGUR[LR[REXWDQLO@
R[RGLD]DVSLUR>@RFWDQRFDUER[LODWRGHterc
EXWLOR
agonista parcial del receptor de NMDA
&+12
]LOGLVWURJHQXPYDURSDUYRYHFXP
]LOGLVWURJHQHYDURSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV
W\SH U$$95HS&DS YHFWRUHQFRGLQJKXPDQ
PLFURG\VWURSKLQ Kȝ' XQGHUFRQWURORI&.
PXVFOHFUHDWLQHNLQDVHSURPRWHUDQGHQKDQFHU
HOHPHQWV
gene therapy (Duchenne muscular dystrophy)
361
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
]LOGLVWURJqQHYDURSDUYRYHF YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW
QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXUOD
PLFURG\VWURSKLQHKXPDLQH KP' VRXVOHFRQWU{OH
GHO DFWLYDWHXUSURPRWHXUGHODFUpDWLQHNLQDVH
PXVFXODLUH&.
thérapie génique (dystrophie musculaire de Duchenne)
]LOGLVWURJpQYDURSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR
UHSOLFDWLYRGHOWLSR U$$95HS&DS TXHFRGLILFD
SDUDODPLFURGLVWURILQDKXPDQD KP' EDMRHO
FRQWUROGHOSURPRWRU\HOHPHQWRVSRWHQFLDGRUHV
HQKDQFHU GHODFUHDWLQDTXLQDVD&.GHP~VFXOR
terapia génica (distrofia muscular de Duchenne)
]LOWLYHNLPDEXP
]LOWLYHNLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens,/
LQWHUOHXNLQ,/ @PRQRFORQDODQWLERG\
JDPPDKHDY\FKDLQKXPDQL]HG >9+ Homo
sapiens ,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 KLQJH
&+0!< 6!7 7!(
&+( 0
&+6 @ GLVXOILGHZLWK
NDSSDOLJKWFKDLQHomo sapiens >9.$33$
Homo sapiens,*.9 ,*.-
>@ Homo sapiens ,*.&
.P$ 9 @
GLPHU ELVGLVXOILGHSURGXFHGLQ
&KLQHVH+DPVWHU2YDU\ &+2 *6FHOOOLQHJO\FRIRUP
DOID
immunomodulator
]LOWLYpNLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens ,/
LQWHUOHXNLQH,/ @DQWLFRUSVPRQRFORQDO
FKDvQHORXUGHJDPPDKXPDQLVpH >9+ Homo
sapiens,*+9 ,*+' ,*+-
>@ Homo sapiens,*+*
*PQ*P &+5 FKDUQLqUH
&+0!< 6!7
7!( &+( 0
&+6 @
GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens
>9.$33$ Homo sapiens,*.9
,*.- >@ Homo
sapiens ,*.& .P$ 9
@
GLPqUH ELVGLVXOIXUHSURGXLWGDQV
GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2
OLJQpHFHOOXODLUH*6JO\FRIRUPHDOID
immunomodulateur
]LOWLYHNLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens ,/
LQWHUOHXNLQD,/ @DQWLFXHUSRPRQRFORQDO
362
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
FDGHQDSHVDGDJDPPDKXPDQL]DGD >9+
Homo sapiens,*+9 ,*+'
,*+- >@ Homo sapiens
,*+* *PQ*P &+5
ELVDJUD &+0!< 6!7
7!( &+( 0
&+6 @
GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo
sapiens >9.$33$ Homo sapiens,*.9
,*.- >@
Homo sapiens ,*.& .P$
9 @
GtPHUR ELVGLVXOIXURSURGXFLGRHQ
ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD
FHOXODU*6JOLFRIRUPDDOID
inmunomodulador
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLVESGGG LVQPGGSLRL SCAASGFTIS SNYMIWVRQA PGKGLEWVSD 50
LYYYAGDTYY ADSVKGRFTM SRDISKNTVY LQMNSLRAED TAVYYCARWA 100
DDHPPWIDLW GRGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLYITREP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
DIQMTQSPST LSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKVLIYK 50
ASTLESGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ SWLGGSFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
3RVWWUDQVODWLRQDO PRGLILFDWLRQV
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+ &&
,QWUD/ &&
,QWHU+/ K &/
,QWHU++ K K
1JO\FRV\ODWLRQ VLWHV 6LWHV GH 1JO\FRV\ODWLRQ 3RVLFLRQHV GH 1JOLFRVLODFLyQ
+ &+ 1
)XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV
FRPSOH[HV IXFRV\OpV JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV
]RULIHUWLQLEXP
]RULIHUWLQLE FKORURIOXRURDQLOLQR PHWKR[\TXLQD]ROLQ\O
R GLPHWK\OSLSHUD]LQHFDUER[\ODWH
tyrosine kinase inhibitor, antineoplastic
]RULIHUWLQLE R GLPpWK\OSLSpUD]LQHFDUER[\ODWHGH
FKORURIOXRURDQLOLQR PpWKR[\TXLQD]ROLQ\OH
inhibiteur de la tyrosine kinase, antinéoplasique
]RULIHUWLQLE R GLPHWLOSLSHUD]LQDFDUER[LODWRGH FORUR
IOXRURDQLOLQR PHWR[LTXLQD]ROLQLOR
inhibidor de la tirosina quinasa, antineoplásico
363
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
&+&O)12
# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
KWWSZZZZKRLQWPHGLFLQHVVHUYLFHVLQQSXEOLFDWLRQHQ
364
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
Names for Radicals and Groups
Some substances for which a proposed international nonproprietary name has been
established may be used in the form of salts or esters. The radicals or groups involved may be
of complex composition and it is then inconvenient to refer to them in a systematic chemical
nomenclature. Consequently, shorter nonproprietary names for some radicals and groups
have been devised or selected, and they are suggested for use with the proposed
international nonproprietary names.
Dénominations applicables aux radicaux et groupes
Certaines substances pour lesquelles une dénomination commune internationale proposée a
été établie sont parfois utilisées sous forme de sels ou d'esters. Les radicaux ou groupes
correspondants sont alors quelques fois si complexes qu'il est malcommode de les désigner
conformément à la nomenclature chimique systématique. Des dénominations communes
abrégées ont donc été formées ou choisies pour certains d'entre eux et il est suggéré de les
employer avec les dénominations communes internationales proposées.
Denominaciones para Radicales y Grupos
Ciertas sustancias para las cuales hay establecidas una denominación común internacional
pueden usarse en forma de sales o de ésteres. Los radicales o grupos correspondientes
pueden llegar a tener una composición tan compleja que resulte incómodo referirse a ellos
mediante la nomenclatura química sistemática. Las siguientes denominaciones comunes
abreviadas han sido ideadas o elegidas para algunos de estos radicales y grupos y se sugiere
que se empleen con las denominaciones comunes internacionales propuestas
DUHQDFDUELOXP
DUHQDFDUELO ^ R > PHWK\OSURSDQR\O R[\@HWKR[\`FDUERQ\O
DUpQDFDUELO ^ R > PpWK\OSURSDQR\O R[\@pWKR[\`FDUERQ\OH
DUHQDFDUELO ^ R > PHWLOSURSDQRLO R[L@HWR[L`FDUERQLOR
&+2
FOH]XWRFOD[XP
FOH]XWRFOD[ RS ^ SSSS DQK\GURGLGHR[\/
glycero/guloRFW\ORQLFDFLG FDUER[\> S
GLK\GUR[\EXW\O@WHWUDPHWK\OKH[DR[R
SURSDQ\O > VXOIRHWKR[\ PHWK\O@GLK\GURH
GLR[DSHQWDD]D LVRTXLQROLQD
>@EHQ]RWKLD]ROD S\ULGLQD S\UD]ROD S\UUROLGLQD
DGDPDQWDQD EHQ]HQDKH[DFRVDSKDQ\O`DPLQR
FDUER[\R[RSURSDQ\ODQG RS ^ SSSS
KH[DFRVDSKDQ\O`DPLQR FDUER[\R[RSURS\O
365
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
FOp]XWRFOD[ RS ^ SSSS DFLGHDQK\GURGLGpVR[\/
glycéro/guloRFW\ORQLTXH FDUER[\> S GLK\GUR[\EXW\O@
WpWUDPpWK\OKH[DR[R SURSDQ\O
> VXOIRpWKR[\ PpWK\O@GLK\GURHGLR[D
SHQWDD]D LVRTXLQROLQD >@EHQ]RWKLD]ROD
S\ULGLQD S\UD]ROD S\UUROLGLQD DGDPDQWDQD
EHQ]pQDKH[DFRVDSKDQ\O`DPLQR FDUER[\R[RSURSDQ
\OHHW RS ^ SSSS «KH[DFRVDSKDQ
\O`DPLQR FDUER[\R[RSURS\OH
FOH]XWRFOD[ RS ^ SSSS iFLGRDQKLGURGLGHVR[\/
glicero/guloRFWLORQLFR FDUER[L> S GLKLGUR[LEXWLO@
WHWUDPHWLOKH[DR[R SURSDQLO
> VXOIRHWR[L PHWLO@GLKLGURHGLR[D
SHQWDD]D LVRTXLQROLQD >@EHQ]RWLD]ROD SLULGLQD
SLUD]ROD SLUUROLGLQD DGDPDQWDQD
EHQFHQDKH[DFRVDIDQLO`DPLQR FDUER[LR[RSURSDQLOR\
RS ^ SSSS KH[DFRVDIDQLO`DPLQR FDUER[L
R[RSURSLOR
&+126 IRUWKH (for the reagent)
VXFFLQLPLGHSUHFXUVRUJURXS
2 2 2
2 +&
&+ 1
1 1+
1+ FRQMXJDLVRQ +2&
+&
2 + 2
2 +2&
&2+ 2 1+
62+ 1+ +&
+2 2
2 +&
1+ 2
+2
2+
+2& 1 1
2 2
&+
2 1+
1 1
1
&+ 6 1
+2
2
&+
2+
FRUL[HWDQXP
FRUL[HWDQ ^>^ELV> K\GUR[\PHWK\OR[RGLK\GURS\ULGLQH
FDUER[DPLGR HWK\O@DPLQR` ^ELV> K\GUR[\PHWK\OR[R
GLK\GURS\ULGLQHFDUER[DPLGR HWK\O@DPLQR`PHWK\O SURS\O@DQLOLQR`
R[REXWDQR\O
FRUL[pWDQ ^>^ELV> K\GUR[\PpWK\OR[RGLK\GURS\ULGLQH
FDUER[DPLGR pWK\O@DPLQR` ^ELV> K\GUR[\PpWK\OR[R
GLK\GURS\ULGLQHFDUER[DPLGR pWK\O@DPLQR`PpWK\O SURS\O@DQLOLQR`
R[REXWDQR\OH
FRUL[HWiQ ^>^ELV> KLGUR[LPHWLOR[RGLKLGURSLULGLQD
FDUER[DPLGR HWLO@DPLQR` ^ELV> KLGUR[LPHWLOR[R
GLKLGURSLULGLQDFDUER[DPLGR HWLO@DPLQR`PHWLO SURSLO@DQLOLQR`
R[REXWDQRLOR
366
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
&+12 (for the acid)
GHUX[WHFDQXP
GHUX[WHFDQ RS > S EHQ]\O^> SS HWK\OIOXRURK\GUR[\
PHWK\OGLR[RKH[DK\GURHH
EHQ]R>de@S\UDQR> @LQGROL]LQR>b@TXLQROLQ\O@DPLQR`
KH[DR[RR[DSHQWDD]DWULFRVDQ
\O@GLR[RS\UUROLGLQ\O
GpUX[WpFDQ RS > S EHQ]\O^> SS pWK\OIOXRURK\GUR[\
PpWK\OGLR[RKH[DK\GURHH
EHQ]R>de@S\UDQR> @LQGROL]LQR>b@TXLQROLQ\O@DPLQR`
KH[DR[RR[DSHQWDD]DWULFRVDQ
\O@GLR[RS\UUROLGLQ\OH
GHUX[WHFiQ RS > S EHQFLO^> SS HWLOIOXRURKLGUR[L
PHWLOGLR[RKH[DKLGURHH
EHQ]R>de@SLUDQR> @LQGROL]LQR>b@TXLQROLQLO@DPLQR`
KH[DR[RR[DSHQWDD]DWULFRVDQ
LO@GLR[RSLUUROLGLQLOR
&+)12 reagent
SDOPLWLOXP
SDOPLWLO KH[DGHF\O
SDOPLWLO Kp[DGpF\OH
SDOPLWLO KH[DGHFLOR
&+
367
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(Crónica de la OMS, Vol. 25, No. 3, 1971)
S suprimáse insertese
IOXRFLQyQLGR IOXRFLQRQLGD
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(Crónica de la OMS, Vol. 26, No. 9, 1972)
S suprimáse insertese
FLFRUWyQLGR FLFRUWRQLGD
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(Crónica de la OMS, Vol. 29, No. 3, 1975)
S suprimáse insertese
DPFLQyQLGR DPFLQRQLGD
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(Crónica de la OMS, Vol. 31, No. 3, 1976)
S suprimáse insertese
EXGHVyQLGR EXGHVRQLGD
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 20, No. 2, 2006)
S LPLVRSDVHPXPPDQJDQXP
LPLVRSDVHPPDQJDQHVH replace the chemical name by the following
LPLVRSDVHPPDQJDQqVH remplacer le nom chimique par le suivant
LPLVRSDVHPPDQJDQHVR sustitúyase el nombre químico por el siguiente
PBPY GLFKORULGR> RRRR WHWUDD]D
S\ULGLQD GLF\FORKH[DQDF\FORXQGHFDSKDQH
țNNNNN@PDQJDQHVH
PBPY GLFKORULGR> RRRR WHWUDD]D
S\ULGLQD GLF\FORKH[DQDF\FORXQGpFDSKDQH
țNNNNN@PDQJDQqVH
PBPY GLFORULGR> RRRR WHWUDD]D
SLULGLQD GLFLFORKH[DQDFLFORXQGHFDIDQR
țNNNNN@PDQJDQHVR
368
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 21, No. 4, 2007)
S LPHJOLPLQXP
LPHJOLPLQ replace the chemical name and the structure by the following ones
LPpJOLPLQH remplacer le nom chimique et la structure par les suivants
LPHJOLPLQD sustitúyase el nombre químico y la estructura por los siguientes
R NNWULPHWK\OGLK\GURWULD]LQHGLDPLQH
R NNWULPpWK\OGLK\GURWULD]LQHGLDPLQH
R NNWULPHWLOGLKLGURWULD]LQDGLDPLQD
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 22, No. 2, 2008)
S suprimáse insertese
GHUTXDQWHO GHUFXDQWHO
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 24, No. 4, 2010)
S VROLWKURP\FLQ
VROLWKURP\FLQ replace the chemical name by the following one
VROLWKURP\FLQH remplacer le nom chimique par le suivant
VROLWURPLFLQD sustitúyase el nombre químico por el siguiente
DSRSRRRRRDR ^> DPLQRSKHQ\O H
WULD]RO\O@EXW\O`HWK\OIOXRURPHWKR[\D
KH[DPHWK\O^>WULGHR[\ GLPHWK\ODPLQR ȕ'xylo
KH[RS\UDQRV\O@R[\`RFWDK\GURH>@R[DF\FORWHWUDGHFLQR>
d@>@R[D]ROH HHH WHWURQH
DSRSRRRRRDR ^> DPLQRSKpQ\O H
WULD]RO\O@EXW\O`pWK\OIOXRURPpWKR[\D
KH[DPpWK\O^>WULGpVR[\ GLPpWK\ODPLQR ȕ'xylo
KH[RS\UDQRV\O@R[\`RFWDK\GURH>@R[DF\FORWpWUDGpFLQR>d@R[D]ROH
HHH WpWURQH
DSRSRRRRRDR ^> DPLQRIHQLO H
WULD]ROLO@EXWLO`HWLOIOXRURDKH[DPHWLO
PHWR[L^>WULGHVR[L GLPHWLODPLQR ȕ'xilo
KH[RSLUDQRVLO@R[L`RFWDKLGURH>@R[DFLFORWHWUDGHFLQR>d@>@R[D]RO
HHH WHWURQD
369
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 31, No. 2, 2017)
S DUIROLWL[RULQXP
DUIROLWL[RULQ replace the CAS RN by the following
DUIROLWL[RULQH remplacer le numéro de registre du CAS par le suivant
DUIROLWL[RULQD sustitúyase el número de registro del CAS por el siguiente
S DYDOJOXFRVLGDVXPDOID
DYDOJOXFRVLGDVHDOID replace the description by the following one
DYDOJOXFRVLGDVHDOID remplacer la description par la suivante
DYDOJOXFRVLGDVDDOID sustitúyase la descripción por la siguiente
PRGLILHGKXPDQDFLGĮJOXFRVLGDVHSURGXFHGLQ&KLQHVHKDPVWHURYDU\ &+2 FHOOV
JO\FRIRUPDOIDFRQMXJDWHGWRDV\QWKHWLFEUDQFKHGKH[DVDFFKDULGHFRQWDLQLQJWZR
WHUPLQDOPDQQRVHSKRVSKDWH 03 YLDDPLQRR[\OLQNHUV
SUHSURO\VRVRPDOĮJOXFRVLGDVH (& KXPDQ SHSWLGHQDWXUDO
>$UJ+LV,OH@YDULDQWH[SUHVVHGLQ&+2FHOOVJO\FRIRUPDOIDZLWKaVLDO\O
HQGJURXSVRIJO\FDQUHVLGXHVEHLQJR[LGL]HGDQGFKHPLFDOO\PRGLILHGWR
DFHWDPLGRWULGHR[\> E R[R^> ^O OSKRVSKRQRĮ'
PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O
ĺ O>O OSKRVSKRQRĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O
ĺ @ȕ'PDQQRS\UDQRV\O`R[\ EXWDQR\O@K\GUD]LQ\O`HWKR[\ LPLQR@ȕ/arabino
KHSWXORS\UDQRV\ORQLFDFLGJURXSV
ĮJOXFRVLGDVHDFLGHKXPDLQHPRGLILpHSURGXLWHGDQVGHVFHOOXOHVRYDULHQQHVGH
KDPVWHUFKLQRLV &+2 JO\FRIRUPHDOIDOLpHjXQKH[DVDFFKDULGHGHV\QWKqVHGRQW
OHVUpVLGXVWHUPLQDX[VRQWGHX[PDQQRVHSKRVSKDWHVYLDXQJURXSHDPLQR[\
SUpSURĮJOXFRVLGDVHO\VRVRPDOH (& KXPDLQH SHSWLGHYDULDQW
QDWXUHO>$UJ+LV,OH@H[SULPpGDQVGHVFHOOXOHV&+2JO\FRIRUPHDOIDa
UpVLGXVVLDO\OWHUPLQDX[VRQWR[LGpVHWFKLPLTXHPHQWPRGLILpVHQDFLGHDFpWDPLGR
WULGpVR[\> E R[R^> ^O OSKRVSKRQRĮ'PDQQRS\UDQRV\O
ĺ OĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O ĺ O>O O
SKRVSKRQRĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O ĺ @ȕ'
PDQQRS\UDQRV\O`R[\ EXWDQR\O@K\GUD]LQ\O`pWKR[\ LPLQR@ȕ/arabinoKHSWXOR
S\UDQRV\ORQLTXH
ĮJOXFRVLGDVDiFLGDKXPDQDPRGLILFDGDSURGXFLGDHQODVFpOXODVRYiULFDVGH
KDPVWHUFKLQR &+2 JOLFRIRUPDDOIDFRQMXJDGDFRQXQJOLFDQRKH[DVDFDUtGLFR
VLQWpWLFRTXHFRQWLHQHGRVPDQRVDIRVIDWRV 03V WHUPLQDOHVYtDXQJUXSR
DPLQR[L
SUHSURĮJOXFRVLGDVDOLVRVRPDO (& KXPDQD SpSWLGRYDULDQWH
QDWXUDO>$UJ+LV,OH@H[SUHVDGDHQODVFpOXODV&+2JOLFRIRUPDDOIDFRQORV
aUHVWRVVLDOLOWHUPLQDOHVHVWiQR[LGDGRV\TXtPLFDPHQWHPRGLILFDGRVHQiFLGR
DFHWDPLGRWULGHVR[L> E R[R^> ^O OIRVIRQRĮ'PDQRSLUDQRVLO
ĺ OĮ'PDQRSLUDQRVLO ĺ OĮ'PDQRSLUDQRVLO ĺ O>O OIRVIRQRĮ
'PDQRSLUDQRVLO ĺ OĮ'PDQRSLUDQRVLO ĺ @ȕ'
PDQRSLUDQRVLO`R[L EXWDQRLO@KLGUD]LQLO`HWR[L LPLQR@ȕ/arabinoKHSWXOR
SLUDQRVLOyQLFR
370
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 32, No. 2, 2018)
S DYRSODFHOXP
DYRSODFHO replace the description by the following one
DYRSODFHO remplacer la description par la suivante
DYRSODFHO sustitúyase la descripción por la siguiente
KXPDQFXOWXUHH[SDQGHGDOORJHQLFPHVHQFK\PDOOLNHDGKHUHQWVWURPDO
FHOOVIRUFHOOEDVHGWKHUDS\&HOOVDUHRIIHWDORULJLQDQGGHULYHGIURP
SODFHQWDHRIKHDOWK\GRQRUVIROORZLQJDFHVDUHDQVHFWLRQ&HOOVH[SUHVV
FHOOVXUIDFHPDUNHUV&'&'DQG&'DQGVHFUHWH WKHIDFWRUV
,/,/DQG0&3
FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PHKXPDLQHV
DOORJpQLTXHVDGKpUHQWHVHQFXOWXUHG H[SDQVLRQSRXUWKpUDSLH
FHOOXODLUH/HVFHOOXOHVVRQWG RULJLQHI°WDOHHWGpULYHQWGXSODFHQWDGH
GRQQHXVHVHQERQQHVDQWpjODVXLWHG XQHFpVDULHQQH/HVFHOOXOHV
H[SULPHQWOHVPDUTXHXUVGHVXUIDFH&'&'HW&'HW
VHFUqWHQWOHVIDFWHXUV,/,/HW0&3
FpOXODVVLPLODUHVDPHVHQTXLPDOHVHVWURPDOHVDORJpQLFDVKXPDQDV
DGKHUHQWHVH[SDQGLGDVHQFXOWLYRSDUDWHUDSLDFHOXODU/DVFpOXODVVRQ
GHRULJHQIHWDO\GHULYDGDVGHSODFHQWDVGHGRQDQWHVVDQDVWUDVXQD
FHViUHD/DVFpOXODVH[SUHVDQORVPDUFDGRUHVGHVXSHUILFLH&'
&'\&'\VHFUHWDQORVIDFWRUHV,/,/\0&3
S ELQWUDIXVSXPDOID
ELQWUDIXVSDOID replace the structure by the following one
ELQWUDIXVSDOID remplacer la structure par la suivante
ELQWUDIXVSDOID sustitúyase la estructura por la siguiente
+HDY\ FKDLQ &KDvQH ORXUGH &DGHQD SHVDGD
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS 50
IYPSGGITFY ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK 100
LGTVTTVDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGA 450
GGGGSGGGGS GGGGSGGGGS GIPPHVQKSV NNDMIVTDNN GAVKFPQLCK 500
FCDVRFSTCD NQKSCMSNCS ITSICEKPQE VCVAVWRKND ENITLETVCH 550
DPKLPYHDFI LEDAASPKCI MKEKKKPGET FFMCSCSSDE CNDNIIFSEE 600
YNTSNPD 607
/LJKW FKDLQ &KDvQH OpJqUH &DGHQD OLJHUD
QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI 50
YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV 100
FGTGTKVTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216
'LVXOILGH EULGJHV ORFDWLRQ 3RVLWLRQ GHV SRQWV GLVXOIXUH 3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR
,QWUD+
,QWUD+ 7*)5
,QWUD/
,QWHU+/
,QWHU++
*O\FRV\ODWLRQ VLWHV 1 6LWHV GH JO\FRV\ODWLRQ 1 3RVLFLRQHV GH JOLFRVLODFLyQ 1
+ &+ $VQ
7*)5 $VQ $VQ $VQ
371
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
S
FLQWLURUJRQXP
FLQWLURUJRQ replace the CAS RN by the following one
FLQWLURUJRQ remplacer le numéro de registre du CAS par le suivant
FLQWLURUJyQ sustitúyase el número de registro del CAS por el siguiente
S GLOSDFLPDEXP
GLOSDFLPDE replace the structure by the following one
GLOSDFLPDE remplacer la structure par la suivante
GLOSDFLPDE sustitúyase la estructura por la siguiente
S HORSXOWLGXP
HORSXOWLGH replace the structure by the following one
pORSXOWLGH remplacer la structure par la suivante
HORSXOWLGD sustitúyase la estructura por la siguiente
372
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
S URGDWULVWDWXP
URGDWULVWDW replace the chemical name, the molecular formula, the CAS RN and
the structure by the following ones
URGDWULVWDW remplacer le nom chimique, la formule moléculaire brute, le numéro
de registre du CAS et la structure par les suivants
URGDWULVWDW sustitúyase el nombre químico, la fórmula molecular, el número de
registro del CAS y la estructura por los siguientes
S ^DPLQR> R FKORUR> ELSKHQ\O@\O
WULIOXRURHWKR[\@S\ULPLGLQ\O`GLD]DVSLUR>@GHFDQH
FDUER[\OLFDFLG
DFLGH S ^DPLQR> R FKORUR> ELSKpQ\O@\O
WULIOXRURpWKR[\@S\ULPLGLQ\O`GLD]DVSLUR>@GpFDQH
FDUER[\OLTXH
iFLGR S ^DPLQR> R FORUR> ELIHQLO@LO
WULIOXRURHWR[L@SLULPLGLQLO`GLD]DVSLUR>@GHFDQRFDUER[tOLFR
&+&O)12
S delete/supprimer/suprimáse insert/insérer/insertese
VHWRJHSUDPXP IH]DJHSUDVXP
VHWRJHSUDP IH]DJHSUDV
VpWRJpSUDP Ip]DJpSUDV
VHWRJHSUDP IH]DJHSUDV
S delete/supprimer/suprimáse insert/insérer/insertese
WDOGLWHUFHSWXPDOID WDOGHIJUREHSDOID
WDOGLWHUFHSWDOID WDOGHIJUREHSDOID
WDOGLWHUFHSWDOID WDOGpIJUREHSDOID
WDOGLWHUFHSWDOID WDOGHIJUREHSDOID
3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW
'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH
'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD
(WHO Drug Information, Vol. 32, No. 4, 2018)
S EHGLQYHWPDEXP
EHGLQYHWPDE replace the description by the following one
EpGLQYHWPDE remplacer la description par la suivante
EHGLQYHWPDE sustitúyase la descripción por la siguiente
LPPXQRJOREXOLQ*ODPEGDDQWL>Canis lupus familiaris 1*)
QHUYHJURZWKIDFWRUEHWDSRO\SHSWLGH1*)% @Canis lupus
familiarisPRQRFORQDODQWLERG\
373
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
JDPPDKHDY\FKDLQCanis lupus familiaris >9+
&DQOXSIDP,*+9 ,*+' ,*+-
>@ &DQOXSIDP,*+* &+ KLQJH
&+0!$ /!$ *!$
&+ &+6 @
GLVXOILGHZLWKODPEGDOLJKWFKDLQCanis lupus familiaris
>9/$0%'$ &DQOXSIDP,*/9 ,*/-
>@ &DQOXSIDP&/$0%'$,*/&
@GLPHU ELVGLVXOILGH
LPPXQRJOREXOLQH*ODPEGDDQWL>Canis familiaris 1*) IDFWHXU
GHFURLVVDQFHGXQHUISRO\SHSWLGHErWD @DQWLFRUSVPRQRFORQDO
Canis lupus familiaris
FKDvQHORXUGHJDPPDCanis lupus familiaris >9+
&DQOXSIDP,*+9 ,*+' ,*+-
>@ &DQOXSIDP,*+* &+
FKDUQLqUH &+0!$ /!$
*!$ &+ &+6
@ GLVXOIXUHDYHFODFKDvQHOpJqUHODPEGDCanis
lupus familiaris >9/$0%'$ &DQOXSIDP,*/9
,*/- >@ &DQOXSIDP&
/$0%'$,*/& @GLPqUH
ELVGLVXOIXUH
LQPXQRJOREXOLQD*ODPEGDDQWL>Canis familiaris 1*) IDFWRUGH
FUHFLPLHQWRGHOQHUYLRSROLSpSWLGREHWD @DQWLFXHUSRPRQRFORQDO
Canis lupus familiaris
FDGHQDSHVDGDJDPPDCanis lupus familiaris >9+
&DQOXSIDP,*+9 ,*+' ,*+-
>@ &DQOXSIDP,*+* &+ ELVDJUD
&+0!$ /!$ *!$
&+ &+6 @
GLVXOIXURFRQODFDGHQDOLJHUDODPEGDCanis lupus familiaris
>9/$0%'$ &DQOXSIDP,*/9
,*/- >@ &DQOXSIDP&/$0%'$
,*/& @GtPHUR ELVGLVXOIXUR
S GHYDILGXJHQXPFLYDSDUYRYHFXP
GHYDILGXJHQHFLYDSDUYRYHF replace the description by the following one
GHYDILGXJqQHFLYDSDUYRYHF remplacer la description par la suivante
GHYDILGXJpQFLYDSDUYRYHF sustitúyase la descripción por la siguiente
DUHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXVW\SH
U$$95HS&DS YHFWRUZKLFKFRQWDLQVDSURPRWHUOHVV
KXPDQDOSKD/LGXURQLGDVH K,'8$ WUDQVJHQHFDVVHWWH
HQFRGLQJSDUWLDOH[RQDQGIXOOH[RQVZLWKWKHILUVW
DPLQRDFLGVUHPRYHGDQGVSOLFHDFFHSWRUVLWHVHTXHQFH 6$
IURPK)H[RQIODQNHGE\DVHTXHQFHKRPRORJRXVWRWKH]LQF
ILQJHUQXFOHDVH =)1 FOHDYDJHVLWHRIWKHKXPDQDOEXPLQ
K$/% LQWURQ
YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW U$$9
5HS&DS QRQUpSOLTXDQWFRQWHQDQWODFDVVHWWHGXWUDQVJqQH
GHO DOSKD/LGXURQLGDVHKXPDLQH K,'8$ VDQVSURPRWHXU
FRGDQWSDUWLHOOHPHQWO H[RQHWHQWLqUHPHQWOHVH[RQVGRQW
ODSDUWLHFRUUHVSRQGDQWDX[SUHPLHUVDFLGHVDPLQpVDpWp
UHWLUpHHWODVpTXHQFHGXVLWHDFFHSWHXU 6$ G pSLVVDJHGH
O H[RQGHO¶K)IODQTXpG XQHVpTXHQFHKRPRORJXHDXVLWHGH
FOLYDJHGHODQXFOpDVHjGRLJWVGH]LQF =)1 GHO LQWURQGH
374
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
O DOEXPLQHKXPDLQH K$/%
XQYHFWRUGHYLUXVDGHQRDVRFLDGRWLSRUHFRPELQDQWH U$$9
5HS&DS QRUHSOLFDWLYRTXHFRQWLHQHXQFDVHWHFRQHO
WUDQVJHQGHODDOID/LGXURQLGDVDKXPDQD K,'8$ VLQSURPRWRU
TXHFRGLILFDSDUDHOH[yQSDUFLDO\ORVH[RQHVFRPSOHWRV
FRQORVSULPHURVDPLQRiFLGRVHOLPLQDGRV\ODVHFXHQFLDGHO
VLWLRDFHSWRU 6$ GHOVSOLFLQJGHOH[yQGHK)IODQTXHDGRSRU
XQDVHFXHQFLDKRPyORJDDOVLWLRGHURWXUDSRUODQXFOHDVHFRQ
GHGRVGH]LQF =)1 GHOLQWURQGHODDOE~PLQDKXPDQD K$/%
S ODFXWDPDEXP
ODFXWDPDE replace the CAS RN by the following one
ODFXWDPDE remplacer le numéro de registre du CAS par le suivant
ODFXWDPDE sustitúyase el número de registro del CAS por el siguiente
S UDQX]LILJHQXPFLYDSDUYRYHFXP
UDQX]LILJHQHFLYDSDUYRYHF replace the description by the following one
UDQX]LILJqQHFLYDSDUYRYHF remplacer la description par la suivante
UDQX]LILJpQFLYDSDUYRYHF sustitúyase la descripción por la siguiente
DUHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXVW\SH
U$$95HS&DS YHFWRUH[SUHVVLQJDF'1$WKDWWDUJHWV
ESRIWKHDOEXPLQORFXV UHODWLYHWRWKHWUDQVFULSWLRQLQLWLDWLRQ
VLWH IXVHGWRWKHREOLJDWHKHWHURGLPHULF)RN,QXFOHDVHGRPDLQ
..5XQGHUWKHFRQWURORIDQDSROLSRSURWHLQ(KHSDWLFFRQWURO
UHJLRQDQGKXPDQDOSKDDQWLWU\SVLQSURPRWHU $SR(K$$7
YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW U$$9
5HS&DS QRQUpSOLTXDQWH[SULPDQWXQ$'1FFLEODQWOHV
SDLUHVGHEDVHVGXORFXVGHO DOEXPLQH HQUHODWLRQ
DYHFOHVLWHLQLWLDOGHWUDQVFULSWLRQ IXVLRQQpDXGRPDLQH
KpWpURGLPpULTXH..5GHODQXFOpDVH)RNOVRXVOHFRQWU{OHG XQH
UpJLRQGHFRQWU{OHGHO DSROLSRSURWpLQH( $SR( VSpFLILTXHGX
IRLHHWGXSURPRWHXUGHO DOSKDDQWLWU\SVLQHKXPDLQH
$SR(K$$7
XQYHFWRUGHYLUXVDGHQRDVRFLDGRWLSRUHFRPELQDQWH U$$9
5HS&DS QRUHSOLFDWLYRTXHH[SUHVDXQF'1$GLULJLGRD
XQLUVHDORVSDUHVGHEDVHV HQUHODFLyQDOVLWLRGH
LQLFLDFLyQGHODWUDQVFULSFLyQ GHOORFXVGHODDOE~PLQDIXVLRQDGR
DOGRPLQLRKHWHURGLPpULFR..5GHODQXFOHDVH)RN,EDMRHO
FRQWUROGHXQDUHJLyQGHFRQWUROKHSiWLFRGHODDSROLSRSURWHtQD(
\HOSURPRWRUGHODDOIDDQWLWULSVLQDKXPDQD $SR(K$$7
375
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ANNEX 1
PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL
NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1
The following procedure shall be followed by the World Health Organization
(hereinafter also referred to as “WHO”) in the selection of recommended international
nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11
of the World Health Assembly, and in the substitution of such names.
Article 1 - Proposals for recommended international nonproprietary names and proposals for
substitution of such names shall be submitted to WHO on the form provided therefore. The
consideration of such proposals shall be subject to the payment of an administrative fee
designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”).
The amount of this fee shall be determined by the Secretariat and may, from time to time, be
adjusted.
Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert
Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations
designated for this purpose, such designated members hereinafter referred to as “the INN
Expert Group”, for consideration in accordance with the “General principles for guidance in
devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this
procedure2. The name used by the person discovering or first developing and marketing a
pharmaceutical substance shall be accepted, unless there are compelling reasons to the
contrary.
Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give
notice that a proposed international nonproprietary name is being considered.
a) Such notice shall be given by publication in WHO Drug Information3and by letter to
Member States and to national and regional pharmacopoeia commissions or other bodies
designated by Member States.
i) Notice shall also be sent to the person who submitted the proposal (“the original
applicant”) and other persons known to be concerned with a name under
consideration.
b) Such notice shall:
i) set forth the name under consideration;
ii) identify the person who submitted the proposal for naming the substance, if so
requested by such person;
iii) identify the substance for which a name is being considered;
iv) set forth the time within which comments and objections will be received and
the person and place to whom they should be directed;
v) state the authority under which WHO is acting and refer to these rules of
procedure.
1
See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution
EB15.R7 and amended in resolutions EB43.R9 and EB115.R4.
2
See Annex 2.
3
Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.
376
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
c) In forwarding the notice, the Secretariat shall request that Member States take such steps
as are necessary to prevent the acquisition of proprietary rights in the proposed name during
the period it is under consideration by WHO.
Article 4 - Comments on the proposed name may be forwarded by any person to WHO within
four months of the date of publication, under article 3, of the name in WHO Drug Information.
Article 5 - A formal objection to a proposed name may be filed by any interested person
within four months of the date of publication, under article 3, of the name in WHO Drug
Information.
Such objection shall:
i) identify the person objecting;
ii) state his or her interest in the name;
iii) set forth the reasons for his or her objection to the name proposed.
Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the
proposed name or use its good offices to attempt to obtain withdrawal of the objection.
Without prejudice to the consideration by WHO of a substitute name or names, a name shall
not be selected by WHO as a recommended international nonproprietary name while there
exists a formal objection thereto filed under article 5 which has not been withdrawn.
Article 7 - Where no objection has been filed under article 5, or all objections previously filed
have been withdrawn, the Secretariatshall give notice in accordance with subsection (a) of
article 3 that the name has been selected by WHO as a recommended international
nonproprietary name.
Article 8 - In forwarding a recommended international nonproprietary name to Member
States under article 7, the Secretariat shall:
a) request that it be recognized as the nonproprietary name for the substance; and
b) request that Member States take such steps as are necessary to prevent the acquisition of
proprietary rights in the name and to prohibit registration of the name as a trademark or
trade name.
Article 9
a) In the extraordinary circumstance that a previously recommended international
nonproprietary name gives rise to errors in medication, prescription or distribution, or a
demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or
prescription practices, and it appears that such errors or potential errors cannot readily be
resolved through other interventions than a possible substitution of a previously
recommended international nonproprietary name, or in the event that a previously
recommended international nonproprietary name differs substantially from the
nonproprietary name approved in a significant number of Member States, or in other such
extraordinary circumstances that justify a substitution of a recommended international
nonproprietary name, proposals to that effect may be filed by any interested person. Such
proposals shall be submitted on the form provided therefore and shall:
i) identify the person making the proposal;
ii) state his or her interest in the proposed substitution; and
377
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
iii) set forth the reasons for the proposal; and
iv) describe, and provide documentary evidence regarding the other interventions
undertaken in an effort to resolve the situation, and the reasons why these other
interventions were inadequate.
Such proposals may include a proposal for a new substitute international nonproprietary
name, devised in accordance with the General principles, which takes into account the
pharmaceutical substance for which the new substitute international nonproprietary name is
being proposed.
The Secretariat shall forward a copy of the proposal, for consideration in accordance with the
procedure described in subsection (b) below, to the INN Expert Group and the original
applicant or its successor (if different from the person bringing the proposal for substitution
and provided that the original applicant or its successor is known or can be found through
diligent effort, including contacts with industry associations).
In addition, the Secretariat shall request comments on the proposal from:
i) MemberStates and national and regional pharmacopoeia commissions or other
bodies designated by Member States (by including a notice to that effect in the
letter referred to in article 3(a), and
ii) any other persons known to be concerned by the proposed substitution.
The request for comments shall:
i) state the recommended international nonproprietary name that is being
proposed for substitution (and the proposed substitute name, if provided);
ii) identify the person who submitted the proposal for substitution (if so requested
by such person);
iii) identify the substance to which the proposed substitution relates and reasons
put forward for substitution;
iv) set forth the time within which comments will be received and the person and
place to whom they should be directed; and
v) state the authority under which WHO is acting and refer to these rules of
procedure.
Comments on the proposed substitution may be forwarded by any person to WHO within
four months of the date of the request for comments.
b) After the time period for comments referred to above has elapsed, the Secretariat shall
forward any comments received to the INN Expert Group, the original applicant or its
successor and the person bringing the proposal for substitution. If, after consideration of the
proposal for substitution and the comments received, the INN Expert Group, the person
bringing the proposal for substitution and the original applicant or its successor all agree that
there is a need to substitute the previously recommended international nonproprietary name,
the Secretariat shall submit the proposal for substitution to the INN Expert Group for further
processing.
378
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to
withhold agreement to a proposal for substitution in the event the original applicant or its
successor has no demonstrable continuing interest in the recommended international
nonproprietary name proposed for substitution.
In the event that a proposal for substitution shall be submitted to the INN Expert
Group for further processing, the INN Expert Group will select a new international
nonproprietary name in accordance with the General principles referred to in article 2 and the
procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under
article 3 and article 7, respectively, including to the original applicant or its successor (if not
the same as the person proposing the substitution, and provided that the original applicant
or its successor is known or can be found through diligent effort, including contacts with
industry associations), shall in such event indicate that the new name is a substitute for a
previously recommended international nonproprietary name and that Member States may
wish to make transitional arrangements in order to accommodate existing products that use
the previously recommended international nonproprietary name on their label in accordance
with national legislation.
If, after consideration of the proposal for substitution and the comments received in
accordance with the procedure described above, the INN Expert Group, the original applicant
or its successor and the person bringing the proposal for substitution do not agree that there
are compelling reasons for substitution of a previously recommended international
nonproprietary name, this name shall be retained (provided always that the original applicant
or its successor shall not be entitled to withhold agreement to a proposal for substitution in
the event that the original applicant or its successor has no demonstrable continuing interest
in the recommended international nonproprietary name proposed to be substituted). In such
an event, the Secretariat shall advise the person having proposed the substitution, as well as
the original applicant or its successor (if not the same as the person proposing the
substitution, and provided that the original applicant or its successor is known or can be
found through diligent effort, including contacts with industry associations), Member States,
national and regional pharmacopoeia commissions, other bodies designated by Member
States, and any other persons known to be concerned by the proposed substitution that,
despite a proposal for substitution, it has been decided to retain the previously
recommended international nonproprietary name (with a description of the reason(s) why
the proposal for substitution was not considered sufficiently compelling).
ANNEX 2
GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL
NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1
1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They
should not be inconveniently long and should not be liable to confusion with names in
common use.
2. The INN for a substance belonging to a group of pharmacologically related substances
should, where appropriate, show this relationship. Names that are likely to convey to a patient
an anatomical, physiological, pathological or therapeutic suggestion should be avoided.
These primary principles are to be implemented by using the following secondary principles:
3. In devising the INN of the first substance in a new pharmacological group, consideration
should be given to the possibility of devising suitable INN for related substances, belonging
to the new group.
379
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
4. In devising INN for acids, one-word names are preferred; their salts should be named
without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and
“ibufenac sodium”.
5. INN for substances which are used as salts should in general apply to the active base or the
active acid. Names for different salts or esters of the same active substance should differ only
in respect of the name of the inactive acid or the inactive base.
For quaternary ammonium substances, the cation and anion should be named appropriately
as separate components of a quaternary substance and not in the amine-salt style.
6. The use of an isolated letter or number should be avoided; hyphenated construction is also
undesirable.
7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t”
instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and
“k” should be avoided.
8. Provided that the names suggested are in accordance with these principles, names
proposed by the person discovering or first developing and marketing a pharmaceutical
preparation, or names already officially in use in any country, should receive preferential
consideration.
9. Group relationship in INN (see General principle 2) should if possible be shown by using a
common stem. The following list contains examples of stems for groups of substances,
particularly for new groups. There are many other stems in active use.2 Where a stem is shown
without any hyphens it may be used anywhere in the name.
Latin English
-acum -ac anti-inflammatory agents, ibufenac derivatives
-adolum -adol } analgesics
-adol- -adol-}
-astum -ast antiasthmatic, antiallergic substances not acting
primarily as antihistaminics
-astinum -astine antihistaminics
-azepamum -azepam diazepam derivatives
bol bol steroids, anabolic
-cain- -cain- class I antiarrhythmics, procainamide and
lidocaine derivatives
-cainum -caine local anaesthetics
cef- cef- antibiotics, cefalosporanic acid derivatives
-cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives
-conazolum -conazole systemic antifungal agents, miconazole
derivatives
cort cort corticosteroids, except prednisolone derivatives
-coxibum -coxib selective cyclo-oxygenase inhibitors
1
In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for
Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments
in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical
substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a
characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are
fully discussed.
The guiding principles were updated during the 13th consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29
April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983).
2
A more extensive listing of stems is contained in the working document WHO/EMP/RHT/TSN/2018.1 which is regularly updated and can be
requested from the INN Programme, WHO, Geneva.
380
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
-entanum -entan endothelin receptor antagonists
gab gab gabamimetic agents
gado- gado- diagnostic agents, gadolinium derivatives
-gatranum -gatran thrombin inhibitors, antithrombotic agents
gest gest steroids, progestogens
gli gli antihyperglycaemics
io- io- iodine-containing contrast media
-metacinum -metacin anti-inflammatory, indometacin derivatives
-mycinum -mycin antibiotics, produced by Streptomyces strains
-nidazolum -nidazole antiprotozoal substances, metronidazole
derivatives
-ololum -olol β-adrenoreceptor antagonists
-oxacinum -oxacin antibacterial agents, nalidixic acid derivatives
-platinum -platin antineoplastic agents, platinum derivatives
-poetinum -poetin erythropoietin type blood factors
-pril(at)um -pril(at) angiotensin-converting enzyme inhibitors
-profenum -profen anti-inflammatory substances, ibuprofen
derivatives
prost prost prostaglandins
-relinum -relin pituitary hormone release-stimulating peptides
-sartanum -sartan angiotensin II receptor antagonists,
antihypertensive (non-peptidic)
-vaptanum -vaptan vasopressin receptor antagonists
vin- / -vin- vin- / -vin- vinca-type alkaloids
ANNEXE 1
PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES
INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES
PHARMACEUTIQUES1
L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS »)
observe la procédure exposée ci-dessous pour l’attribution de dénominations communes
internationales recommandées pour les substances pharmaceutiques, conformément à la
résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles
dénominations.
Article 1 - Les propositions de dénominations communes internationales recommandées et
les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la
formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe
administrative destinée uniquement à couvrir les coûts correspondants assumés par le
Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le
Secrétariat et peut être modifié de temps à autre.
Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin
parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et
des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts
des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour
la formation de dénominations communes internationales pour les substances
pharmaceutiques » reproduites ci-après2.La dénomination acceptée est la dénomination
employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché
une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de
cette règle.
1
Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans
sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4.
2
Voir annexe 2.
381
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de
dénomination commune internationale est à l’étude.
a) Cette notification est faite par une insertion dans WHO Drug Information1 et par l’envoi
d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée
ou autres organismes désignés par les Etats Membres.
i) Notification est également faite à la personne qui a soumis la proposition (« le
demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un
intérêt notoire.
b) Cette notification contient les indications suivantes :
i) dénomination mise à l’étude;
ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la
substance, si cette personne le demande ;
iii) définition de la substance dont la dénomination est mise à l’étude ;
iv) délai pendant lequel seront reçues les observations et les objections à l’égard de
cette dénomination ; nom et adresse de la personne habilitée à recevoir ces
observations et objections ;
v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement.
c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les
mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination
proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par
l’OMS.
Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par
toute personne, dans les quatre mois qui suivent la date de publication de la dénomination
dans WHO Drug Information (voir l’article 3).
Article 5 - Toute personne intéressée peut formuler une objection formelle contre la
dénomination proposée dans les quatre mois qui suivent la date de publication de la
dénomination dans WHO Drug Information (voir l’article 3).
Cette objection doit s’accompagner des indications suivantes :
i) nom de l’auteur de l’objection ;
ii) intérêt qu’il ou elle porte à la dénomination en cause ;
iii) raisons motivant l’objection contre la dénomination proposée.
Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit
soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter
d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs
1
Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la
Santé.
382
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination
commune internationale recommandée tant qu’une objection formelle présentée
conformément à l’article 5 n’est pas levée.
Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les
objections présentées ont été levées, le Secrétariat fait une notification conformément aux
dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie
par l’OMS en tant que dénomination commune internationale recommandée.
Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une
dénomination commune internationale recommandée, le Secrétariat :
a) demande que cette dénomination soit reconnue comme dénomination commune de la
substance considérée ; et
b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir
l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette
dénomination comme marque ou appellation commerciale.
Article 9 -
a) Dans le cas exceptionnel où une dénomination commune internationale déjà
recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou
en comporte un risque démontrable, en raison d’une similitude avec une
autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que
ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres
interventions que le remplacement éventuel d’une dénomination commune internationale
déjà recommandée, ou dans le cas où une dénomination commune internationale déjà
recommandée diffère sensiblement de la dénomination commune approuvée dans un
nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui
justifient le remplacement d’une dénomination commune internationale recommandée,
toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est
présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes :
i) nom de l’auteur de la proposition ;
ii) intérêt qu’il ou elle porte au remplacement proposé ;
iii) raisons motivant la proposition ; et
iv) description, faits à l’appui, des autres interventions entreprises pour tenter de
régler le problème et exposé des raisons pour lesquelles ces interventions ont
échoué.
Les propositions peuvent comprendre une proposition de nouvelle dénomination commune
internationale de remplacement, établie conformément aux Directives générales, compte
tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune
internationale de remplacement est proposée.
Le Secrétariat transmet une copie de la proposition pour examen, conformément à la
procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur
initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la
proposition de remplacement et pour autant que le demandeur initial ou son successeur soit
connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec
les associations industrielles).
De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des
observations sur la proposition :
383
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou
d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet
dans la lettre mentionnée à l’article 3.a), et
ii) toutes autres personnes portant au remplacement proposé un intérêt notoire.
La demande d’observations contient les indications suivantes :
i) dénomination commune internationale recommandée pour laquelle un
remplacement est proposé (et la dénomination de remplacement proposée, si elle est
fournie) ;
ii) nom de l’auteur de la proposition de remplacement (si cette personne le
demande) ;
iii) définition de la substance faisant l’objet du remplacement proposé et raisons
avancées pour le remplacement ;
iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la
personne habilitée à recevoir ces commentaires ; et
v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent
règlement.
Des observations sur la proposition de remplacement peuvent être communiquées par toute
personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations.
b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat
transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son
successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la
proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur
de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent
tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà
recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts
des DCI pour qu’il y donne suite.
Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à
refuser son accord à une proposition de remplacement au cas où il ne peut être démontré
qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il
est proposé de remplacer.
Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des
DCI pour qu’il y donne suite, le Groupe choisit une nouvelle dénomination commune
internationale conformément aux Directives générales mentionnées à l’article 2 et selon la
procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu
de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son
successeur (si ce n’est pas la même personne que celle qui a proposé le remplacement et
pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé
moyennant des efforts diligents, notamment des contacts avec les associations industrielles),
doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination
commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter
prendre des mesures transitoires pour les produits existants qui utilisent la dénomination
commune internationale déjà recommandée sur leur étiquette conformément à la législation
nationale.
384
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
Si, après examen de la proposition de remplacement et des observations
communiquées conformément à la procédure exposée plus haut, le Groupe d’experts des
DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne
s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination
commune internationale déjà recommandée, cette dernière est conservée (étant entendu
toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à
une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt
durable à la dénomination commune internationale recommandée qu’il est proposé de
remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement,
ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle
qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son
successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment
des contacts avec les associations industrielles), les Etats Membres, les commissions
nationales et régionales de pharmacopée, les autres organismes désignés par les Etats
Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé
que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination
commune internationale déjà recommandée (avec une brève description de la ou des raisons
pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative).
ANNEXE 2
DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS
COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES
PHARMACEUTIQUES1
1. Les dénominations communes internationales (DCI) devront se distinguer les unes des
autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur
excessive, ni prêter à confusion avec des appellations déjà couramment employées.
2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les
dénominations susceptibles d’évoquer pour les malades des considérations anatomiques,
physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du
possible.
Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants :
3. Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique,
on tiendra compte de la possibilité de former ultérieurement d’autres DCI appropriées pour
les substances apparentées du même groupe.
4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront
être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple
«oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique».
5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la
base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même
substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive).
1
Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes
pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et
la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La
modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances
tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes
(segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces
segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies.
Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques
(Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983).
385
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination
s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une
substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé.
6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au
trait d’union.
7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place
de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ;
l’usage des lettres « h » et « k » sera aussi évité.
8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les
dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont
fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les
dénominations déjà officiellement adoptées par un pays.
9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible
indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des
exemples de segments-clés pour des groupes de substances, surtout pour des groupes
récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés
indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination.
Latin Français
-acum -ac substances anti-inflammatoires du groupe de l’ibufénac
-adolum -adol } analgésiques
-adol- -adol- }
-astum -ast antiasthmatiques, antiallergiques n’agissant pas
principalement en tant qu’antihistaminiques
-astinum -astine antihistaminiques
-azepamum -azépam substances du groupe du diazépam
bol bol stéroïdes anabolisants
-cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et
de la lidocaïne
-cainum -caïne anesthésiques locaux
cef- céf- antibiotiques, dérivés de l’acide céphalosporanique
-cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique
-conazolum -conazole agents antifongiques systémiques du groupe du
miconazole
cort cort corticostéroïdes, autres que les dérivés de la
prednisolone
-coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase
-entanum -entan antagonistes du récepteur de l’endothéline
gab gab gabamimétiques
gado- gado- agents diagnostiques, dérivés du gadolinium
-gatranum -gatran antithrombines, antithrombotiques
gest gest stéroïdes progestogènes
gli gli antihyperglycémiants
io- io- produits de contraste iodés
-metacinum -métacine substances anti-inflammatoires du groupe de
l’indométacine
-mycinum -mycine antibiotiques produits par des souches de
Streptomyces
1
Une liste plus complète de segments-clés est contenue dans le document de travail WHO/EMP/RHT/TSN/2018.1 qui est régulièrement mis à
jour et qui peut être demandé auprès du programme des DCI, OMS, Genève.
386
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
-nidazolum -nidazole substances antiprotozoaires du groupe du
métronidazole
-ololum -olol antagonistes des récepteurs β-adrénergiques
-oxacinum -oxacine substances antibactériennes du groupe de l’acide
nalidixique
-platinum -platine antinéoplasiques, dérivés du platine
-poetinum -poétine facteurs sanguins de type érythropoïétine
-pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine
-profenum -profène substances anti-inflammatoires du groupe de
l’ibuprofène
prost prost prostaglandines
-relinum -réline peptides stimulant la libération d’hormones
hypophysaires
-sartanum -sartan antagonistes d’un récepteur de l’angiotensine II,
antihypertenseurs (non peptidiques)
-vaptanum -vaptan antagonistes du récepteur de la vasopressine
vin- vin- } alcaloïdes du type vinca
-vin- -vin- }
ANEXO 1
PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES
INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1
La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a conti-
nuación tanto para seleccionar denominaciones comunes internacionales recomendadas
para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11,
como para sustituir esas denominaciones.
Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las
propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios
que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de
una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría
de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla
periódicamente.
Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de
Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su
estudio, en adelante designados como «el Grupo de Expertos en DCI», para que las examinen
de conformidad con los «Principios generales de orientación para formar denominaciones
comunes internacionales para sustancias farmacéuticas», anexos a este procedimiento.2 A
menos que haya poderosas razones en contra, la denominación aceptada será la empleada
por la persona que haya descubierto o fabricado y comercializado por primera vez esa
sustancia farmacéutica.
Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en
estudio un proyecto de denominación internacional.
a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3 y el
envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las
farmacopeas u otros organismos designados por los Estados Miembros.
1
Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución
EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4..
2
Véase el anexo 2.
3
Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud.
387
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
i) La notificación será enviada también a la persona que haya presentado la pro-
puesta («el solicitante inicial») y a otras personas que tengan un interés especial en
una denominación objeto de estudio.
b) En esa notificación se incluirán los siguientes datos:
i) la denominación sometida a estudio;
ii) la identidad de la persona que ha presentado la propuesta de denominación de la
sustancia, si lo pide esa persona;
iii) la identidad de la sustancia cuya denominación está en estudio;
iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la
dirección de la persona a quien deban dirigirse; y
v) los poderes conferidos para el caso a la OMS y una referencia al presente
procedimiento.
c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de
todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la de-
nominación propuesta, durante el periodo en que la OMS la tenga en estudio.
Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación
propuesta dentro de los cuatro meses siguientes a su publicación en Información
Farmacéutica OMS, conforme a lo dispuesto en el artículo 3.
Artículo 5 - Toda persona interesada puede presentar una objeción formal a una
denominación propuesta dentro de los cuatro meses siguientes a su publicación en
Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3.
Esa objeción deberá acompañarse de los siguientes datos:
i) la identidad de la persona que formula la objeción;
ii) las causas que motivan su interés por la denominación; y
iii) las causas que motivan su objeción a la denominación propuesta.
Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo
5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar
lograr que se retire la objeción. La OMS no seleccionará como denominación común
internacional una denominación a la que se haya hecho una objeción formal, presentada
según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la
Organización examine otra denominación o denominaciones sustitutivas.
Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo
5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará,
conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido
seleccionada por la OMS como denominación común internacional recomendada.
Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional,
conforme a lo previsto en el artículo 7, la Secretaría:
388
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
a) solicitará que esta denominación sea reconocida como denominación común para la sus-
tancia de que se trate; y
b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la
adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada
como marca de fábrica o como nombre comercial.
Artículo 9
a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en
las prácticas farmacéuticas y/o de prescripción, una denominación común internacional
recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o
suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales
errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución
de esa denominación común internacional recomendada anteriormente; en el caso de que
una denominación común internacional recomendada anteriormente difiera
considerablemente de la denominación común aprobada en un número importante de Es-
tados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una
denominación común internacional recomendada, cualquier persona interesada puede
presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que
se proporcionen a estos efectos e incluirán los siguientes datos:
i) la identidad de la persona que presenta la propuesta;
ii)las causas que motivan su interés en la sustitución propuesta;
iii) las causas que motivan la propuesta; y
iv) una descripción, acompañada de pruebas documentales, de las otras medidas
que se hayan adoptado con el fin de resolver la situación y de los motivos por los
cuales dichas medidas no han sido suficientes.
Entre esas propuestas podrá figurar una relativa a una nueva denominación común
internacional sustitutiva, formulada con arreglo a los Principios generales y que tenga en
cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común
internacional sustitutiva.
La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su
sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de
sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser
encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones
industriales) una copia de la propuesta, para que sea examinada de conformidad con el
procedimiento descrito en el párrafo b) infra.
Además, la Secretaría solicitará observaciones sobre la propuesta:
i) a los Estados Miembros y a las comisiones nacionales y regionales de las far-
macopeas u otros organismos designados por los Estados Miembros (ello se hará in-
cluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del
artículo 3), y
ii) a cualquier persona que tenga un interés especial en la sustitución propuesta.
Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos:
i) la denominación común internacional recomendada que se propone sustituir (y la
denominación sustitutiva propuesta, si se ha facilitado);
389
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo
pide esa persona);
iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las
razones para presentar la propuesta de sustitución;
iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la
persona a quien deban dirigirse; y
v) los poderes conferidos para el caso a la OMS y una referencia al presente pro-
cedimiento.
Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro
de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones.
b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría
enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a
su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de
examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en
DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su
sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional
recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de
Expertos en DCI para que la tramite.
No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el
acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un
interés demostrable en la denominación común internacional cuya sustitución se propone.
En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI
para que la tramite, este grupo seleccionará una nueva denominación común internacional
de conformidad con los Principios generales a los que se refiere el artículo 2 y al
procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones
que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la
notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que
propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o
puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones
industriales), se indicará que la nueva denominación sustituye a una denominación común
internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman
oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya
etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional
recomendada anteriormente que se haya sustituido.
En caso de que, después de haber estudiado la propuesta de sustitución y los comen-
tarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de
Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la
propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas
para sustituir una denominación común internacional recomendada anteriormente, esta
denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su
sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el
caso de que hayan dejado de tener un interés demostrable en la denominación común in-
ternacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona
que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de
que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o
su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el
contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones
390
WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121
nacionales y regionales de las farmacopeas o a otros organismos designados por los Estados
Miembros y a cualquier otra persona que tenga interés en la sustitución propuesta, que, pese
a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación
común internacional recomendada anteriormente (con una descripción de la o las razones
por las que se ha considerado que la propuesta de sustitución no estaba respaldada por
razones suficientemente poderosas).
ANEXO 2
PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES
COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS1
1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética
como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con
denominaciones de uso común.
2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente
emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las
denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o
terapéuticas para el paciente.
Estos principios primarios se pondrán en práctica utilizando los siguientes principios
secundarios:
3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en
cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas
que se agreguen al nuevo grupo.
4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán
denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica»,
«ibufenaco» y «ibufenaco sódico».
5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la
base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma
sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos.
En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse
adecuadamente por separado, como componentes independientes de una sustancia
cuaternaria y no como sales de una amina.
6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo
de guiones.
7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en
lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá
evitar el empleo de las letras «h» y «k».
8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios,
recibirán una consideración preferente las denominaciones propuestas por la persona que
haya descubierto las sustancias, o que fabrique y comercialice por primera vez una sustancia
farmacéutica, así como las denominaciones ya adoptadas oficialmente en cualquier país.
1
En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las
Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de
selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante
había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las
sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que
indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este
cambio.
Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias
farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983).
391
Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019
9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase
el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican
ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen
muchas otras partículas que se usan habitualmente.1 Cuando una partícula aparece sin guión
alguno, puede utilizarse en cualquier lugar de la palabra.
Latin Español
-acum -aco antiinflamatorios derivados del ibufenaco
-adolum -adol ) analgésicos
-adol- -adol- )
-astum -ast antiasmáticos, sustancias antialérgicas cuya acción principal no
es la antihistamínica
-astinum -astina antihistamínicos
-azepamum -azepam derivados del diazepam
bol bol esteroides anabolizantes
-cain- -caína- antiarrítmicos de clase I, derivados de procainamida y lidocaína
-cainum -caína- anestésicos locales
cef- cef- antibióticos, derivados del ácido cefalosporánico
-cillinum -cilina antibióticos derivados del ácido 6-aminopenicilánico
-conazolum -conazol antifúngicos sistémicos derivados del miconazol
cort cort corticosteroides, excepto derivados de prednisolona
-coxibum -coxib inhibidores selectivos de ciclooxigenasa
-entanum -entán antagonistas del receptor de endotelina
gab gab gabamiméticos
gado- gado- agentes para diagnóstico derivados de gadolinio
-gartranum -gatrán inhibidores de la trombina antitrombóticos
gest gest esteroides progestágenos
gli gli hipoglucemiantes,antihiperglucémicos
io- io- medios de contraste iodados
-metacinum -metacina antiinflamatorios derivados de indometacina
-mycinum -micina antibióticos producidos por cepas de Streptomyces
-nidazolum -nidazol antiprotozoarios derivados de metronidazol
-ololum -olol antagonistas de receptores E-adrenérgicos
-oxacinum -oxacino antibacterianos derivados del ácido nalidíxico
-platinum -platino antineoplásicos derivados del platino
-poetinum -poetina factores sanguíneos similares a la eritropoyetina
-pril(at)um -pril(at) inhibidores de la enzima conversora de laangiotensina
-profenum -profeno antiinflamatorios derivados del ibuprofeno
prost prost prostaglandinas
-relinum -relina péptidos estimulantes de la liberación de hormonas
hipofisarias
-sartanum -sartán antihipertensivos (no peptídicos) antagonistas del
receptor de angiotensina II
-vaptanum -vaptán antagonistas del receptor de vasopresina
vin- vin- ) alcaloides de la vinca
-vin- -vin- )
1
En el documento de trabajo WHO/EMP/RHT/TSN/2018.1, que se actualiza periódicamente y puede solicitarse al Programa sobre
Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas.
392